Use these links to rapidly review the document
TABLE OF CONTENTS
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
(Rule 14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No. )
|
|
|
Filed by the Registrant
ý
|
Filed by a Party other than the Registrant
o
|
Check the appropriate box:
|
o
|
|
Preliminary Proxy Statement
|
o
|
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
ý
|
|
Definitive Proxy Statement
|
o
|
|
Definitive Additional Materials
|
o
|
|
Soliciting Material Pursuant to §240.14a-12
|
|
|
|
|
|
Boston Scientific Corporation
|
(Name of Registrant as Specified in its Charter)
|
|
(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)
|
Payment of Filing Fee (Check the appropriate box):
|
ý
|
|
No fee required.
|
o
|
|
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
|
|
|
(1)
|
|
Title of each class of securities to which transaction applies:
|
|
|
(2)
|
|
Aggregate number of securities to which transaction applies:
|
|
|
(3)
|
|
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
|
|
|
(4)
|
|
Proposed maximum aggregate value of transaction:
|
|
|
(5)
|
|
Total fee paid:
|
o
|
|
Fee paid previously with preliminary materials.
|
o
|
|
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration
statement number, or the Form or Schedule and the date of its filing.
|
|
|
(1)
|
|
Amount Previously Paid:
|
|
|
(2)
|
|
Form, Schedule or Registration Statement No.:
|
|
|
(3)
|
|
Filing Party:
|
|
|
(4)
|
|
Date Filed:
|
Table of Contents
March 24, 2015
Dear
Boston Scientific Stockholder:
You
are cordially invited to attend the Annual Meeting of Stockholders of Boston Scientific Corporation (the Company) to be held on Tuesday, May 5, 2015, at 11:00 a.m. Eastern Time, at
the Company's Corporate Headquarters located at 300 Boston Scientific Way, Marlborough, Massachusetts 01752 (Annual Meeting).
This
year you are being asked to:
-
1.
-
elect
to the Board of Directors eleven nominees for director;
-
2.
-
consider
and vote upon an advisory vote to approve named executive officer compensation;
-
3.
-
ratify
the appointment of Ernst & Young LLP as our independent registered public accounting firm for the 2015 fiscal year;
-
4.
-
consider
and vote upon a stockholder proposal described in this Proxy Statement, if properly presented at the Annual Meeting; and
-
5.
-
consider
and vote upon such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
These
matters are more fully described in the accompanying Notice of Annual Meeting and Proxy Statement. Our Board of Directors urges you to read the accompanying Proxy Statement and recommends that
you vote "FOR" all of the director nominees, our named executive officer compensation and the ratification of the appointment of Ernst & Young LLP as our independent registered public
accounting firm and "AGAINST" the stockholder proposal described in this Proxy Statement. At the meeting, you will be provided with the opportunity to ask questions.
We
are pleased to continue to take advantage of the Securities and Exchange Commission rule allowing companies to furnish proxy materials to their stockholders via the Internet. We believe this
e-proxy process, also known as "notice and access," expedites stockholders' receipt of proxy materials, lowers our printing and mailing costs and reduces the environmental impact of producing the
materials for our Annual Meeting. On or about March 24, 2015, we will mail to our stockholders of record at the close of business on Friday, March 13, 2015, the record date for our
Annual Meeting, an Important Notice of Internet Availability of Proxy Materials (Notice) containing instructions on how to access our Proxy Statement and Annual Report for the year ended
December 31, 2014 (Annual Report) on the Internet and also how to vote their shares via the Internet. If you received a Notice by mail you will not receive printed proxy materials unless you
specifically request them. Both the Notice and the
Proxy Statement contain instructions on how you can request a paper copy of the Proxy Statement and Annual Report.
Table of Contents
The
Board of Directors appreciates and encourages stockholder participation in the Company's affairs. Whether or not you plan to attend the Annual Meeting, we encourage you to vote your shares.
Accordingly, we request that as soon as possible, you vote via the Internet or, if you have received printed proxy materials, you vote via the Internet, by telephone or by mailing your completed proxy
card or voter instruction form.
Thank
you for your continuing support.
Pete M. Nicholas
Chairman of the Board of Directors
Table of Contents
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
Marlborough,
Massachusetts
March 24, 2015
The
Annual Meeting of Stockholders of Boston Scientific Corporation (Annual Meeting) will be held on Tuesday, May 5, 2015, at 11:00 a.m. Eastern Time, at the Company's Corporate
Headquarters located at 300 Boston Scientific Way, Marlborough, Massachusetts 01752, for the following purposes:
-
1.
-
to
elect to the Board of Directors eleven nominees for director;
-
2.
-
to
consider and vote upon an advisory vote to approve named executive officer compensation;
-
3.
-
to
ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the 2015 fiscal year;
-
4.
-
to
consider and vote upon a stockholder proposal described in the attached Proxy Statement, if properly presented at the Annual Meeting; and
-
5.
-
to
consider and vote upon such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
Only
stockholders of record at the close of business on Friday, March 13, 2015, are entitled to notice of and to vote at the meeting or any adjournments or postponements thereof.
It
is important that your shares be represented and voted at the Annual Meeting. Whether or not you plan to attend the Annual Meeting in person, we encourage you to submit your proxy as soon as
possible. For specific instructions, please refer to your Important Notice of Internet Availability of Proxy Materials or to the question on page 3 of the accompanying Proxy Statement entitled
"How do I vote by
proxy?"
At
the direction of the Board of Directors,
Timothy A. Pratt
Secretary
Table of Contents
TABLE OF CONTENTS
i
Table of Contents
300 Boston Scientific Way
Marlborough, Massachusetts 01752
March 24, 2015
PROXY STATEMENT
Information About the Annual Meeting and Voting
The Annual Meeting
The Annual Meeting of Stockholders of Boston Scientific Corporation (Annual Meeting) will be held on Tuesday, May 5, 2015, at
11:00 a.m. Eastern Time, at the Company's Corporate Headquarters located at 300 Boston Scientific Way, Marlborough, Massachusetts 01752. At this meeting, stockholders will be asked to elect
eleven nominees for director, consider and vote upon an advisory vote to approve named executive officer compensation, ratify the appointment of Ernst & Young LLP as our independent
registered public accounting firm for the 2015 fiscal year, and consider and vote upon a stockholder proposal described in this Proxy Statement, if properly presented at the Annual Meeting. Management
will also report on our performance during fiscal year 2014 and will respond to appropriate questions from stockholders. Our principal executive offices are located at 300 Boston Scientific Way,
Marlborough, Massachusetts 01752, and our telephone number is (508) 683-4000. When used in this Proxy Statement, the terms "we," "us," "our," "Boston Scientific" and "the Company" mean Boston
Scientific Corporation and its businesses and subsidiaries.
Why am I receiving these materials?
In connection with its solicitation of proxies for use at our Annual Meeting, our Board of Directors (Board) (i) has made these materials
available to you via the Internet or, upon your request, via email, or (ii) upon your request, has delivered or will deliver printed versions of these materials to you by mail. As a stockholder
of record of our common stock at the close of business on March 13, 2015, the record date for our Annual Meeting, you are invited to attend the Annual Meeting, and are entitled to and requested
to vote on the items of business described in this Proxy Statement.
Why did I receive a notice in the mail regarding the
Internet availability of proxy materials instead of a full set of printed proxy materials?
Pursuant to rules adopted by the Securities and Exchange Commission (SEC), we are making this Proxy Statement and our Annual Report for the year
ended December 31, 2014 (Annual Report and, together with this Proxy Statement, the proxy materials) available to stockholders electronically via the Internet. Stockholders will be able to
access the proxy materials on the website referred to in the Important Notice of Internet Availability of Proxy Materials (Notice) or request to receive printed copies of the proxy materials and a
proxy card. Instructions on how to access the proxy materials via the Internet or to request a printed copy may be found in the Notice and in this Proxy Statement. We
1
Table of Contents
believe
that this electronic process expedites your receipt of the proxy materials and reduces the cost and environmental impact of printing proxy materials for our Annual Meeting.
On
or about March 24, 2015, stockholders of record and beneficial owners of our common stock at the close of business on March 13, 2015, will be sent a Notice instructing them as to how
to receive their proxy materials via the Internet. The proxy materials will be available on the Internet as of March 24, 2015.
How can I electronically access the proxy materials?
Beginning March 24, 2015, you can access the proxy materials and vote your shares online at
www.proxyvote.com
. The proxy materials are also available on our own website
(
www.bostonscientific.com
).
How can I obtain a full set of printed proxy
materials?
If you prefer to receive paper copies of the proxy materials and a proxy card, you may still do so. You may request printed materials by
(i) calling 1-800-579-1639; (ii) sending an email to
sendmaterial@proxyvote.com
; or (iii) logging onto
www.proxyvote.com
using the
credentials provided on your Notice or proxy card.
Who is entitled to vote at the Annual Meeting?
Stockholders who held shares of our common stock at the close of business on Friday, March 13, 2015, are entitled to vote at the Annual
Meeting. Each share of our common stock is entitled to one vote.
How many shares are eligible to be voted and how many
shares are required to hold the Annual Meeting?
A quorum is required to hold the Annual Meeting and conduct business. The presence at the Annual Meeting, in person or by proxy, of stockholders
holding a majority of our common stock outstanding as of the close of business on Friday, March 13, 2015, the record date, will constitute a quorum for purposes of holding and conducting
business at the Annual Meeting. As of March 13, 2015, we had 1,339,180,800 shares of our common stock outstanding each entitled to one vote at the Annual
Meeting meaning that 669,590,401 shares of common
stock must be represented in person or by proxy to have a quorum. Our common stock is our only outstanding class of voting securities. For purposes of determining whether a quorum exists, broker
non-votes (as described further below) and proxies received but marked "ABSTAIN" will be counted.
What am I voting on?
You are voting on proposals to:
-
1.
-
elect
to the Board eleven nominees for director;
-
2.
-
consider
and vote upon an advisory vote to approve named executive officer compensation;
-
3.
-
ratify
the appointment of Ernst & Young LLP as our independent registered public accounting firm for the 2015 fiscal year;
2
Table of Contents
-
4.
-
consider
and vote upon a stockholder proposal described in this Proxy Statement, if properly presented at the Annual Meeting; and
-
5.
-
consider
and vote upon such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
How does the Board recommend that I vote?
The Board recommends that you vote:
-
1.
-
FOR
the election of each of the eleven director nominees;
-
2.
-
FOR
our named executive officer compensation;
-
3.
-
FOR
the ratification of the appointment of Ernst & Young LLP as our independent registered
public accounting firm for the 2015 fiscal year; and
-
4.
-
AGAINST
the stockholder proposal described in this Proxy Statement.
How do I vote by proxy?
Your vote is very important. Whether or not you plan to attend the Annual Meeting in person, you may give a proxy to be voted at the Annual Meeting
either:
-
-
via the Internet pursuant to the instructions provided in the Notice; or
-
-
if you received printed proxy materials, via the Internet or by telephone or mail pursuant to the instructions provided on the proxy
card.
If
you vote by mail, no postage is required if your proxy card is mailed in the United States. If you properly vote pursuant to the instructions provided in the Notice or properly complete and deliver
your proxy card (whether electronically, by mail or by telephone) and our Inspector of Election receives your instructions in time to vote at the Annual Meeting, your "proxy" (one of the individuals
named on your proxy card) will vote your shares as you have directed.
If you sign and return your proxy card, but do not make specific selections, your proxy will vote your
shares as recommended by the Board. If any other matter is properly presented at the Annual Meeting, including a proposal to postpone or adjourn the meeting, your proxy will vote your shares in
accordance with his or her discretion. At present, the Board knows of no other business that is intended to be brought before or acted upon at the Annual Meeting.
How are votes counted?
In the election of directors, your vote may be cast "FOR" one or more of the nominees or your vote may be "WITHHELD" with respect to one or more of
the nominees. If you sign your proxy card with no further instructions, your shares will be voted in accordance with the recommendation of the Board.
In
the advisory vote to approve named executive officer compensation, your vote may be cast "FOR" or "AGAINST" or you may "ABSTAIN." If you "ABSTAIN," it will not count as a share actually voted with
respect to determining if a majority vote is obtained under our By-Laws and will have no effect on the
3
Table of Contents
determination
of this proposal. If you sign your proxy card with no further instructions, your shares will be voted in accordance with the recommendation of the Board.
In
the ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm, your vote may be cast "FOR" or "AGAINST" or you may "ABSTAIN." If you
"ABSTAIN," it will not count as a share actually voted with respect to determining if a majority vote is obtained under our By-Laws and will have no effect on the determination of this proposal. If
you sign your proxy card with no further instructions, your shares will be voted in accordance with the recommendation of the Board.
In
the stockholder proposal described in this Proxy Statement, your vote may be cast "FOR" or "AGAINST" or you may "ABSTAIN." If you "ABSTAIN," it will not count as a share actually voted with respect
to determining if a majority vote is obtained under our By-Laws and will have no effect on the determination of this proposal. If you sign your proxy card with no further instructions, your shares
will be voted in accordance with the recommendation of the Board.
How many votes are required to approve each proposal?
-
1.
-
Under
our By-Laws our directors are elected by plurality vote. That means that for Proposal 1, the eleven nominees for director named in this Proxy Statement
receiving the most votes from those shares present or represented at the Annual Meeting will be elected as directors. The majority voting policy set forth in our Corporate Governance Guidelines
requires that, in an uncontested election, any nominee for director who receives a greater number of votes "WITHHELD" from his or her election than votes "FOR" his or her election shall promptly
tender his or her resignation from the Board following the certification of the stockholder vote. The Board will then decide whether to accept the resignation (based on the recommendation of the
Nominating and Governance Committee of our Board) within 90 days following certification of the stockholder vote, and will disclose its determination and its reasoning either in a press release
and/or an SEC filing.
-
2.
-
The
affirmative vote of a majority of shares with voting power present in person or represented by proxy and which have actually voted on the proposal is
required to approve, on an advisory basis, our named executive officer compensation. The vote is advisory and non-binding in nature, but the Executive Compensation and Human Resources Committee of our
Board (Compensation Committee) will take into consideration the outcome of the vote when considering future executive compensation arrangements. You may vote "FOR," "AGAINST" or "ABSTAIN." If you
"ABSTAIN," it will be counted for the purpose of determining whether a quorum is present for conducting the Annual Meeting, but it will not count as a share actually voted with respect to determining
if a majority vote is obtained and will have no effect on the determination of this proposal.
-
3.
-
The
affirmative vote of a majority of shares with voting power present in person or represented by proxy and which have actually voted on the proposal is
required to ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the 2015 fiscal year. You may vote "FOR," "AGAINST" or "ABSTAIN." If you
"ABSTAIN," it will be counted for the purpose of determining whether a quorum is present for conducting the Annual Meeting, but it will not count as a share actually voted with respect to determining
if a majority vote is obtained and will have no effect on the determination of this proposal.
-
4.
-
The
affirmative vote of a majority of shares with voting power present in person or represented by proxy and which have actually voted on the proposal is
required to approve
4
Table of Contents
the
stockholder proposal described in this Proxy Statement. You may vote "FOR," "AGAINST" or "ABSTAIN." If you "ABSTAIN," it will be counted for the purpose of determining whether a quorum is present
for conducting the Annual Meeting, but your vote will not count as a share actually voted with respect to determining if a majority vote is obtained and will have no effect on the determination of
this proposal.
At
present, the Board knows of no other matters to be presented for stockholder action at the Annual Meeting.
What is the difference between holding shares as a
stockholder of record and as a beneficial owner?
Most of our stockholders hold their shares through a broker, trustee, bank, other financial intermediary or other nominee rather than directly in
their own name. As summarized below, there are some differences between stockholders of record and beneficial owners.
Stockholders of Record
If your shares are registered directly in your name with our transfer agent, Computershare Shareowner Services, as of the close of business on
Friday, March 13, 2015, you are considered the
stockholder of record
with respect to those shares, and the Notice or proxy materials are being
made available, electronically or otherwise, directly to you by the Company. As the stockholder of record, you have the right to grant your voting proxy directly to the Company or a third party, or to
vote in person at the Annual Meeting. The Company has made available a proxy card or electronic voting means for you to use for voting purposes.
Beneficial Owners
If your shares are held through a brokerage firm, trustee, bank, other financial intermediary or nominee, as of the close of business on Friday,
March 13, 2015, you are considered the beneficial owner of those shares held in street name, and the Notice or proxy materials are being made available, electronically or otherwise, by the
Company to your broker, trustee, bank, other financial intermediary or other nominee (the "intermediary") and they will forward these materials to you, together with a voting instruction form if
furnished via paper copy to your intermediary. As the beneficial owner, you have the right to direct your intermediary on how to vote and are also invited to attend the Annual Meeting; however, since
you are not the
stockholder of record
, you may not vote these shares in person at the Annual Meeting, unless you request, complete and deliver a legal
proxy from your intermediary. If you requested printed proxy materials, your intermediary will enclose a voting instruction form for you to use in directing the intermediary regarding how to vote your
shares.
What discretion does my broker have to vote my shares
held in "street name?"
The NYSE rules allow your broker to vote your shares in its discretion on "routine" proposals when it has not received instructions from you at least
ten days prior to the Annual Meeting. The proposal regarding the ratification of the appointment of our independent registered public accounting firm is a matter considered routine under applicable
rules and, therefore, your broker may vote on your behalf for this matter if you do not otherwise provide instructions. The election of directors, the advisory vote on our named executive officer
compensation, and the stockholder proposal described in this Proxy Statement are not considered routine matters. If you do
not instruct your broker how to vote your shares on the non-routine matters, your broker will not be permitted to vote your shares on such matters. This is referred to as a "broker non-vote."
5
Table of Contents
Broker
non-votes (shares held by brokers that do not have discretionary authority to vote on the matter and have not received voting instructions from their clients) are counted for purposes of
determining whether a quorum is present, but are not counted or deemed to be present, represented or voted for the purpose of determining whether stockholders have approved a proposal. A broker
non-vote will have no effect on the outcome of the non-routine proposals voted on at the Annual Meeting.
How do I vote my 401(k) shares?
If you participate in our 401(k) Retirement Savings Plans, as amended and restated (401(k) Plans), you will receive a single proxy card (together
with the proxy materials) or Notice that covers all shares credited to your plan account(s) and shares that you own of record that are registered in the same name. If your plan account(s) are
registered in different names, you will receive separate proxy cards or Notices for your record and plan holdings. You may vote your shares by following the instructions provided in your proxy card or
Notice and utilizing the credentials provided therein. Your vote will serve to instruct the trustees and fiduciaries of our 401(k) Plans how to vote any shares of our common stock held in our 401(k)
Plans on your behalf. Shares of our common stock held in our 401(k) Plans must be voted on or before 11:59 p.m. Eastern Time on April 30, 2015. The trustee and fiduciaries of our 401(k)
Plans will vote shares for which timely instructions are not received in the same proportion as other plan shares that were voted.
What happens if I don't specify how I want my shares
voted on one or all of the proposals?
If you are the
stockholder of record
and you sign, date and return your proxy and do not mark how you
want to vote, your proxy will be counted as a vote "FOR" all of the nominees for directors, "FOR" our named executive officer compensation, "FOR" the ratification of our independent registered public
accounting firm, Ernst & Young LLP and "AGAINST" the stockholder
proposal described in this Proxy Statement. If you hold your shares in
street name,
please see the discussion on
"What
discretion does my broker have to vote my shares held in 'street name?',"
above.
Can I change my vote or revoke my proxy after I have
already voted or given my proxy?
Yes. If you are a
stockholder of record
, you may change your vote or revoke your proxy at any time
before the proxy is voted at the Annual Meeting. To change your vote, you may:
-
-
mail a written notice "revoking" your earlier vote to Broadridge Financial Solutions, Inc. (Broadridge), 51 Mercedes Way,
Edgewood, NY 11717;
-
-
submit to Broadridge a properly completed and signed proxy card with a later date;
-
-
vote again telephonically or electronically (available until 11:59 p.m. Eastern Time on May 4, 2015); or
-
-
vote in person at the Annual Meeting; however, your attendance at the Annual Meeting alone will not revoke your proxy.
Your
last dated proxy, properly completed and timely received prior to, or vote cast at, the Annual Meeting will be counted.
If
you own your shares in
street name
, please contact your broker or other intermediary for instructions on changing your vote or revoking your proxy.
6
Table of Contents
Can I vote in person at the meeting?
Yes. If you are the
stockholder of record
of the shares, you can vote in person by coming to the
Annual Meeting, and we will give you a ballot or a new proxy card when you arrive with proper identification. However, since a beneficial owner holding shares in
street
name
is not the
stockholder of record
, if you are such a beneficial owner of shares, you may not vote your shares in person at
the Annual Meeting unless you obtain a legal proxy from the broker or other intermediary that holds your shares giving you the right to vote the shares at the Annual Meeting. Please bring the legal
proxy with you to the Annual Meeting. If you plan to attend the Annual Meeting in person, you must provide proper identification. Please visit our website,
www.bostonscientific.com
, for directions to
the Annual Meeting.
Who will count the votes?
Broadridge has been engaged as our independent agent to tabulate stockholder votes and act as Inspector of Election for the meeting.
Is voting confidential?
Proxy instructions, ballots and voting tabulations that identify individual stockholders are handled in a manner that protects your voting privacy.
Your vote will not be disclosed either within the Company or to third parties, except:
-
-
as necessary to meet applicable legal requirements;
-
-
to allow for the tabulation and certification of votes; and
-
-
to facilitate a successful proxy solicitation.
Occasionally,
stockholders provide written comments on their proxy cards, which may be forwarded to the Company's management and the Board.
What happens if the Annual Meeting is adjourned or
postponed?
Your proxy will still be effective and will be voted at the rescheduled Annual Meeting. You will still be able to change or revoke your proxy until
it is voted, provided such new proxy or revocation is properly completed and timely received.
Will any other business be considered or presented at
the Annual Meeting?
Our By-Laws provide that a stockholder may present business to be considered at the Annual Meeting only if proper prior written notice was timely
received by us. Other than the items of business described in this Proxy Statement, our Board is not aware of any other business to be acted upon at the Annual Meeting; however, if any other business
does properly come before the Annual Meeting, the persons named as proxies on the proxy card will vote your shares in accordance with their discretion.
How can I find the results of the Annual Meeting?
We will report the final voting results on a Current Report on Form 8-K filed with the SEC within four business days after the Annual Meeting.
The Form 8-K will be available on the SEC's website,
www.sec.gov
, as well as on our own website,
www.bostonscientific.com
, under the "
Investor Relations
" section.
7
Table of Contents
Who is soliciting my vote pursuant to this Proxy
Statement?
Our Board is soliciting your vote.
Is there a list of stockholders entitled to vote at
the Annual Meeting?
A list of stockholders entitled to vote at the Annual Meeting will be available at the Annual Meeting and for ten days prior to the Annual Meeting,
between the hours of 8:30 a.m. and 5:00 p.m. Eastern Time, at our Corporate Headquarters located at 300 Boston Scientific Way, Marlborough, Massachusetts 01752. If you would like to view
the stockholder list, please contact our Secretary to schedule an appointment by calling (508) 683-4000 or writing to him at 300 Boston Scientific Way, Marlborough, Massachusetts 01752.
8
Table of Contents
Internet Availability of Proxy Materials
Under rules adopted by the SEC, we are furnishing proxy materials to our stockholders primarily via the Internet instead of mailing
printed copies of those materials to each stockholder. On or about March 24, 2015, we will mail to our stockholders (other than those who previously requested electronic or paper delivery) an
Important Notice of Internet Availability of Proxy Materials containing instructions on how to access our proxy materials, including our Proxy Statement and our Annual Report. The Notice also
instructs stockholders on how to vote via the Internet.
This
process is designed to expedite stockholders' receipt of proxy materials, lower the cost of the Annual Meeting and help conserve natural resources; however, if you would prefer to receive printed
proxy materials and a proxy card, please follow the instructions included in the Notice and in this Proxy Statement. If you have previously elected to receive our proxy materials electronically, these
materials will continue to be made available to you via email until you elect otherwise. If you have previously elected to receive printed proxy materials, you will continue to receive these materials
and a proxy card in paper format until you elect otherwise.
Cautionary Statement Regarding Forward-Looking and Other Statements
This Proxy Statement contains forward-looking statements within the meaning of the federal securities laws.
Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "may," "estimate," "intend" and other similar words. These forward-looking statements
are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. Factors that may cause actual
results to differ materially from those contemplated by the statements in this Proxy Statement can be found in our most recent Annual Report on Form 10-K filed with the SEC and in the Quarterly
Report on Form 10-Q that we have filed or will file hereafter under the heading "Risk Factors" and "Safe Harbor for Forward-Looking Statements." The forward-looking statements speak only as of
the date of this Proxy Statement and undue reliance should not be placed on these statements. We disclaim any intention or obligation to publicly update or revise any forward- looking statements. This
cautionary statement is applicable to all forward- looking statements contained in this document.
This Proxy Statement contains statements regarding individual and Company performance objectives and targets. These objectives and targets are disclosed in the limited context
of our compensation plans and programs and should not be understood to be statements of management's future expectations or estimates of future results or other guidance. We specifically caution
investors not to apply these statements to other contexts.
9
Table of Contents
PROPOSAL 1: ELECTION OF DIRECTORS
Summary
Our entire Board is elected annually by our stockholders and currently consists of eleven members. On March 3, 2015, we
announced that our Board elected Charles J. Dockendorff and Stephen P. MacMillan to serve as directors, effective April 1, 2015 for a term expiring at this Annual Meeting.
John
E. Abele, our co-founder, has served at the request of the Board as director emeritus since his retirement from the Board at the 2011 Annual Meeting of Stockholders so that the Board may continue
to avail itself of his wisdom, judgment, and experience. Serving as director emeritus, Mr. Abele may attend Board and committee meetings and participate in discussion of matters that come
before the Board or its committees, but he is not a director and is not entitled to vote upon any such matters.
On
December 30, 2014, Pete M. Nicholas, the Chairman of our Board, in order to facilitate an orderly transition of his responsibilities, notified the Board that he expects to retire from the
Board in 2017 and not stand for re-election at our annual meeting of stockholders in 2017.
Bruce
L. Byrnes, a director of Boston Scientific since August 2009, and Uwe E. Reinhardt, a director of Boston Scientific since May 2002, will be retiring from our Board when their terms end at this
Annual Meeting. We are deeply grateful for the enormous contributions that each of Mr. Byrnes and Dr. Reinhardt has made to our Company, our Board and our stockholders.
Eleven
of our directors have been nominated by our Board, upon the recommendation of our Nominating and Governance Committee, to stand for election at the Annual Meeting for a one-year term, to hold
office until the 2016 Annual Meeting of Stockholders and until their successors have been elected and qualified. The nominees for election at the Annual Meeting are: Nelda J. Connors, Charles J.
Dockendorff, Kristina M. Johnson, Edward J. Ludwig, Stephen P. MacMillan, Michael F. Mahoney, Ernest Mario, N.J. Nicholas, Jr., Pete M. Nicholas, David J. Roux and John E. Sununu.
Each
of the director nominees is willing and able to stand for election at the Annual Meeting, and we know of no reason why any of the nominees would be unable to serve as a director. Should such a
situation arise, however, the Board may designate a substitute nominee or, alternatively, reduce the number of directors to be elected. If a substitute nominee is selected, the persons named as
proxies will vote for that substitute nominee. Any vacancies not filled at the Annual Meeting may be filled by the Board.
Director Nominees
The biographies of each of the nominees are listed below and contain information regarding the person's service as a director,
business experience, public company director positions currently held or held at any time during the last five years, information regarding involvement in certain legal or administrative proceedings
(if applicable) and the experiences, qualifications, attributes or skills that caused the Nominating and Governance Committee and the Board to determine that the person should serve as a director in
light of our business and structure. Each of the director nominees listed below exemplifies how our Board values professional experience in business, education, policy and governmental fields as well
as strong moral character and diversity in terms of viewpoint as well as age, ethnicity and gender. Our Board believes that these strong backgrounds and sets of skills provide it, as a whole, with a
strong foundation of technical expertise and a wealth of diverse experience in a wide variety of areas.
10
Table of Contents
Nelda J. Connors
|
|
|
|
|
Nelda J. Connors, age 49, has been a director of Boston Scientific since December 2009. Ms. Connors is the founder, Chairwoman and Chief Executive Officer of Pine Grove Holdings, LLC, which invests in
companies that offer original equipment, manufactured and remanufactured products, and aftermarket services. She served as President and Chief Executive Officer of Atkore International Inc. from December 2010 until June 2011. Atkore, formerly
the Electrical and Metal Products division of Tyco International, became a privately-held company in December 2010. Ms. Connors served as President of this Tyco division from 2008 through 2010. Prior to joining Tyco, she served as Vice President
at Eaton Corporation from 2002 to 2008, where she held several positions in operations, continuous improvement, and general management. Prior to joining Eaton, Ms. Connors was employed in a number of executive and management capacities in the
automotive industry. Her work over twenty-five years has involved responsibilities in the U.S., Europe, and Asia. Ms. Connors is a Class B director of the Federal Reserve Bank of Chicago, a director of Blount International, Inc.,
Vesuvius plc and Echo Global Logistics, Inc., and, was previously a trustee for the Peggy Notebaert Nature Museum and the Museum of Contemporary Arts. She previously served on the Board of Atkore. Ms. Connors holds B.S. and M.S.
degrees in mechanical engineering from the University of Dayton. Ms. Connors' qualifications to serve our Board include her executive leadership skills and her experience in the areas of operations and financial management, quality, engineering
and business strategy, as well as her knowledge of public company matters resulting from her service on other public company boards.
|
Charles J. Dockendorff
|
|
|
|
|
Charles J. Dockendorff, age 60, will be a director of Boston Scientific, effective April 1, 2015. He was Executive Vice President and Chief Financial Officer of Covidien plc, a publicly traded medical
device and supplies company, a position he held at Covidien and its predecessor, Tyco Healthcare, from 1995 to 2015. Mr. Dockendorff joined the Kendall Healthcare Products Company, the foundation of the Tyco Healthcare business, in 1989 as
Controller and was named Vice President and Controller in 1994. He was appointed CFO of Tyco Healthcare in 1995. Prior to joining Kendall/Tyco Healthcare, Mr. Dockendorff was the Chief Financial Officer, Vice President of Finance and Treasurer
of Epsco Inc. and Infrared Industries, Inc. In addition, Mr. Dockendorff worked as an accountant for Arthur Young & Company (now Ernst & Young) and the General Motors Corporation. Mr. Dockendorff is a director of
Haemonetics Corporation and Keysight Technologies, Inc. Mr. Dockendorff holds a bachelor's degree in accounting from the University of Massachusetts at Amherst and a M.S. in finance from Bentley College. Mr. Dockendorff's
qualifications to serve on our board include his executive leadership experience at public medical device companies, as well as his extensive expertise in accounting, finance and business strategy.
|
11
Table of Contents
Kristina M. Johnson, Ph.D.
|
|
|
|
|
Kristina M. Johnson, Ph.D., age 57, has been a director of Boston Scientific since January 2011. She previously served as a director from April 2006 to May 2009. Dr. Johnson has served as the Chief Executive
Officer of Enduring Hydro, LLC, an energy consulting firm, since January 2011. From May 2009 to October 2010, Dr. Johnson served as Under Secretary of Energy at the U.S. Department of Energy. Prior to this, Dr. Johnson was Provost and
Senior Vice President of Academic Affairs at The Johns Hopkins University from 2007 to 2009 and Dean of the Pratt School of Engineering at Duke University from 1999 to 2007. Previously, she served as a professor in the Electrical and Computer
Engineering Department, University of Colorado and as director of the National Science Foundation Engineering Research Center for Optoelectronics Computing Systems at the University of Colorado, Boulder. Dr. Johnson is a director of AES
Corporation and Cisco Systems, Inc. She previously served on the boards of directors of AES Corporation from 2004 until 2009, Nortel Networks from 2006 to 2009 and Minerals Technologies from 2000 until 2009. Dr. Johnson was a Fulbright
Faculty Scholar in the Department of Electrical Engineering at the University of Edinburgh, Scotland and a NATO Post-Doctoral Fellow at Trinity College, Dublin, Ireland. Dr. Johnson received B.S., M.S. and Ph.D. degrees in electrical engineering
from Stanford University. Dr. Johnson's qualifications to serve on our Board include her expertise in science, technology, business, education and government as well as her leadership experience as Provost and Dean of nationally recognized
academic institutions. In addition, Dr. Johnson's service on other public company boards contributes to her knowledge of public company matters.
|
Edward J. Ludwig
|
|
|
|
|
Edward J. Ludwig, age 63, has been a director of Boston Scientific since March 2014. Mr. Ludwig is the former Chairman of the Board of Becton, Dickinson and Company ("BDX"), a global medical technology company,
having served in that position from February 2002 through June 2012. He also served as BDX's Chief Executive Officer from January 2000 to September 2011 and as its President from May 1999 to December 2008. Mr. Ludwig joined BDX as a Senior
Financial Analyst in 1979. Prior to joining BDX, Mr. Ludwig served as a senior auditor with Coopers and Lybrand (now PricewaterhouseCoopers), where he earned his CPA, and as a financial and strategic analyst at Kidde, Inc. Mr. Ludwig
serves as Lead Director on Aetna Inc.'s Board of Directors and chairs its Finance Committee and is a member of the Board of Directors of Xylem, Inc. Additionally, Mr. Ludwig serves as Vice Chair of the Board of Trustees of the
Hackensack University Medical Center Network. Mr. Ludwig received a B.A. degree in economics and accounting from The College of the Holy Cross and a M.B.A. degree from Columbia University. Mr. Ludwig's qualifications to serve on our Board
include his executive leadership experience, including his service as a director and executive of a public medical technology company, along with his extensive expertise in business strategy, finance, management and manufacturing.
|
12
Table of Contents
Stephen P. MacMillan
|
|
|
|
|
Stephen P. MacMillan, age 51, will be a director of Boston Scientific, effective April 1, 2015. He is currently the President and CEO of Hologic, Inc., a position he has held since December 2013. Prior to
assuming his role with Hologic, Mr. MacMillan was the Chief Executive Officer of sBioMed, LLC, from October 2012 to December 2013. From 2003 to 2012, Mr. MacMillan served in various roles at Stryker Corporation, including Chief
Operating Officer from June 2003 to January 2005, President from June 2003 to February 2012, Chief Executive Officer from January 2005 to February 2012 and Chairman from January 2010 to February 2012. Prior to 2003, Mr. MacMillan was a senior
executive with Pharmacia Corporation where he oversaw five global businesses. Prior to joining Pharmacia, Mr. MacMillan spent 11 years with Johnson & Johnson in a variety of senior roles both in the U.S. and Europe, including
President of the joint venture between Johnson & Johnson and Merck. Mr. MacMillan began his career with Procter and Gamble in 1985. Additionally, Mr. MacMillan currently serves on the board of directors of Alere Inc. and he
served on the board of directors of Texas Instruments Inc. from 2008 to 2012. Mr. MacMillan received a Bachelor of Arts degree in Economics from Davidson College and is a graduate of Harvard Business School's Advanced Management Program.
Mr. MacMillan's qualifications to serve on our Board include his executive leadership experience, including his service as a director and chief executive of public medical technology companies.
|
Michael F. Mahoney
|
|
|
|
|
Michael F. Mahoney, age 50, became our President, Chief Executive Officer and director in November 2012. He served as President of the Company from October 17, 2011 until assuming his current role. As President
of the Company, he was specifically responsible for our Cardiac Rhythm Management and Endoscopy businesses, as well as certain corporate functions. Prior to joining the Company, he was Worldwide Chairman of the Medical Devices and Diagnostics
division of Johnson & Johnson from January 2011 to September 2011, overseeing 50,000 employees and seven franchises. Prior to assuming this position, Mr. Mahoney served as Worldwide Group Chairman of Johnson & Johnson's DePuy
franchise, an orthopedics and neurosciences business, from April 2007 through January 2011. From January 2001 through March 2007, Mr. Mahoney served as President and Chief Executive Officer of Global Healthcare Exchange (GHX), a provider of
supply chain solutions and services that brings together hospitals, manufacturers, distributors and GPOs. Mr. Mahoney began his career at General Electric Medical Systems, where he spent 12 years, culminating in the role of General
Manager of the Healthcare Information Technology business. Mr. Mahoney earned a B.B.A. in Finance from the University of Iowa and a M.B.A. from Wake Forest University. Mr. Mahoney's qualifications to serve on our Board, in addition to being
our Chief Executive Officer, include his management experience leading complex organizations in medical device and other healthcare-related businesses, expertise in building strong leadership teams, developing international markets, and a proven
ability to execute successful business strategies and drive operational excellence.
|
13
Table of Contents
Ernest Mario, Ph.D.
|
|
|
|
|
Ernest Mario, age 76, has been a director of Boston Scientific since October 2001. Since August 2007, Dr. Mario has served as the Chairman of Capnia, Inc., a pharmaceutical company. From August 2007 until
February 2014, he also served as the Chief Executive Officer of Capnia, Inc. From April 2003 to August 2007, Dr. Mario was Chairman of Reliant Pharmaceuticals and also served as its Chief Executive Officer from 2003 to 2006. Prior to
joining Reliant, he was the Chairman and Chief Executive Officer of IntraBiotics Pharmaceuticals, Inc., a biopharmaceutical company, and its predecessor, Apothogen, Inc., from January 2002 to April 2003. From 1993 to 1997, Dr. Mario
served as Chairman and Chief Executive Officer of ALZA Corporation, a research based pharmaceutical company with leading drug delivery technologies, and Co-Chairman and Chief Executive Officer from 1997 to 2001. Prior to joining ALZA, Dr. Mario
served as the Chief Executive of Glaxo Holdings plc from 1989 to 1993 and as Deputy Chairman and Chief Executive from 1992 to March 1993. Dr. Mario presently serves on the boards of directors of Celgene Corporation, TONIX Pharmaceuticals
Holdings Corp., XenoPort, Inc., Chimerix, Inc., Capnia, Inc. and Kindred Biosciences, Inc. He previously served as a member of the board of directors of Maxygen, Inc. and Vivus, Inc. and was a Trustee of Duke University
from 1988 to 2007 and Chairman of the Board of the Duke University Health System, which he chaired from its inception in 1996 until he retired in 2007. He is Chairman of the American Foundation for Pharmaceutical Education and serves as an advisor to
The Ernest Mario School of Pharmacy at Rutgers University. Dr. Mario holds a B.S. in Pharmacy from Rutgers University, and a M.S. and a Ph.D. in Physical Sciences from the University of Rhode Island. He also holds honorary doctorates from
Rutgers University and the University of Rhode Island. In 2007, Dr. Mario was awarded the Remington Honor Medal by the American Pharmacists Association, the pharmacy profession's highest honor. Dr. Mario's qualifications to serve our Board
include his strong executive leadership experience and specifically his experience as an active Chief Executive Officer. In addition, Dr. Mario has successfully led several pharmaceutical companies over the last several decades. He has extensive
experience in financial and operations management, risk oversight, quality and business strategy as a result of this experience, as well as his membership on public company boards.
|
14
Table of Contents
N.J. Nicholas, Jr.
|
|
|
|
|
N.J. Nicholas, Jr., age 75, has been a director of Boston Scientific since October 1994 and is a private investor. Previously, he served as President of Time Inc. from September 1986 to May 1990 and Co-Chief
Executive Officer of Time Warner, Inc. from May 1990 until February 1992. Mr. N.J. Nicholas is a director of Time Warner Cable, Inc. and he previously served as a director of Xerox Corporation. He has also served as a member of the
President's Advisory Committee for Trade Policy and Negotiations and the President's Commission on Environmental Quality. Mr. N.J. Nicholas is a member of the Council of Foreign Relations. He is also a member of the board of advisors of The
Nicholas Institute for Environmental Policy Solutions at Duke University. Mr. N.J. Nicholas received an A.B. degree from Princeton University and an M.B.A. degree from Harvard Business School. He is the brother of Pete M. Nicholas, Chairman of
the Board. Mr. N.J. Nicholas' qualifications to serve on our Board include his executive experience as President and Co-Chief Executive Officer of Time Inc. and Time Warner, Inc. He shares his extensive expertise in the areas of
business strategy, risk oversight and financial management with our Board, which is further complemented by his active participation on public and private company boards.
|
Pete M. Nicholas
|
|
|
|
|
Pete M. Nicholas, age 73, our co-founder, has been Chairman of the Board since February 1995. He has been a director since 1979 and served as our Chief Executive Officer from 1979 to March 1999 and Co-Chairman of the
Board from 1979 to 1995. Prior to joining Boston Scientific, he was corporate director of marketing and general manager of the Medical Products Division at Millipore Corporation, a medical device company, and served in various sales, marketing and
general management positions at Eli Lilly and Company. He is also a Trustee Emeritus of the Board of Trustees of Duke University. Mr. Pete M. Nicholas is a Fellow of the American Academy of Arts and Sciences and Vice Chairman of the Trust
for that organization. He also serves on several for profit and not-for-profit boards including CEOs for Fundamental Change in Education, Massachusetts High Technology Council, and the Boys and Girls Clubs of Boston. After college, Mr. Pete M.
Nicholas served as an officer in the U.S. Navy, resigning his commission as lieutenant in 1966. Mr. Pete M. Nicholas received a B.A. degree from Duke University, and an M.B.A. degree from The Wharton School of the University of Pennsylvania. He
is the brother of Mr. N.J. Nicholas, one of our directors. Mr. Pete M. Nicholas is uniquely qualified to serve our Board due to his institutional knowledge of our Company as its co-founder and former Chief Executive Officer. He has
expertise in the areas of general executive management, business strategy and risk management and oversight, and is an active participant in the medical device community.
|
15
Table of Contents
David J. Roux
|
|
|
|
|
David J. Roux, age 58, has been a director of Boston Scientific since January 2014. Mr. Roux is a co-founder and Senior Director of Silver Lake, a private equity firm focused on technology investing. He was
formerly Chairman and Chief Executive Officer of Liberate Technologies, Executive Vice President at Oracle Corporation and Senior Vice President at Lotus Development. Mr. Roux served as a member of the boards of directors of Avaya Inc. from
December 2008 until December 2012, Avaya Holdings Corp. from January 2007 until December 2012, Serena Software, Inc. from March 2006 until March 2011 and Intelsat S.A. from May 2010 until January 2012. Mr. Roux holds an M.B.A. from
Harvard Business School and an M. Phil. from King's College, Cambridge University. He is a graduate of Harvard College. Mr. Roux's qualifications to serve on the Board include his extensive experience regarding operations, management and
business strategy, his financial expertise, and his background as an entrepreneur, executive and director.
|
John E. Sununu
|
|
|
|
|
John E. Sununu, age 50, has been a director of Boston Scientific since April 2009. From 2003 to 2009, Senator Sununu served as a U.S. Senator from New Hampshire. He was a member of the Committees on Banking, Commerce,
Finance and Foreign Relations, and he was appointed the Congressional Representative to the United Nations General Assembly. Before his election to the Senate, Senator Sununu served three terms as a Member of the U.S. House of Representatives from
New Hampshire's 1st District from 1996 to 2002. He was Vice Chairman of the Budget Committee and a member of the Appropriations Committee. During his twelve years in Congress, he drafted and helped pass several important pieces of legislation,
including the Internet Tax Freedom Act, the Survivors Benefit Act and the New England Wilderness Act. Prior to serving in Congress, Senator Sununu served as Chief Financial Officer for Teletrol Systems, a manufacturer of building control systems. He
serves on the board of directors of Time Warner Cable, Inc. He holds B.S. and M.S. degrees in Mechanical Engineering from the Massachusetts Institute of Technology and an M.B.A. from Harvard Business School. Among other qualifications, Senator
Sununu complements our Board with his experience in government and corporate leadership. Senator Sununu provides important insights on government relations, public policy and other matters relevant to our Company due to his extensive experience in
both the public and private industry sectors.
|
OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT YOU VOTE
"FOR" THE ELECTION OF ALL ELEVEN OF THESE NOMINEES FOR DIRECTOR.
16
Table of Contents
CORPORATE GOVERNANCE
Overview
To guide the operation and direction of the Board and its committees, our Board has established our Corporate Governance Guidelines,
charters for its standing committees and our Code of Conduct to reflect our commitment to good corporate governance and to comply with Delaware law, the rules and listing standards of the NYSE, the
rules and regulations of the SEC and other legal requirements. These materials are available under "
Corporate Governance
" in the
"
Investor
Relations
" section of our website at
www.bostonscientific.com
. These materials are also available in print free of charge to
stockholders, upon written request to Boston Scientific Corporation, Investor Relations, 300 Boston Scientific Way, Marlborough, Massachusetts 01752.
Our
Board believes that good corporate governance is fundamental to the overall success of our business. To that end, our Board evaluates our corporate governance practices in light of applicable
changes in Delaware law, the rules and listing standards of the NYSE, the rules and regulations of the SEC and the rules and regulations under the Internal Revenue Code of 1986, as amended (Internal
Revenue Code), as well as best practices suggested by recognized governance authorities, and makes modifications to our corporate governance practices that it determines are warranted.
Director Independence
Under the NYSE's Corporate Governance Standards, a majority of the Board must qualify as independent directors. However, our
Corporate Governance Guidelines require that a significant majority of the Board qualify as independent directors. The NYSE Corporate Governance Standards define specific relationships that disqualify
directors from being independent and further require that for a director to qualify as independent, the Board must affirmatively determine that the director has no material relationship with our
Company (either directly or as a partner, stockholder or officer of an organization that has a relationship with our Company).
In
making determinations regarding independence, the Board applies the NYSE standards and broadly considers all relevant facts and circumstances known to it. In addition, in making independence
determinations with respect to directors who will serve on the Compensation Committee, the Board considers all factors specifically relevant to determining whether a director has a relationship with
our Company that is material to that director's ability to be independent from management in connection with the duties of a Compensation Committee member, including, but not limited to:
(i) the source of compensation of such director, including any consulting, advisory or other compensatory fee paid by our Company to such director and (ii) whether such director is
affiliated with our Company, a subsidiary of our Company or an affiliate of a subsidiary of our Company as required by the NYSE independence standards for compensation committee members.
The
Board has determined that the following directors are independent under the independence standards set forth in the NYSE Corporate Governance Standards: Bruce L. Byrnes, Nelda J. Connors, Charles
J. Dockendorff, Kristina M. Johnson, Edward J. Ludwig, Stephen P. MacMillan, Ernest Mario, N.J. Nicholas, Jr., Pete M. Nicholas, Uwe E. Reinhardt, David J. Roux and John E. Sununu.
The
Board monitors its compliance with NYSE requirements for director independence on an ongoing basis, including through an annual review of director questionnaires and consideration of transactions
and relationships between each director or any member of his or her immediate family and the
17
Table of Contents
Company
as well as other relevant facts and circumstances. The Board and the Nominating and Governance Committee considered the directors' responses to a questionnaire asking about their relationships
with the Company (and their immediate family members' relationships with the Company) and other potential conflicts of interest, as well as material provided by management related to transactions,
relationships, or arrangements between the Company and the directors or parties related to the directors. The Board made its determination as to whether any relationship between a director and our
Company is a material relationship based on the facts and circumstances of the relationship, the amounts involved in the relationship, the director's interest in such relationship, if any, and such
other factors as the Board, in its judgment, deemed appropriate.
In
making its determinations regarding independence, the Board and the Nominating and Governance Committee approved an arrangement between the Company and Mr. Pete M. Nicholas with respect to
the provision of office space to him in accord with his founder's benefits. This relationship was determined by the Board not to affect the Mr. Pete M. Nicholas' independence. For additional
information regarding the arrangement between the Company and Mr. Pete M. Nicholas, please see the "
Related Party Transactions
" section below.
Director Nomination Process
The Nominating and Governance Committee is responsible for determining the appropriate skills and characteristics required of new
Board members in the context of the current make-up of the Board. In so doing, the Nominating and Governance Committee considers, with input from the Board, those factors it deems appropriate, such as
independence, experience, strength of character, judgment, technical skills, diversity, age and the extent to which the individual would fill a present need on the Board. The aim is to assemble a
Board that is strong in its collective knowledge and that consists of individuals who bring a variety of complementary attributes and who, taken together, have the appropriate skills and experience to
oversee the Company's business. The Nominating and Governance Committee considers diversity as one of a number of factors in identifying nominees for director. It does not, however, have a formal
policy in this regard. The Nominating and
Governance Committee views diversity broadly to include diversity of experience, skills and viewpoint as well as traditional diversity concepts such as ethnicity and gender.
Director
nominees must, at a minimum, meet the general criteria outlined in our Corporate Governance Guidelines. Generally, directors should be individuals who have succeeded in their particular field
and who demonstrate integrity, reliability, knowledge of corporate affairs and an ability to work well with others, and should also satisfy at least one of the following
criteria:
-
-
demonstrated management ability at senior levels in successful organizations;
-
-
current or recent employment in positions of significant responsibility and decision making;
-
-
expertise in leading rapidly growing multi-national organizations; or
-
-
current and prior experience related to anticipated board and committee responsibilities in other areas of importance to our Company.
The
Nominating and Governance Committee receives suggestions for new directors from a number of sources, including Board members and our Chief Executive Officer. It also may, in its discretion, employ
a third-party search firm to assist in identifying candidates for director.
18
Table of Contents
The
Nominating and Governance Committee will also consider recommendations for Board membership submitted by our stockholders and other sources in accordance with the advance notice provisions of our
By-Laws. The qualifications of candidates recommended by stockholders will be reviewed and considered by the Nominating and Governance Committee with the same degree of care and consideration as
candidates for nomination to the Board submitted by Board members and our Chief Executive Officer.
The
full Board is responsible for final approval of new director candidates, as well as the nomination of existing directors for reelection. With respect to existing directors, prior to making its
recommendation to the full Board, the Nominating and Governance Committee, in consultation with the Chairman of the Board, reviews each director's continuation on the Board as a regular part of the
annual nominating process.
Under
the advance notice provisions of our By-Laws, director nominations and proposals to bring any other business before the 2016 Annual Meeting of Stockholders by our stockholders must be received
by our Secretary at our principal executive offices on or before November 25, 2015. Director nominations by our stockholders must also satisfy the other procedures set forth in the advance
notice provisions of our By-Laws. Should you wish to submit a director recommendation or nomination, have it addressed to our Secretary at Boston Scientific Corporation, 300 Boston Scientific Way,
Marlborough, Massachusetts 01752.
Code of Conduct
We maintain a Code of Conduct, which has been approved by our Board, to ensure that our directors, employees, and officers, including
our Chief Executive Officer and Chief Financial Officer, understand the basic principles that govern our corporate conduct. The Code of Conduct is available under "
Corporate
Governance
" in the "
Investor Relations
" section of our website at
www.bostonscientific.com
. A stockholder may request a copy of the
Code of Conduct by contacting our Secretary at Boston Scientific Corporation, 300
Boston Scientific Way, Marlborough, Massachusetts 01752. Any waivers or substantive amendments of the Code of Conduct will be disclosed on our website at
www.bostonscientific.com
.
Chief Executive Officer Succession
Pursuant to our Corporate Governance Guidelines, the Nominating and Governance Committee reports to the full Board periodically on
succession planning for our Chief Executive Officer (and other executive officers, as appropriate). Our Chief Executive Officer makes available to the Board, and meets with the Nominating and
Governance Committee at least once per year to discuss, his recommendations and evaluations of potential successors to his position, including in the event of an unexpected emergency, and reviews
development plans, if any, recommended for such individuals.
Board Leadership Structure
Our Corporate Governance Guidelines require that the offices of Chief Executive Officer and Chairperson of the Board be held by
separate individuals, and that the Chairperson of the Board not be an executive of the Company. Our Chairman of the Board is Mr. Pete M. Nicholas, our co-founder and former Chief Executive
Officer. Our Chief Executive Officer is Mr. Mahoney. Our Board believes that the separation of the critical roles of Chief Executive Officer and Chairperson of the Board best serves our Company
at this time because it allows Mr. Mahoney to focus on his role as President and Chief
19
Table of Contents
Executive
Officer and provide leadership over our day-to-day operations, while Mr. Pete M. Nicholas focuses on leadership of the Board.
Risk Oversight
Our Board oversees an enterprise-wide approach to risk management, designed to support the achievement of our strategic and
organizational objectives, to improve long-term organizational performance and to enhance stockholder value. A fundamental part of risk oversight is to understand the individual risks our Company
faces, the steps management is taking to manage those risks, including the framework used by management for the coordinated oversight, control, and continuous improvement of processes used to manage
risk, and to assess management's appetite for risk. It is management's responsibility to manage risk and bring to the Board's attention material risks facing our Company. Our Board receives regular
reports from management on matters relating to strategic and operational initiatives, financial performance and legal developments, which are each integrated with enterprise-risk exposures. The
involvement of the full Board in approving our strategic plan is a key part of its assessment of the risks inherent in our corporate strategy.
While
the Board has the ultimate responsibility for risk oversight, each committee of the Board also oversees risk to the extent that it relates to the committee's responsibilities, as outlined
below:
-
-
The Audit Committee focuses on financial risk, including internal controls, legal and regulatory risks, as well as compliance risks of
a financial nature, including those related to federal healthcare programs and healthcare providers, and receives an annual risk assessment report from our internal auditors.
-
-
The Finance Committee focuses on risk exposure and risk management strategies associated with our strategic initiatives, current and
potential investments, as well as cash, debt and equity management and our ongoing ability to access capital markets. In addition, the Finance Committee consults with the Audit Committee, as
necessary, to share information pertinent to the Audit Committee's consideration and oversight of the Company's risk and risk management programs and policies.
-
-
The Compliance and Quality Committee assists the Board in fulfilling its oversight responsibility with respect to compliance risks of
a non-financial nature, including those related to federal healthcare programs and healthcare providers, and regulatory, quality and product safety issues that affect us. The Compliance and Quality
Committee and the Audit Committee together receive an annual risk assessment from our global compliance group.
-
-
The Executive Compensation and Human Resources Committee evaluates and sets compensation programs that encourage decision-making
predicated upon a level of risk consistent with our business strategy. The Executive Compensation and Human Resources Committee also reviews compensation and benefit plans affecting employees in
addition to those applicable to executive officers.
-
-
The Nominating and Governance Committee oversees governance and succession risk, including Board and Chief Executive Officer
succession, and evaluates director skills and qualifications to ensure the appropriate appointment of particular directors to our standing committees based upon the needs of that committee. Each
committee makes reports in its respective area of responsibility to the Board at the next regularly scheduled Board meeting immediately following the committee meeting. Such reports may identify
current risks
20
Table of Contents
As
previously discussed, our Corporate Governance Guidelines currently require that the offices of Chief Executive Officer and Chairperson of the Board be held by separate individuals, and that the
Chairperson of the Board not be an executive of the Company. We believe that this leadership structure helps facilitate the Board's enterprise-wide risk oversight function. For example, our Chief
Executive Officer, in his dual role as the member of management responsible for setting the overall strategic direction of our Company and as a member of the Board, is able to provide valuable insight
to the Board concerning the risks facing our Company, while our Chairman leads the Board's risk oversight responsibilities.
Communications with the Board
Stockholders and other interested parties who wish to communicate directly with any member of our Board, or our non-management
directors as a group, may do so by writing to the Board of Directors or Non-Management Directors, Boston Scientific Corporation, c/o General Counsel, 300 Boston Scientific Way, Marlborough,
Massachusetts 01752 or by contacting the Board via email at BSCboardofdirectors@bsci.com or non-management directors via email at non-managementdirectors@bsci.com. The Board has authorized the office
of our General Counsel to review and organize, but not screen, communications from stockholders and other interested parties and deliver them to the Board or non-management directors, as applicable.
We do screen commercial solicitations for appropriateness.
Board and Committee Service Limitation
Without the approval of the Nominating and Governance Committee, no director may sit on more than four public company boards
(including our Board) and our Chief Executive Officer may not sit on more than one public company board (in addition to our Board). No member of the Audit Committee may serve on the audit committee of
more than three public companies, including our Company. All of our Board members have complied with these limitations or procedures.
Related Party Transactions
Our Board has adopted a written related party transaction policy to monitor transactions, arrangements or relationships in which the
Company and any of the following
have an interest: (i) any person who is or was (since the beginning of fiscal year 2014, even if they do not presently serve in that role) an executive officer or director or director nominee;
(ii) any person who is a director emeritus; (iii) any person or entity who holds more than a 5% beneficial ownership of our common stock; (iv) any immediate family member of any
of the foregoing; or (v) any entity in which any of the foregoing persons is employed or is a general partner or principal or acts in any similar position in which such person or persons
collectively have a 10% or greater beneficial ownership interest. The policy covers any related party transaction that meets the minimum threshold for disclosure under relevant SEC rules (generally,
transactions involving amounts exceeding $120,000 in which a related person has a direct or indirect material interest).
Related
party transaction oversight is the responsibility of our Nominating and Governance Committee. Our General Counsel is responsible for identifying any potential related party transactions and,
if he determines that an existing or proposed transaction constitutes a related party transaction under the
21
Table of Contents
policy,
he will provide relevant details and an analysis of the related party transaction to the Nominating and Governance Committee. The General Counsel provides an annual summary to the Nominating
and Governance Committee of all transactions or relationships which he considered under this policy, including those that he determined do not constitute a related party transaction. If the General
Counsel has an interest in a potential related party transaction, he will provide all relevant information to the Chairperson of the Nominating and Governance Committee who will provide the
information to the other members of such Committee. The Nominating and Governance Committee reviews relevant information concerning any existing or proposed transaction contemplated by the Company
with an entity that is the subject of a disclosed relationship, and approves or rejects the transaction, with or without conditions or additional protections for the Company. Our related party
transactions policy can be found in our Corporate Governance Guidelines available under "
Corporate Governance
" in the "
Investor
Relations
" section of our website at
www.bostonscientific.com
.
In
December 2013, following approval by the Nominating and Governance Committee, the Company entered into an arrangement with Mr. Pete M. Nicholas to provide office space in accordance with his
founders' benefits to assist him in the performance of his duties as Chairman and other services provided to the Company. This office space is provided to Mr. Pete M. Nicholas at a monthly
invoiced amount of $3,750 (for a total of $45,000 per year), subject to renewal annually at the same rate, and to reimburse up to $50,000 in aggregate amount of documented renovation expenses,
including for the installation of secure telephone- and data-lines and/or such other protections required by the Company.
22
Table of Contents
MEETINGS AND BOARD COMMITTEES
Board Meetings
The Board met six times in fiscal year 2014. In 2014, each incumbent director attended at least 75% of the aggregate of
(1) the total number of meetings of our Board of Directors (held during the period for which he or she has been a director) and (2) the total number of
meetings of all committees of our Board of Directors on which the director served (during the periods that he or she served).
Executive Sessions
Directors who qualify as "non-management directors" within the meaning of the NYSE Corporate Governance Standards meet in executive
sessions without management at every regularly scheduled Board meeting and at such other times as they deem appropriate. Our independent directors meet in executive session at least once annually. In
2014, our independent directors met in executive session without non-independent directors five times. The Chairman of the Board presides at executive sessions of independent directors. In his
absence, the Chairperson of the Nominating and Governance Committee presides at these executive sessions, and, in his absence, the Chairperson of the Audit Committee presides.
Director Attendance at Board, Board Committee and Annual Meetings
Directors are expected to prepare for and use reasonable efforts to participate in all Board meetings and meetings of the committees
on which they serve. The Board and each committee will meet as frequently as necessary to properly discharge their responsibilities, provided that the full Board will meet at least four times per
year. Generally, the Board meets in February, May, July, September/October and December. In addition, directors are expected to use reasonable efforts to attend Annual Meetings of Stockholders. At our
2014 Annual Meeting of Stockholders, eleven of our twelve directors at the time of such meeting were in attendance.
Committees of the Board of Directors
Our Board has standing Audit, Compensation, Nominating and Governance, Finance, and Compliance and Quality Committees. All of the
members of the Audit Committee, Compensation Committee, Nominating and Governance Committee and Compliance and Quality Committee meet the applicable independence requirements of the NYSE and the SEC.
Our Board also establishes special committees from time to time to address specific issues or discrete matters as the need arises.
23
Table of Contents
Board Committee Membership (as of March 1, 2015)
|
|
|
|
|
|
|
|
|
|
|
Name
|
|
Audit
Committee
|
|
Executive
Compensation
and Human
Resources
Committee
|
|
Nominating and
Governance
Committee
|
|
Finance
Committee
|
|
Compliance and
Quality Committee
|
|
Bruce L. Byrnes
|
|
|
|
*
|
|
+
|
|
|
|
|
Nelda J. Connors
|
|
|
|
|
|
|
|
*
|
|
*
|
Kristina M. Johnson
|
|
|
|
*
|
|
|
|
*
|
|
|
Edward J. Ludwig
|
|
*
|
|
*
|
|
|
|
|
|
|
Michael F. Mahoney
|
|
|
|
|
|
|
|
|
|
|
Ernest Mario
|
|
*
|
|
+
|
|
|
|
|
|
|
N.J. Nicholas, Jr.
|
|
|
|
|
|
*
|
|
+
|
|
|
Pete M. Nicholas
|
|
|
|
|
|
|
|
|
|
|
Uwe E. Reinhardt
|
|
+
|
|
|
|
|
|
|
|
*
|
David J. Roux
|
|
|
|
|
|
*
|
|
*
|
|
|
John E. Sununu
|
|
|
|
|
|
*
|
|
|
|
+
|
|
|
|
*
|
|
Committee Member
|
+
|
|
Committee Chair
|
Audit Committee
Our Audit Committee met twelve times during fiscal year 2014, including two joint meetings with other committees of the Board. Our
Audit Committee is comprised of Mr. Ludwig and Drs. Mario and Reinhardt, each of whom meet the independence requirements of the NYSE and the SEC. The Board has also determined that each of
Mr. Ludwig and Drs. Mario and Reinhardt is an "audit committee financial expert" as that term is defined in the rules and regulations of the SEC.
The
Audit Committee is governed by a written charter approved by our Board, which is subject to review on an annual basis. As outlined in its written charter (which is available under
"
Corporate Governance
" in the "
Investor Relations
" section of our website at
www.bostonscientific.com
), the
primary purpose of the Audit Committee is to provide oversight to our accounting and financial reporting processes and
audits of our financial statements. The Audit Committee primarily provides assistance to our Board in the areas of corporate accounting, internal control, independent audit and reporting practices,
and maintains, by way of regularly scheduled meetings, a direct line of communication among our directors, management, our internal auditors and our independent registered public accounting firm. The
Audit Committee appoints our independent registered public accounting firm, evaluates its qualifications, independence and performance, and reviews its reports and other services. In addition, the
Audit Committee pre-approves audit, audit-related and non-audit services performed for us by our independent registered public accounting firm and has the right to terminate our independent registered
public accounting firm. Together with the Compliance and Quality Committee, the Audit Committee assists the Board in its oversight of legal and regulatory compliance. The Audit Committee has sole
oversight over matters of financial compliance, including financial reporting, internal controls and financial risk exposure to the Company resulting from legal and regulatory compliance matters, and
the Compliance and Quality Committee has primary oversight responsibilities as to all other areas of compliance. The Audit Committee Report can be found on page 101 of this Proxy Statement.
24
Table of Contents
Executive Compensation and Human Resources Committee
Our Executive Compensation and Human Resources Committee (the "Compensation Committee") met five times during fiscal year 2014. The
Compensation Committee is, and has been during 2014, comprised exclusively of "independent directors," as defined by the NYSE, including under the heightened independence standards applicable to
compensation committee members, "non-employee directors" within the meaning of Rule 16b-3 promulgated under the Securities Exchange Act of 1934, as amended (Exchange Act), and "outside
directors" within the meaning of Section 162(m) of the Internal Revenue Code.
As
outlined in its written charter (which is available under "
Corporate Governance
" in the "
Investor
Relations
" section of our website at
www.bostonscientific.com
), the Compensation Committee has the authority, among other
things, to:
-
-
set the corporate goals and objectives relative to the Chief Executive Officer's compensation and evaluate the Chief Executive
Officer's performance against those goals and objectives;
-
-
determine and approve our Chief Executive Officer's compensation;
-
-
review, oversee and determine (or make recommendations to the Board regarding) the total compensation package for our other executive
officers;
-
-
review and make recommendations to the Board regarding all new employment, consulting, retirement, severance and change in control
agreements, indemnification agreements and other arrangements proposed for our executive officers and periodically review and evaluate these arrangements for continuing appropriateness;
-
-
review and make recommendations to the Board regarding the compensation of our non-employee directors;
-
-
adopt and periodically review a comprehensive statement of executive compensation philosophy, strategy and principles; and
-
-
review and discuss with management how the Company's compensation policies and programs for all of its employees may create incentives
that can affect risk and the management of that risk, as well as whether the Company's compensation programs are appropriately aligned with the Company's risk management.
The
Compensation Committee may delegate its authority and duties to subcommittees or individual members of the Compensation Committee, as it deems appropriate in accordance with applicable laws and
regulations. The Compensation Committee has delegated authority to our Chief Executive Officer to make equity grants to new hires who are not executive officers within predetermined guidelines. These
grants are reviewed with the Compensation Committee at its next regularly scheduled meeting.
Pursuant
to its charter, the Compensation Committee has sole authority to retain or obtain advice from any compensation consultant, legal counsel or other advisor, as the Compensation Committee deems
appropriate to assist the Committee in the performance of its duties, including the sole authority to approve the compensation and other terms and conditions of retention. Prior to any such retention,
the Compensation Committee considers any factors relevant to such consultant's, legal counsel's or advisor's independence from management, including the factors specified in the NYSE Corporate
25
Table of Contents
Governance
Standards or other listing rules, to evaluate whether the services to be performed will raise any conflict of interest or compromise the independence of such consultant, legal counsel or
advisor. In May 2014, the Compensation Committee renewed the engagement of the independent compensation consultant Frederic W. Cook & Co., Inc. (Cook & Co.) to
provide advisory services, including a market perspective on executive and director compensation matters. During 2014, Cook & Co. provided the following compensation services to the
Compensation Committee:
-
-
reviewed and recommended the peer group of companies used in evaluating executive and director compensation;
-
-
provided information and commentary on executive and director compensation trends as they related to our current compensation
programs;
-
-
collected and analyzed market data on director and executive compensation;
-
-
reviewed and provided commentary and recommendations on our executive and director compensation arrangements in comparison to market;
and
-
-
reviewed and provided commentary on developments regarding proxy disclosures and management proposals concerning executive pay.
For
additional information regarding the services provided by Cook & Co., please see the Compensation Discussion & Analysis section.
In
2014, Cook & Co. and its affiliates did not provide additional services to the Company other than at the request of the Compensation Committee. After review and consultation with
Cook & Co., the Compensation Committee determined that Cook & Co. is independent and there is no conflict of interest resulting from retaining Cook & Co.
currently or during the year ended December 31, 2014. In reaching these conclusions, the Compensation Committee considered the factors set forth in the SEC rules and the NYSE listing standards.
In
accordance with its annual review of its compensation consultant engagement, the Compensation Committee will evaluate the engagement of Cook & Co. in May 2015.
The
Compensation Committee Report can be found on page 68 of this Proxy Statement.
Nominating and Governance Committee
The Nominating and Governance Committee met five times during fiscal year 2014. The Nominating and Governance Committee is comprised
exclusively of non-employee directors, all of whom meet the independence requirements of the NYSE.
As
outlined in its written charter (which is available under "
Corporate Governance
" in the "
Investor
Relations
" section of our website at
www.bostonscientific.com
), the Nominating and Governance Committee has responsibility for
recommending nominees for election and re-election to the Board, ensuring that Board nominees are qualified and consistent with our needs, monitoring significant developments in the law and practice
of corporate governance for directors of public companies, recommending Board committee assignments, reviewing and recommending Board policies and procedures, reviewing political contributions made by
the Company, monitoring compliance with our stock ownership guidelines and with our related party transactions and board service policies, and
26
Table of Contents
overseeing
the Board and each committee of the Board in their annual performance self-evaluations. In addition, the Nominating and Governance Committee is responsible for recommending to the Board
candidates for Chairperson and Chief Executive Officer and for reviewing and assessing a succession plan for the Chief Executive Officer. For additional information on the nomination process conducted
by the Nominating and Governance Committee and our policies regarding stockholder nominations of directors, please see the Corporate Governance section titled "
Director
Nomination Process.
"
The
Nominating and Governance Committee is responsible for reviewing with the Board, on an annual basis, the current size, structure and composition of the Board as a whole, and whether the Company is
being well served by the current directors taking into account the following: the directors' degree of independence; business background, including any areas of particular expertise, such as
accounting or related financial management expertise, marketing or technology; record of service (for incumbent directors), including attendance record; meeting preparation; overall contribution to
the Board; employment status; gender; ethnicity; age; availability for service to us; and our anticipated needs.
Finance Committee
The Finance Committee met six times during fiscal year 2014, including one joint meeting with the Audit Committee. The primary role
of the Finance Committee is to provide a forum within the Board to review our overall financing plans and long-term strategic objectives, as well as our shorter-term acquisition and investment
strategies and how these shorter-term activities fit within our overall business objectives. As outlined in its written charter (which is available under "
Corporate
Governance
" in the "
Investor Relations
" section of our website at
www.bostonscientific.com
), the Finance Committee is charged with
providing Board oversight of the financial management of the Company, approving
strategic transactions for which the Board has delegated authority, making recommendations to the Board regarding larger transactions, and evaluating our financial strategies and policies. The Finance
Committee has responsibility to review periodically with management our strategic business objectives and the manner in which transactional activity can contribute to the achievement of those
objectives, and to review with management on a regular basis contemplated strategic opportunities. The Finance Committee conducts periodic reviews of completed transactions for the purposes of
assessing the degree of success achieved, testing the extent to which the projections and other assumptions relied upon in approving past transactions have borne out, identifying the factors
differentiating more successful transactions from less successful ones and evaluating the strategic contributions resulting from these transactions. The Finance Committee is further charged with
conducting periodic reviews of our cash investments and cash management policies, debt ratings and global financing objectives and strategies, including the review and approval of certain borrowing
arrangements, capital expenditures and dispositions, and activities that may impact our capital structure.
Compliance and Quality Committee
The Compliance and Quality Committee met six times during fiscal year 2014, including one joint meeting with the Audit Committee. The
primary role of the Compliance and Quality Committee is to oversee and evaluate our global compliance programs and practices and our quality compliance and quality assurance systems and initiatives.
As outlined in its written charter (which is available under "
Corporate Governance
" in the "
Investor
Relations
" section of our website at
www.bostonscientific.com
), the Compliance and Quality Committee's role includes oversight
of matters related to compliance with federal healthcare program requirements and other compliance obligations, the systems in place to maintain, and identify deviations from, our quality compliance
and control standards, and our efforts to meet or exceed our compliance and quality assurance standards. The
Compliance and Quality Committee reviews and discusses with senior management the adequacy and effectiveness of our
27
Table of Contents
global
compliance program, including compliance monitoring, audits and investigations, and third-party reviews required under an agreement with the Department of Health and Human Services, and our
compliance and quality assurance systems and initiatives. The Compliance and Quality Committee reviews periodic reports regarding any deviations from our standards and practices. The Compliance and
Quality Committee also reviews correspondence from any external quality assurance inspectors, such as the Food and Drug Administration, or global compliance monitors, such as the Office of Inspector
General of the Department of Health and Human Services, and discusses with senior management our responses to those communications. In addition, the Compliance and Quality Committee monitors, with
senior management, training and education programs for our employees. The Compliance and Quality Committee's oversight responsibilities over global compliance programs and practices are shared with
the Audit Committee in that the Audit Committee has sole oversight responsibility as to matters of financial compliance and the Compliance and Quality Committee has primary oversight responsibilities
as to all other areas of compliance. These committees met jointly once during 2014. The Compliance and Quality Committee recommends to the Board any actions it deems necessary or appropriate to
improve the effectiveness of our global compliance and quality control systems and initiatives.
Compensation Committee Interlocks and Insider Participation
The members of our Compensation Committee during 2014 were Messrs. Byrnes and Ludwig, Drs. Johnson and Mario and
Ms. Bartlett. None of these Compensation Committee members is or has ever been an officer or employee of our Company. During 2014, no member of the Compensation Committee had a relationship
that must be described under the SEC rules relating to disclosure of related person transactions. In 2014, none of our executive officers served on the board of directors or compensation committee (or
other board committee performing equivalent functions) of any entity that had one or more of its executive officers serving on the Board or the Compensation Committee of the Company.
28
Table of Contents
DIRECTOR COMPENSATION
Elements of Director Compensation
The Compensation Committee evaluates the appropriate level and form of compensation for non-employee directors at least annually and
recommends changes to our Board when appropriate. Non-employee directors receive a combination of cash and equity compensation for their service on our Board. To determine the appropriate level of
compensation for 2014, the
Compensation Committee relied on the consulting services of Cook & Co., as well as publicly available data describing director compensation in our peer group companies. The Compensation
Committee also took into consideration the significant amount of time and dedication required by our directors to fulfill their duties on our Board and Board committees as well as the need to continue
to attract highly qualified candidates to serve on our Board. Our director compensation is as follows:
Non-Employee Directors
2014 Compensation
In 2014, we compensated our non-employee directors (other than the Chairman of the Board) as described
below:
-
-
an annual cash retainer of $90,000 (increased from $75,000 effective as of the beginning of the 2014 Board term, which commenced at
the 2014 Annual Meeting of Stockholders);
-
-
an annual grant of equity with a value of $175,000; and
-
-
an annual cash fee of $20,000 for the chair of each of our Board committees.
The
equity granted to our non-employee directors are subject to forfeiture restrictions, and become free from restriction on the date of the annual meeting of stockholders immediately following the
date of grant, subject to the director's continuation of service during such term. The grants are also subject to the terms and conditions of our Long-Term Incentive Plans. The annual equity grants
are generally made on the date of each Annual Meeting of Stockholders unless they are approved during a closed trading window, in which case such awards are made on the first trading day of the next
open trading window period following approval. If a non-employee director is appointed to the Board on a date other than the Annual Meeting of Stockholders, however, an equity grant in an amount equal
to the then-current non-employee director annual award, prorated for the time period from the effective date of the appointment to the next annual meeting of stockholders, is made on the first trading
day of the month following the month in which the new director was appointed to the Board. Such awards made to new non-employee directors become free from restriction upon the expiration of the new
director's current term of office on the date of the annual meeting of stockholders immediately following the date of grant, subject to the director's continuation of service during such term.
Additionally, if a non-employee director is appointed to the Board on a date other than the Annual Meeting of Stockholders, the annual cash retainer for such director will be prorated for the time
period from the effective date of the appointment to the next annual meeting of stockholders.
Cash Compensation
Each non-employee director may elect to receive such retainers and fees in cash, payable on a quarterly basis. Each non-employee director, however,
may elect to convert all or a portion of his or
29
Table of Contents
her
cash compensation into one or more of three equity alternatives, each to vest on the date of the annual meeting of stockholders immediately following the date of grant: (i) restricted stock
valued based on the closing price of our common stock on the date of grant (with shares of our common stock released from restriction upon vesting); (ii) stock options valued based on a Black
Scholes valuation on the date of grant and exercisable for up to one year after a director's separation from Board Service; and/or (iii) deferred stock units, valued based on the closing price
of our common stock on the date of grant (with shares of our common stock to be issued only after a director's separation from Board service in accordance with the Boston Scientific Non-Employee
Director Deferred Compensation Plan, as amended and restated effective, January 1, 2014 (the 2014 Non-Employee Director Deferred Compensation Plan)). Each non-employee director may also choose
to defer receipt of all or a portion of his or her annual cash compensation under the 2014 Non-Employee Director Deferred Compensation Plan, as described further below.
Equity Compensation
Each non-employee director may elect to receive their annual equity award as one or more of the following three equity compensation alternatives,
each to vest on the date of the annual meeting of stockholders immediately following the date of grant: (i) restricted stock valued based on the closing price of our common stock on the date of
grant (with shares of our common stock released from restriction upon vesting); (ii) stock options valued based on a Black Scholes valuation on the date of grant and exercisable until the
earlier of ten years from the date of grant or one year after a director's separation from Board service; and/or (iii) deferred stock units valued based on the closing price of our common stock
on the date of grant (with shares of our common stock to be issued only after a director's separation from Board service in accordance with the 2014 Non-Employee Director Deferred Compensation Plan).
Employee Directors
Directors who are also employees of the Company receive no additional compensation for serving on the Board or its committees.
Chairman of the Board
Our Chairman of the Board receives an annual cash retainer of $210,000 and, in 2014, an annual grant of equity with a value of
$175,000. With respect to his annual cash retainer, Mr. Pete M. Nicholas, Chairman of the Board, is entitled to elect to convert it into, and, with respect to his annual equity compensation he
is entitled to elect to receive, one or more of the three equity alternatives described under the section titled "Non-Employee Directors" above. Mr. Pete M. Nicholas also receives certain
benefits under his founders retirement arrangements, including continued medical coverage under our benefit policies, so long as he remains a director or director emeritus of our Company. For
additional information, please see the section titled "
Founders' Benefits
" below and the "Director Compensation" table and related footnotes.
Director Emeritus
Under our Corporate Governance Guidelines, each of our co-founders is eligible, at the Board's discretion, to become a director
emeritus of the Company. In connection with his retirement from the Board in 2011, Mr. Abele agreed to serve as director emeritus at the request of the Board. Mr. Abele does not receive
any compensation for his role as director emeritus. However, Mr. Abele receives certain benefits under his founders retirement arrangements, including continued medical coverage under our
benefit policies, for as long as he remains a director or director emeritus of our Company.
30
Table of Contents
For
additional information regarding Mr. Abele's founders' benefits, please see the section titled "
Founders' Benefits
" below.
Other Payments and Benefits
We pay or reimburse our directors for transportation, hotel, meals and other incidental expenses incurred in connection with their
performance of services for us, including attending Board and committee meetings and participating in director education programs. Our corporate aircraft is made available to our directors for travel
to and from our Board meetings, as well as for certain other Company business travel. We also extend directors' and officers' indemnity insurance coverage to each of our directors.
Non-Employee Director Deferred Compensation Plans
With respect to compensation for the Board term beginning in 2013, non-employee directors could, by written election, defer receipt
of all or a portion of the annual cash
retainer, the annual cash committee chair fees and the equity grant under our Non-Employee Director Deferred Compensation Plan then in effect. Cash amounts deferred could be invested in common stock
equivalent units or another investment option in which we credit the amount deferred plus accrued interest (compounded annually based upon the Moody's Composite Yield on Seasoned Corporate Bonds as
reported for the month of September of each calendar year). Deferred cash amounts are payable only after a director's termination of Board service or on a Fixed Date Payout (as defined in the plan),
and may be paid either as a lump sum or in installments as specified by the director at the time of election. With respect to deferred restricted equity, shares of common stock will be issued to the
director in settlement thereof after a director's termination of Board service in accordance with the plan.
Beginning
in 2014, each non-employee director may, by written election, defer receipt of all or a portion of the annual cash retainer, annual cash committee chair fees and equity compensation under
our 2014 Non-Employee Director Deferred Compensation Plan. Cash amounts deferred can be invested in deemed investment options in which we credit the amount deferred plus any earnings from the chosen
investment options investment options under the plan are generally the same as those offered under the Company's 401(k) plan through Vanguard, except that, among other things, directors may not elect
to invest in the BSC Stock Fund. Deferred cash amounts are payable, at the non-employee director's written election, in either a lump-sum or in annual installments after a director's separation from
Board service or in a lump-sum on an earlier fixed date (each in accordance with the plan).
Director Stock Ownership Guidelines
Non-employee directors are required to hold a significant personal investment in the Company through their ownership of shares of our
common stock. Our director stock ownership guidelines provide that each non-employee director should own shares with a value equal to at least three times the director annual cash retainer (currently
$90,000) within five years of his or her joining the Board. For purposes of satisfying this obligation, deferred stock units, restricted stock, stock equivalent units or restricted stock deferrals
under our Non-Employee Director Deferred Compensation Plans may be included in the value of the shares held by a director. We believe the stock ownership requirements for our non-employee directors
align the interests of our directors with the long-term interests of our stockholders. All of our non-employee directors either currently meet our director stock ownership guidelines or we expect that
they will meet the guidelines within five years of becoming a director. The Nominating and Governance Committee monitors compliance with these guidelines on an annual basis. For information regarding
the stock ownership guidelines applicable to our Chief Executive
31
Table of Contents
Officer,
please see the Compensation Discussion & Analysis section titled
"Executive Stock Ownership Guidelines."
Director Compensation Table
The table below summarizes the compensation we paid to our non-employee directors for the fiscal year ended December 31, 2014.
|
|
|
|
|
|
|
|
|
|
|
|
|
Name(1)
|
|
Fees
Earned or
Paid in
Cash
($)(2)
|
|
Stock
Awards
($)(3)
|
|
Option
Awards
($)(4)
|
|
Change in
Pension
Value and
Non-Qualified
Deferred
Compensation
Earnings
($)(5)
|
|
All Other
Compensation
($)(6)
|
|
Total
($)
|
|
Katharine T. Bartlett*
|
|
$32,500
|
|
$0
|
|
$0
|
|
$0
|
|
$0
|
|
$32,500
|
Bruce L. Byrnes
|
|
$105,000
|
|
$174,991
|
|
$0
|
|
$0
|
|
$0
|
|
$279,991
|
Nelda J. Connors
|
|
$85,000
|
|
$174,991
|
|
$0
|
|
$2,651
|
|
$0
|
|
$262,642
|
Kristina M. Johnson
|
|
$85,000
|
|
$174,991
|
|
$0
|
|
$0
|
|
$0
|
|
$259,991
|
Edward J. Ludwig
|
|
$72,500
|
|
$206,630
|
|
$0
|
|
$0
|
|
$0
|
|
$279,130
|
Ernest Mario
|
|
$105,000
|
|
$174,991
|
|
$0
|
|
$0
|
|
$0
|
|
$279,991
|
N.J. Nicholas, Jr.
|
|
$106,240
|
|
$174,991
|
|
$0
|
|
$0
|
|
$0
|
|
$281,231
|
Pete M. Nicholas
|
|
$227,488
|
|
$174,991
|
|
$0
|
|
$0
|
|
$245,667
|
|
$648,146
|
Uwe E. Reinhardt
|
|
$105,000
|
|
$174,991
|
|
$0
|
|
$0
|
|
$0
|
|
$279,991
|
David Roux
|
|
$85,000
|
|
$234,485
|
|
$0
|
|
$0
|
|
$0
|
|
$319,485
|
John E. Sununu
|
|
$105,000
|
|
$174,991
|
|
$0
|
|
$0
|
|
$0
|
|
$279,991
|
|
|
|
*
|
|
Ms. Bartlett retired from our Board at our 2014 Annual Meeting on May 6, 2014, when her term ended.
|
(1)
|
|
Mr. Mahoney, a director and our President and Chief Executive Officer, is an employee of the Company and is not included in this table. Mr. Mahoney did not receive any compensation for his services as a
director in 2014, and his compensation as an executive of the Company is discussed in the Compensation Discussion & Analysis and Executive Compensation sections
|
(2)
|
|
The annual cash retainer paid to Mr. Ludwig for his service as a director in 2014 was prorated to reflect his appointment to the Board on March 1, 2014. During 2014, Mr. Pete Nicholas' annual cash
retainer was paid in the form of $52,500 of cash and 11,877 shares of restricted stock. Mr. N.J. Nicholas, Jr. elected to defer his annual cash retainers for the Board terms that began at the annual meetings of stockholders in 2013 and 2014.
Accordingly, during 2014, we issued to him 1,970.63 common stock equivalent units and 6,221 deferred stock units (reflecting an overpayment of approximately $1,250). As a result of an administrative error in connection with our recent transition to
new director compensation equity and deferral choices, during 2014, we erroneously paid Mr. Pete Nicholas a cash payment of $17,500 and issued to Mr. N.J. Nicholas, Jr. deferred stock units with a value of approximately $1,250. Accordingly,
we will reduce their respective cash retainer payments for the first quarter of 2015 by such amounts.
|
(3)
|
|
Each non-employee director elected at our 2014 Annual Meeting of Stockholders was granted an equity award with a value of $175,000. For each director that elected to receive restricted stock, the restricted stock
vests upon the expiration of the director's current term of office. For each director that elected to receive deferred stock units, the deferred stock units vest upon the expiration of the director's current term of office and vested shares of stock
will be issued to the director upon his or her separation from Board service in accordance with the 2014 Non-Employee Director Deferred Compensation Plan.
|
32
Table of Contents
|
|
|
|
|
The unvested shares of restricted stock and deferred stock units awarded to our directors and outstanding at December 31, 2014, all of which will vest on May 5, 2015, the date of our Annual Meeting, are
shown below:
|
|
|
|
|
|
|
|
|
|
|
|
Name
|
|
Equity Award
|
|
Grant Date
|
|
Number of
Shares/Units
|
|
Grant Date
Fair Value
|
|
Vesting Date
|
|
Katherine T. Bartlett
|
|
*
|
|
*
|
|
0
|
|
$0
|
|
*
|
Bruce L. Byrnes
|
|
Restricted Stock
|
|
October 31, 2014
|
|
13,177
|
|
$174,991
|
|
May 5, 2015
|
Nelda J. Connors
|
|
Restricted Stock
|
|
October 31, 2014
|
|
13,177
|
|
$174,991
|
|
May 5, 2015
|
Kristina M. Johnson
|
|
Restricted Stock
|
|
October 31, 2014
|
|
13,177
|
|
$174,991
|
|
May 5, 2015
|
Edward J. Ludwig
|
|
Deferred Stock Units
|
|
October 31, 2014
|
|
13,177
|
|
$174,991
|
|
May 5, 2015
|
Ernest Mario
|
|
Restricted Stock
|
|
October 31, 2014
|
|
13,177
|
|
$174,991
|
|
May 5, 2015
|
N.J. Nicholas, Jr.
|
|
Deferred Stock Units
|
|
October 31, 2014
|
|
13,177
|
|
$174,991
|
|
May 5, 2015
|
Pete M. Nicholas
|
|
Restricted Stock
|
|
October 31, 2014
|
|
13,177
|
|
$174,991
|
|
May 5, 2015
|
Uwe E. Reinhardt
|
|
Restricted Stock
|
|
October 31, 2014
|
|
13,177
|
|
$174,991
|
|
May 5, 2015
|
David J. Roux
|
|
Restricted Stock
|
|
October 31, 2014
|
|
13,177
|
|
$174,991
|
|
May 5, 2015
|
John E. Sununu
|
|
Deferred Stock Units
|
|
October 31, 2014
|
|
13,177
|
|
$174,991
|
|
May 5, 2015
|
|
|
|
|
|
The stock award amount for each of Messrs. Ludwig and Roux includes a restricted stock award valued at $31,639 and $59,495, respectively, representing the annual equity award of $175,000 for the 2013 Board term,
prorated for the time period from the effective date of his appointment to the date of the 2014 annual meeting of stockholders.
|
(4)
|
|
No stock options were granted to non-employee directors in 2014. The outstanding, unexercised stock options, pursuant to stock option awards previously granted to non-employee directors, at December 31, 2014 (all
of which are fully vested), are shown below.
|
|
|
|
Name
|
|
Outstanding
Vested Stock
Options
|
|
Ernest Mario
|
|
2,000
|
N.J. Nicholas, Jr.
|
|
2,000
|
Pete M. Nicholas
|
|
3,000
|
Uwe E. Reinhardt
|
|
2,000
|
|
|
|
(5)
|
|
The amounts in this column represent the "above-market" portion of 2014 earnings under the interest crediting investment option available under the Non-Employee Director Deferred Compensation Plan. The interest rate used
under the plan each year is the Moody's Composite Yield on Seasoned Corporate Bonds for the month of September of the preceding year. For 2014, the interest rate used under the plan was 4.95%, the Moody's rate in September 2013. Under SEC rules,
interest on non-qualified deferred compensation is considered "above-market" if the interest rate exceeds 120% of the federal long-term interest rate, with compounding at the rate that corresponds most closely to the rate under the plan, at the time
the interest rate or formula is set. For 2014, 120% of the applicable federal long-term interest rate was 3.94%.
|
(6)
|
|
The amount in this column represents all other compensation earned by the following non-employee director in fiscal year 2014:
|
|
|
|
|
|
|
|
|
|
Name
|
|
Annual
Founders
Benefits(a)
|
|
Medical
Benefits(a)
|
|
Personal
Use of
Aircraft(b)
|
|
Total
|
|
Pete M. Nicholas
|
|
$225,000
|
|
$12,779
|
|
$7,888
|
|
$245,667
|
|
|
|
|
|
|
|
(a)
|
|
The amounts included in these columns represent 2014 payments to Mr. Pete M. Nicholas pursuant to his founder retirement arrangements described in the section titled "
Founders'
Benefits
" below.
|
|
|
(b)
|
|
This amount represents the incremental costs to the Company of limited personal use of our corporate aircraft. The reflected amount excludes $25,026 of disallowed Company tax deductions attributable to Mr. Pete
M. Nicholas for his personal use of the aircraft during the year. Mr. Pete M. Nicholas was taxed on the imputed income attributable to his personal use of the corporate aircraft and did not receive tax assistance from the Company with respect to
such amount. For information about how the Company calculates incremental cost, please see footnote 7(b) under the Executive Compensation section titled "
Summary Compensation Table
."
|
Founders' Benefits
In May 2005, Mr. Pete M. Nicholas, our co-founder and Chairman of the Board, and Mr. Abele, our co-founder and director
emeritus, retired as employees of the Company. In connection with their retirement, the Board approved the following arrangements for Messrs. Pete M. Nicholas and Abele in May
2005:
-
-
Mr. Pete M. Nicholas receives an annual payment of $225,000 for life, and medical coverage under our benefit policies for as
long as he remains a director or "director emeritus," and continued provision of an office space and secretarial and administrative support to assist him in the performance of his duties as Chairman
and other services he provides to the
33
Table of Contents
Company.
During 2014, Mr. Pete M. Nicholas continued to have secretarial and administrative support to assist him in the performance of the services he provides to the Company. During 2014,
Mr. Pete Nicholas continued to have the use of an office at our Natick headquarters until the summer following the relocation of our corporate headquarters to Marlborough in June 2014. In
December 2013, the Company entered into an arrangement with Mr. Pete M. Nicholas to provide office space in accordance with his founders' benefits to assist him in the performance of his duties
as Chairman and other services provided to the Company. For additional information regarding the arrangement between the Company and Mr. Pete M. Nicholas, please see the "Related Party
Transactions" section above. Mr. Pete M. Nicholas also receives transportation services on an as-needed basis.
-
-
Mr. Abele receives an annual payment of $150,000 for life, and medical coverage under our benefit policies for as long as he
remains a director or "director emeritus," and continued provision of an office space and secretarial and administrative support to assist him in the performance of the services he provides to the
Company, as may be required.
34
Table of Contents
EXECUTIVE OFFICERS
Our Executive Officers
As of March 1, 2015, our executive officers were as follows:
|
|
|
|
|
Name
|
|
Age
|
|
Title
|
|
Michael F. Mahoney
|
|
50
|
|
President and Chief Executive Officer
|
Kevin J. Ballinger
|
|
42
|
|
Senior Vice President and President, Interventional Cardiology
|
Supratim Bose
|
|
62
|
|
Executive Vice President and President, Asia-Pacific, Middle East and Africa
|
Daniel J. Brennan
|
|
49
|
|
Executive Vice President and Chief Financial Officer
|
Wendy Carruthers
|
|
46
|
|
Senior Vice President, Human Resources
|
Keith D. Dawkins, M.D.
|
|
64
|
|
Executive Vice President and Global Chief Medical Officer
|
Joseph M. Fitzgerald
|
|
51
|
|
Executive Vice President and President, Rhythm Management
|
Jeffrey B. Mirviss
|
|
49
|
|
Senior Vice President and President, Peripheral Interventions
|
Edward F. Mackey
|
|
52
|
|
Executive Vice President, Operations
|
Maulik Nanavaty
|
|
53
|
|
Senior Vice President and President, Neuromodulation
|
Michael P. Phalen
|
|
55
|
|
Executive Vice President and President, MedSurg
|
David A. Pierce
|
|
51
|
|
Senior Vice President and President, Endoscopy
|
Karen Prange
|
|
51
|
|
Senior Vice President and President, Urology and Women's Health
|
Timothy A. Pratt
|
|
65
|
|
Executive Vice President, Chief Administrative Officer, General Counsel and Secretary
|
John B. Sorenson
|
|
47
|
|
Senior Vice President, Manufacturing and Supply Chain
|
Eric Thépaut
|
|
53
|
|
Senior Vice President and President, Europe
|
Biographical Information About Our Executive Officers
For Michael F. Mahoney, please see his biography in
Proposal 1: Election of
Directors
.
Kevin
J. Ballinger has been our Senior Vice President and President, Interventional Cardiology since January 2013 and was our President, Interventional Cardiology from July 2011 to January 2013. In
his current role, Mr. Ballinger is responsible for developing and bringing to market innovative solutions that diagnose and treat coronary artery disease and cardiac valve disorders.
Mr. Ballinger has more than 18 years of interventional cardiology experience. Prior to serving as our President, Interventional Cardiology, he held a variety of engineering and general
management positions within our Interventional Cardiology business unit, including Vice President and General Manager, Group Program Management Cardiology, Rhythm and Vascular from January 2010 to
July 2011; Vice President of Research and Development, Peripheral Interventions from September 2008 to January 2010; and Vice President of Program Management, Cardiovascular from September 2006 to
September 2008. Mr. Ballinger earned a B.S. in Mechanical Engineering from Michigan Technological University and an M.B.A. from the University of Minnesota.
Supratim
Bose is our Executive Vice President and President, Asia-Pacific, Middle East and Africa, a position he has held since January 2013. Mr. Bose joined Boston Scientific in December 2011
as our Executive Vice President and President, Asia-Pacific and served in that role until he also assumed
35
Table of Contents
responsibility
for the Company's Middle East and Africa units. Before joining Boston Scientific, Mr. Bose was Founder and Chief Executive Officer of Singapore-based Bose Consulting Group, which
specialized in strategic management consulting services for the healthcare industry, from January 2010 to
December 2011. He previously worked for nearly thirty years at Johnson & Johnson where he concluded his tenure as Company Group Chairman of its Medical Devices and Diagnostics business in 2009.
Mr. Bose joined Johnson & Johnson Ltd. India in 1981, and held a variety of management positions of increasing responsibility. He earned a B.S. in Chemistry/Physics, a M.S. in
Biophysics and a Masters in Management Studies from the Jamnalal Bajaj Institute for Management Studies at the University of Bombay. He has served as a member of the board of directors at Quattro
Vascular Pte. Ltd. and Trireme Medical, and as a member of the advisory board at Singapore Management University's Lee Kong Chian School of Business. He currently serves as a member of the
board of directors of CareFusion Corporation, a role that he has held since May 2014.
Daniel
J. Brennan is our Executive Vice President and Chief Financial Officer, a position he has held since January 2014. In this role, he is responsible for several Company functions, including
Global Controllership, Corporate Finance, Treasury, Corporate Tax, Corporate Analysis and Control, Investor Relations, and Corporate Business Development. Prior to that, he was the Company's Senior
Vice President and Corporate Controller, a role he served in since January of 2010. Since joining Boston Scientific in December 1996, Mr. Brennan held roles with increased responsibilities. For
2009, Mr. Brennan served as Vice President and Assistant Corporate Controller and from 2001 through 2008, he served as Vice President of Finance and Information Technology for Worldwide
Financial & Strategic Planning (2008), Investor Relations (2006-2007), International Finance (2005-2006) and the Cardiovascular Division (2001-2005). In 1999, Mr. Brennan became Group
Controller of the Non-Vascular Division after previously serving as Controller of the Meditech Vascular Division. He holds a B.S. degree in Finance and Investments and an M.B.A from Babson College.
Mr. Brennan is also a certified public accountant.
Wendy
Carruthers has been our Senior Vice President, Human Resources since December 2012 and served as the head of Human Resources on an interim basis from August 2012 to November 2012. In her current
role, Ms. Carruthers oversees the Company's human resources activities globally, including Human Resources operations and services, total rewards, talent management, and diversity and
inclusion. Prior to her current role, she served as our Vice President of Global Talent Management from January 2011 to November 2012, responsible for all aspects of global talent management including
the design, development and implementation of global processes and systems to enable managers to identify, attract, leverage and develop people. Ms. Carruthers has been with Boston Scientific
since 2004 and was previously Vice President of Human Resources for our Europe, Middle East and Africa (EMEA) region, based in Paris, from June 2007 to December 2010; our Vice President of Human
Resources for Europe from January 2006 to June 2007; and our Director of Human Resources for Europe from March 2004 to December 2005. Prior to joining us, Ms. Carruthers was Vice President of
Human Resources, Europe for global telecommunications company Cable & Wireless. She also previously worked in human resources for Diageo, a food and beverage company, and Tesco, a U.K.
supermarket chain. Ms. Carruthers holds a B.A. First Class Honors Degree in Modern Languages from the University of Salford and is a Fellow of the Chartered Institute of Personnel and
Development.
Keith
D. Dawkins, M.D. has been our Executive Vice President and Global Chief Medical Officer since January 2012. Prior to that, he was Senior Vice President and Chief Medical Officer of our
Cardiology, Rhythm and Vascular Group. From 2008 until May 2010, he was our Senior Vice President and Associate Chief Medical Officer of our Cardiovascular business. Prior to joining Boston Scientific
in 2008, Dr. Dawkins was a practicing interventional cardiologist for more than 20 years in England. He has earned a series of clinical, research and academic distinctions, including a
Post-Doctoral Research
36
Table of Contents
Fellowship
at Stanford University as a Fulbright Scholar. He served as President of the British Cardiovascular Intervention Society, and held numerous appointments on hospital, regional and national
committees, including the National Institute for Health and Clinical Excellence. He has been an author on more than 600 academic publications and presentations on a variety of cardiac topics.
Dr. Dawkins was educated at London University and Guys Hospital, earning a First Class Honors degree in Pathology. He trained in cardiology at Oxford and at the Brompton &
St. George's Hospital in London.
Joseph
M. Fitzgerald has been our Executive Vice President and President, Rhythm Management since February 2014, having previously served as Senior Vice President and President, Cardiac Rhythm
Management from July 2011. He served as Senior Vice President and President, Endovascular from February 2010 until July 2011. Prior to that, Mr. Fitzgerald was President and General Manager of
our Peripheral Interventions business from June 2008 to February 2010 and President of Electrophysiology business from 2005 to 2008. Previously, he held a variety of management positions in our
Neurovascular and Peripheral Interventions businesses. These included numerous regional and divisional sales management assignments up to and including his roles as Vice President, Global Marketing
for the Neurovascular business from January 2001 to July 2005 and Vice President of U.S. Sales for the Neurovascular business from 1997 to January 2001. Prior to joining Boston Scientific in 1990 as a
sales representative, Mr. Fitzgerald was with Anheuser Busch, Inc., where he held a variety of sales, marketing and training assignments. Mr. Fitzgerald holds a B.S. in Business
from Indiana University and an M.B.A. from Southern Illinois University with a concentration in Marketing and Finance.
Edward
F. Mackey has been our Executive Vice President, Operations since February 2015. Prior to joining Boston Scientific, from November 2012 to January 2015, Mr. Mackey was Worldwide
President of DePuy Synthes Power Tools, a division of Johnson & Johnson, after having served, from June 2010, as Vice President of Integration for Johnson & Johnson's acquisition of
Synthes. Early in his career, Mr. Mackey held management positions in Operations, Quality and Product Development at Raytheon's Mille Systems division. In 1995, he moved to Johnson &
Johnson Orthopaedics as a plant manager and progressed through a series of manufacturing and supply chain leadership roles, becoming Worldwide Vice President of Supply Chain and Manufacturing for
DePuy in 2007, a position he held until 2010. Mr. Mackey holds a Bachelor's degree in Mechanical Engineering from Worcester Polytechnic Institute and an M.B.A from the University of
Massachusetts.
Jeffrey
B. Mirviss has been our Senior Vice President and President, Peripheral Interventions since January 2013 and was our President, Peripheral Interventions from July 2011 to January 2013.
Mr. Mirviss has more than 23 years of experience in medical device and pharmaceutical general management, marketing and sales. Since joining us in 1997, Mr. Mirviss also served as
our Vice President, Group Global Marketing, CRV from July 2009 to July 2011 and Vice President, Global Cardiology Marketing from December 2004 to July 2009. In addition to his positions at Boston
Scientific, Mr. Mirviss has worked for companies ranging in size from a pre-revenue venture-backed
medical device startup to Dow 30 companies. He holds a Bachelor's degree from the University of Minnesota and an M.B.A. from the University of St. Thomas.
Maulik
Nanavaty became our Senior Vice President and President, Neuromodulation in September 2011. Prior to his current role, Mr. Nanavaty was President of Boston Scientific Japan from December
2007 until September 2011. From January 2007 through November 2007, he served as Vice President and General Manager, Interventional Cardiology of Boston Scientific Japan. Mr. Nanavaty joined
our Company in 2005 as Vice President, Corporate Strategy of Boston Scientific Japan and served in that capacity through December 2006. Prior to joining our Company, Mr. Nanavaty spent
16 years working in various executive positions at Baxter International, Inc. and Baxter Japan. Mr. Nanavaty is a member
37
Table of Contents
of
the board of directors for the California Health Institute. Mr. Nanavaty earned a Ph.D. in Pharmaceutical Sciences from the University of Illinois and an M.B.A. from the University of
Chicago.
Michael
P. Phalen has been our Executive Vice President and President, MedSurg since January 2012. Prior to his current role, he served as Executive Vice President and President, International from
January 2011. Mr. Phalen served as Senior Vice President and President of our Endoscopy business from 2010 to 2011 and Vice President and President of Endoscopy from 2001 to 2010.
Mr. Phalen joined us in 1988 and has held a variety of management positions at the Company. Prior to becoming President of the Endoscopy business, he was Vice President, Business Unit Manager
for Endoscopic Surgery and Vice President of Global Marketing for Endoscopy. Prior to these appointments, Mr. Phalen held positions as Director of Marketing, Group Product Manager, Regional
Sales Manager, Product Manager and Territory Manager. Before joining us, he held management positions with MD Technology, Kendall Healthcare and Pennwalt Pharmaceuticals. He earned a B.S. in General
Science from Villanova University and an M.B.A. from Fairleigh Dickinson University.
David
A. Pierce has served as our Senior Vice President and President, Endoscopy since January 2011. Prior to his current role, Mr. Pierce served as Vice President, Marketing for the Company's
Endoscopy Division from April 2006 until January 2011. From December 2004 until March 2006, Mr. Pierce was the Group Marketing Director in the Company's Endoscopy Division. He joined our
Company in 1991 as a Territory Manager before assuming management-level positions of increasing responsibility. Before joining our Company, Mr. Pierce worked as a Senior Sales Representative
for Airborne Express and served as a Captain in the United States Army. He earned a B.S. in Business Administration from Norwich University and an M.B.A. from Boston University.
Karen
Prange is our Senior Vice President and President, Urology and Women's Health, a position she has held since June 2012. Prior to her career with Boston Scientific, Ms. Prange spent
17 years with Johnson & Johnson in various medical device businesses, including as Vice President and General
Manager, Micrus Endovascular LLC and Codman Neurovascular from September 2010 to June 2012; Vice President and General Manager, Codman Neurovascular from August 2008 to September 2010; and Vice
President, Global Marketing for Codman from June 2006 to July 2008. Ms. Prange holds a B.S. in Business Administration with honors from the University of Florida.
Timothy
A. Pratt is our Executive Vice President, Chief Administrative Officer, General Counsel and Secretary, a position he has held since February 2010. He is responsible for the worldwide
management of our Legal functions, Global Compliance, Global Security, Government Affairs, Enterprise Strategy and Marketing, Health Economics and Reimbursement, Corporate Communications, and Aviation
Services. Mr. Pratt joined Boston Scientific in May 2008 as our Executive Vice President, General Counsel and Secretary. Previously, Mr. Pratt worked for the law firm of Shook,
Hardy & Bacon. He joined the firm in 1977 and became partner in 1981. He concentrated his practice in the defense of pharmaceutical and medical device litigation and toxic tort cases.
Mr. Pratt serves as a director on the boards of the Lawyers for Civil Justice, DRI The Voice of the Defense Bar, and the New England Legal Foundation. He is also active in
the Federation of Defense and Corporate Counsel, where he serves on the board, executive committee and as their Chairman. Mr. Pratt has served as a member of the board of directors and
executive committee of AdvaMed. Mr. Pratt earned a B.A. degree at Tarkio College and graduated Order of the Coif from Drake University Law School, where he served as editor-in-chief of the
Drake Law Review
. After graduating, Mr. Pratt was law clerk to Judge Floyd R. Gibson of the U.S. Court of Appeals for the Eighth Circuit.
John
B. Sorenson is our Senior Vice President, Manufacturing and Supply Chain, a position he has held since February 2015. In this role, he is responsible for the global manufacturing and distribution
of our products. Mr. Sorenson has more than 16 years of medical device manufacturing experience. Prior
38
Table of Contents
to
his current role, he held a variety of Operations positions at Boston Scientific, supporting the Cardiac Rhythm Management, Neuromodulation, Interventional Cardiology, Peripheral Interventions and
Structural Heart businesses. For six years prior to his current appointment, he served as Multi-Site Vice President, Operations. Before joining Boston Scientific, he was president and COO of QRS
Diagnostic and held manufacturing management positions at Federal Cartridge. Mr. Sorenson earned a B.A. in Economics from Gustavus Adolphus College and an M.B.A. from the University of
Minnesota.
Eric
Thépaut is our Senior Vice President and President, Europe, a position he has held since January 2015. Prior to his current role, Mr. Thépaut was Vice
President Interventional Cardiology & Structural Heart, Europe, a position he held since 2012. He joined Boston Scientific Europe, in 1996, as a business finance manager and earned roles of
increasing responsibility in marketing and finance, becoming Vice President, Finance, Europe, from 2002 to 2005, General Manager and Vice President, France, from 2005 to 2008, and General Manager and
Vice President of the France Group, comprised of France, Benelux and Middle East North Africa, from 2009 to 2011. Before coming to Boston Scientific, Mr. Thépaut held management
positions in treasury operations and auditing at Nestlé and
financial planning & analysis at Apple Computer. Mr. Thépaut earned his M.B.A. at Paris Dauphine University.
Named Executive Officers
Under applicable SEC rules, we are required to disclose certain compensation and other information regarding our Chief Executive
Officer, our Chief Financial Officer, and our three other most highly-compensated executive officers (referred to as our named executive officers or NEOs). Our named executive officers for the year
ended December 31, 2014, are:
|
|
|
Michael F. Mahoney
|
|
President and Chief Executive Officer
|
Daniel J. Brennan
|
|
Executive Vice President and Chief Financial Officer
|
Kevin J. Ballinger
|
|
Senior Vice President and President, Interventional Cardiology
|
Joseph M. Fitzgerald
|
|
Executive Vice President and President, Rhythm Management
|
Timothy A. Pratt
|
|
Executive Vice President, Chief Administrative Officer, General Counsel and Secretary
|
Kenneth J. Pucel
|
|
Former Executive Vice President, Global Operations, Quality and Technology
|
SEC
rules require that we disclose the compensation of up to two additional individuals for whom compensation disclosure would have been required but for the fact that the individual was not serving
as an executive officer at December 31, 2014. Accordingly, Mr. Pucel is discussed in that capacity. Mr. Pucel left the Company effective November 28, 2014.
39
Table of Contents
CERTAIN BENEFICIAL OWNERSHIP MATTERS
Security Ownership of Principal Stockholders
Set forth below are stockholders known by us to be the beneficial owner of more than 5% of our common stock as of March 1,
2015. As of March 1, 2015, there were 1,338,851,837 shares of our common stock outstanding.
|
|
|
|
|
Name and Address
|
|
Number of Shares
Beneficially Owned
|
|
Percent of Shares
Outstanding
|
|
BlackRock, Inc.
|
|
80,559,195
|
(1)
|
6.02%
|
40 East 52nd Street, New York, NY 10022
|
|
|
|
|
FMR LLC/Edward C. Johnson 3d/Abigail P. Johnson
|
|
198,973,477
|
(2)
|
14.86%
|
245 Summer Street, Boston, MA 02210
|
|
|
|
|
JPMorgan Chase & Co.
|
|
76,902,926
|
(3)
|
5.74%
|
270 Park Ave., New York, NY 10017
|
|
|
|
|
The Vanguard Group
|
|
101,699,412
|
(4)
|
7.60%
|
100 Vanguard Blvd., Malvern, PA 19355
|
|
|
|
|
Wellington Management Group LLP
|
|
70,746,109
|
(5)
|
5.28%
|
c/o Wellington Management Company LLP
|
|
|
|
|
280 Congress Street, Boston, MA 02210
|
|
|
|
|
|
|
|
(1)
|
|
Based solely on an Amendment to Schedule 13G filed with the SEC on February 9, 2015, BlackRock, Inc. (BlackRock) reported aggregate beneficial ownership of 80,559,195 shares of Boston Scientific common
stock as of December 31, 2014. BlackRock reported that it possessed sole voting power with respect to 68,813,070 shares and sole dispositive power with respect to 80,559,195 shares. BlackRock also reported that it did not possess shared voting
or dispositive power over any shares beneficially owned.
|
(2)
|
|
Based solely on an Amendment to Schedule 13G jointly filed by FMR LLC, Edward C. Johnson 3d, and Abigail P. Johnson with the SEC on February 13, 2015, FMR LLC, Edward C. Johnson 3d, and Abigail P.
Johnson each reported aggregate beneficial ownership of the same 198,973,477 shares of Boston Scientific common stock. FMR LLC reported sole voting power with respect to 4,012,624 shares of Boston Scientific common stock and each of FMR LLC,
Edward C. Johnson 3d, and Abigail P. Johnson reported sole dispositive power with respect to the same 198,973,477 shares, in each case, as of December 31, 2014. FMR LLC, Edward C. Johnson 3d, and Abigail P. Johnson reported that the
following subsidiaries of FMR LLC beneficially own shares of the Company: (i) Fidelity Management Trust Company, Inc.; (ii) Fidelity Management and Research Company; (iii) Pyramis Global Advisors Trust Company;
(iv) Pyramis Global Advisors, LLC; and (v) Strategic Advisors Inc.
|
(3)
|
|
Based solely on a Schedule 13G filed with the SEC on January 23, 2015, JPMorgan Chase & Co. (JP Morgan) reported aggregate beneficial ownership of 76,902,926 shares of Boston Scientific common
stock as of December 31, 2014. JPMorgan reported that it possessed sole voting power with respect to 68,739,753 shares, sole dispositive power with respect to 76,241,104 shares, shared voting power with respect to 638,559 shares, and shared
dispositive power with respect to 661,822 shares.
|
(4)
|
|
Based solely on an Amendment to Schedule 13G filed with the SEC on February 11, 2015, The Vanguard Group (Vanguard) reported aggregate beneficial ownership of 101,699,412 shares of Boston Scientific common
stock as of December 31, 2014. Vanguard reported that it possessed sole voting power with respect to 2,288,639 shares, sole dispositive power with respect to 99,577,965 shares and shared dispositive power with respect to 2,121,447 shares and
that it did not possess shared voting power over any shares beneficially owned. Vanguard also reported that (i) Vanguard Fiduciary Trust Company, a wholly-owned subsidiary of Vanguard, is the beneficial owner of 1,787,430 shares as a result of
its serving as investment manager of collective trust accounts and (ii) Vanguard Investments Australia, Ltd., a wholly-owned subsidiary of Vanguard, is the beneficial owner of 835,226 shares as a result of its serving as investment manager
of Australian investment offerings.
|
40
Table of Contents
|
|
|
(5)
|
|
Based solely on a Schedule 13G filed with the SEC on February 12, 2015, Wellington Management Group LLP (Wellington) reported aggregate beneficial ownership of 70,746,109 shares of Boston Scientific
common stock as of December 31, 2014. Wellington reported that it shared voting power with respect to 7,028,039 shares and shared dispositive power with respect to 70,746,109 shares. Wellington also reported that it did not possess sole voting
power or sole dispositive power over any shares beneficially owned.
|
Security Ownership of Directors and Executive Officers
The following table shows, as of March 1, 2015, the amount of our common stock beneficially owned
by:
-
-
our directors and director nominees;
-
-
our executive officers named in the Summary Compensation Table; and
-
-
all of our directors and executive officers as a group.
"Beneficial
ownership" includes those shares of our common stock the reporting person has the power to vote or transfer, stock options that are currently exercisable or exercisable within
60 days, and deferred stock units that will vest within 60 days. Unless otherwise indicated, the persons named below have sole voting and investment power over the shares listed.
|
|
|
|
|
Name
|
|
Number of Shares
Beneficially Owned
|
|
Percent of Shares
Outstanding
|
|
Bruce L. Byrnes(1)
|
|
112,097
|
|
*
|
Nelda J. Connors(2)
|
|
90,746
|
|
*
|
Charles J. Dockendorff(3)
|
|
0
|
|
*
|
Kristina M. Johnson(4)
|
|
101,328
|
|
*
|
Edward J. Ludwig(5)
|
|
25,500
|
|
*
|
Stephen P. MacMillan(6)
|
|
0
|
|
*
|
Ernest Mario(7)
|
|
393,130
|
|
*
|
N.J. Nicholas, Jr.(8)
|
|
1,281,130
|
|
*
|
Pete M. Nicholas(9)
|
|
6,702,764
|
|
*
|
Uwe E. Reinhardt(10)
|
|
166,379
|
|
*
|
David J. Roux(11)
|
|
17,750
|
|
*
|
John E. Sununu(12)
|
|
91,757
|
|
*
|
Michael F. Mahoney(13)
|
|
2,177,576
|
|
*
|
Kevin J. Ballinger(14)
|
|
411,022
|
|
*
|
Daniel J. Brennan(15)
|
|
385,935
|
|
*
|
Joseph M. Fitzgerald(16)
|
|
688,363
|
|
*
|
Timothy A. Pratt(17)
|
|
1,211,837
|
|
*
|
Kenneth J. Pucel**(18)
|
|
1,048,550
|
|
*
|
All directors and executive officers as a group (26 persons)(19)
|
|
16,401,381
|
|
1.23%
|
|
|
|
*
|
|
Reflects beneficial ownership of less than one percent (1%) of our outstanding common stock.
|
**
|
|
As of November 28, 2014, the date Mr. Pucel's employment with the Company terminated.
|
(1)
|
|
Mr. Byrnes' beneficial ownership includes 13,177 shares of restricted stock as to which Mr. Byrnes has sole voting but not investment power.
|
(2)
|
|
Ms. Connors' beneficial ownership includes 13,177 shares of restricted stock as to which Ms. Connors has sole voting but not investment power and 77,569 shares of restricted stock deferred pursuant to our
Non-Employee Director Deferred Compensation Plan as to which Ms. Connors has neither voting nor investment power until such shares are distributed in accordance with the plan.
|
41
Table of Contents
|
|
|
(3)
|
|
Mr. Dockendorff will receive an initial equity award on May 1, 2015.
|
(4)
|
|
Dr. Johnson's beneficial ownership includes 13,177 shares of restricted stock as to which Dr. Johnson has sole voting but not investment power and 85,027 shares of restricted stock deferred pursuant to our
Non-Employee Director Deferred Compensation Plan as to which Dr. Johnson has neither voting nor investment power until such shares are distributed in accordance with the plan. It excludes 9,815 common stock equivalents which Dr. Johnson
received under our Non-Employee Director Deferred Compensation Plan in connection with her deferral of certain director cash retainer amounts.
|
(5)
|
|
Mr. Ludwig's beneficial ownership excludes 13,177 deferred stock units deferred pursuant to our 2014 Non-Employee Director Deferred Compensation Plan the underlying shares of which Mr. Ludwig has neither
voting nor investment power until such shares are distributed in accordance with the plan.
|
(6)
|
|
Mr. MacMillan will receive an initial equity award on May 1, 2015.
|
(7)
|
|
Dr. Mario's beneficial ownership includes 13,177 shares of restricted stock as to which Dr. Mario has sole voting but not investment power, 130,098 shares of restricted stock deferred pursuant to our
Non-Employee Director Deferred Compensation Plan as to which Dr. Mario has neither voting nor investment power until such shares are distributed in accordance with the plan and 2,000 shares of common stock subject to exercisable stock options.
It excludes 17,593 common stock equivalents which Dr. Mario received under our Non-Employee Director Deferred Compensation Plan in connection with his deferral of certain director cash retainer amounts.
|
(8)
|
|
Mr. N.J. Nicholas' beneficial ownership includes 106,475 shares of common stock held by Mr. N.J. Nicholas, as sole trustee of a revocable trust, and 8,000 shares of common stock held in a trust of which
Mr. N.J. Nicholas is co-trustee, his child is a beneficiary and co-trustee and to which Mr. N.J. Nicholas disclaims beneficial ownership. It also includes 834,361 shares of common stock held by Ms. Ruth L. Nicholas and Mr. N.J.
Nicholas, as sole trustees of an irrevocable trust for the benefit of Mr. Pete M. Nicholas' children and spouse, as to which Mr. N.J. Nicholas disclaims beneficial ownership and which shares are pledged as security and held in
collateral accounts predating, and "grandfathered" under, the Company's Prohibition on Hedging and Pledging Policy described in the Compensation Discussion & Analysis section titled "
Prohibition on Pledging and Hedging
the Economic Value of our Common Stock
." 225,000 shares held in IRA accounts, 1,900 shares held in a charitable trust of which Mr. N.J. Nicholas is a trustee and to which he disclaims beneficial ownership, 83,996 shares
of restricted stock deferred and 19,398 deferred stock units deferred pursuant to our Non- Employee Director Deferred Compensation Plans as to which Mr. N.J. Nicholas has neither voting nor investment power until such shares are distributed in
accordance with the plan and 2,000 shares of common stock subject to exercisable stock options. It excludes 152,000 shares held by Mr. Pete M. Nicholas, Llewellyn Nicholas and Anastasios Parafestas, as Trustees of five irrevocable trusts for the
benefit of Mr. N.J. Nicholas' children as to which Mr. N.J. Nicholas disclaims beneficial ownership and 66,826 common stock equivalents which Mr. N.J. Nicholas received pursuant to our Non-Employee Director Compensation Plan
in connection with his deferral of certain director cash retainer amounts.
|
(9)
|
|
Mr. Pete M. Nicholas' beneficial ownership includes 21,803 shares of restricted stock as to which Mr. Pete M. Nicholas has sole voting but not investment power and 3,000 shares of common stock subject to
exercisable stock options. It also includes 1,918,854 shares owned jointly with his spouse and 3,085,215 shares of common stock held by Promerica L.P., a family limited partnership of which Mr. Pete M. Nicholas is general partner and as to
which he is deemed to have beneficial ownership. All shares owned by Mr. Pete M. Nicholas jointly with his spouse and all shares held by Promerica L.P., as well as 1,390,042 of the shares held directly by Mr. Pete M. Nicholas, are
pledged as security and held in collateral accounts predating, and "grandfathered" under, the Company's Prohibition on Hedging and Pledging Policy described in the Compensation Discussion & Analysis section titled "
Prohibition on Pledging and Hedging the Economic Value of our Common Stock
." Mr. Pete M. Nicholas' beneficial ownership includes an aggregate of 152,000 shares held by Mr. Pete M. Nicholas, Llewellyn
Nicholas and Anastasios Parafestas, as trustees of five irrevocable trusts for the benefit of Mr. N.J. Nicholas' children as to which Mr. Pete M. Nicholas disclaims beneficial ownership. Mr. Pete M. Nicholas' beneficial ownership
excludes 834,361 shares of common stock held by Ms. Ruth L. Nicholas and Mr. N.J. Nicholas, as sole trustees of an irrevocable trust for the benefit of Mr. Pete M. Nicholas' children and spouse, as to which Mr. Pete M.
Nicholas disclaims beneficial ownership and which shares are pledged as security and held in collateral accounts.
|
(10)
|
|
Dr. Reinhardt's beneficial ownership includes 13,177 shares of restricted stock as to which Dr. Reinhardt has sole voting but not investment power, 2,000 shares of common stock subject to exercisable stock
options, and 5,000 shares of stock held by Dr. Reinhardt's spouse as to which he disclaims beneficial ownership.
|
42
Table of Contents
|
|
|
(11)
|
|
Mr. Roux's beneficial ownership includes 13,177 shares of restricted stock as to which Mr. Roux has sole voting but not investment power.
|
(12)
|
|
Senator Sununu's beneficial ownership includes 68,580 shares of restricted stock deferred and 13,177 deferred stock units deferred pursuant our Non-Employee Director Deferred Compensation Plans as to which Senator
Sununu has neither voting nor investment power until such shares are distributed in accordance with the plan.
|
(13)
|
|
Mr. Mahoney's beneficial ownership includes 922,993 shares of common stock subject to stock options exercisable within 60 days of March 1, 2015.
|
(14)
|
|
Mr. Ballinger's beneficial ownership includes 348,009 shares of common stock subject to stock options exercisable within 60 days of March 1, 2015.
|
(15)
|
|
Mr. Brennan's beneficial ownership includes 272,289 shares of common stock subject to stock options exercisable within 60 days of March 1, 2015.
|
(16)
|
|
Mr. Fitzgerald's beneficial ownership includes 491,218 shares of common stock subject to stock options exercisable within 60 days of March 1, 2015.
|
(17)
|
|
Mr. Pratt's beneficial ownership includes 888,944 shares of common stock subject to stock options exercisable within 60 days of March 1, 2015.
|
(18)
|
|
Mr. Pucel's beneficial ownership includes 920,033 shares of common stock subject to stock options exercisable within 60 days of March 1, 2015.
|
(19)
|
|
This amount includes an aggregate of 4,594,486 shares of common stock subject to stock options exercisable within 60 days of March 1, 2015, and 71,324 shares held in the 401(k) Plan accounts of our executive
officers. Please refer to footnotes one through 18 above for additional details regarding the holdings of our directors, our director nominees and our NEOs. This amount does not include Mr. Pucel, who was no longer an executive officer of the
Company as of November 28, 2014 and Messrs. Dockendorff and MacMillan, who were not directors as of March 1, 2015.
|
Section 16(a) Beneficial Ownership Reporting Compliance
Section 16(a) of the Exchange Act requires our directors, executive officers and persons beneficially holding more than 10% of
our common stock to file reports of their ownership of our common stock and any changes in that ownership with the SEC. Specific due dates for these reports have been established and we are required
to report any failure to file by these dates during fiscal year 2013. To our knowledge, all of these filing requirements were timely satisfied by our directors, executive officers and 10% stockholders
except that (1) on February 20, 2014, a Form 4 was filed on behalf of John E. Sununu reporting a transaction that took place on February 14, 2014 and (2) on
February 26, 2015, an amendment to a Form 4 filed on February 26, 2014 was filed on behalf of Timothy A. Pratt to correct the number of shares that were reported as withheld for
taxes in a transaction on February 24, 2014. In making these statements, we have relied upon the written representations of our directors and executive officers and copies of reports that have
been filed with the SEC.
43
Table of Contents
COMPENSATION DISCUSSION & ANALYSIS
This discussion and analysis describes material elements of our 2014 compensation program for our NEOs.
Executive Summary
Company Strategic Imperatives and Select Business
Results Linked to 2014 Executive Compensation
During 2014, we continued to focus on the five strategic imperatives we launched in 2013 to help drive innovation, accelerate
profitable revenue growth and increase stockholder value:
-
-
Strengthen execution to grow share in our served markets.
-
-
Expand into high growth adjacencies that complement our core businesses.
-
-
Drive global expansion, including in emerging markets.
-
-
Fund the journey to fuel growth through optimization and cost reduction initiatives and a re-allocation of spending to support growth
initiatives.
-
-
Develop key capabilities to enable delivery of economic- and customer-focused products and solutions aligned with marketplace needs.
With
respect to our performance in 2014 relative to the financial performance metrics used in our short- and long-term incentive programs, we:
-
-
Generated GAAP (as defined below) net sales of $7.380 billion and net sales on a constant currency basis excluding
$37 million of sales from businesses acquired in 2014 (SFX net sales) of $7.429 billion.
-
-
With the inclusion of intangible asset impairment charges, acquisition- and divestiture-related net credits, restructuring- and
litigation-related charges, discrete tax items and amortization expense (after tax) of $1.248 billion, or $0.93 per share, we reported a GAAP net loss of $119 million, or $0.09 per
share. Excluding these net charges, we generated adjusted net income of $1.129 billion, or $0.84 per share (adjusted EPS).
-
-
Generated strong GAAP cash flow from operating activities of $1.269 billion and adjusted free cash flow of
$1.259 billion.
-
-
Used approximately $125 million of cash generated from operating activities to repurchase approximately 10 million
shares of our common stock to return value to our stockholders.
SFX
net sales, adjusted net income, adjusted EPS and adjusted free cash flow are not prepared in accordance with generally accepted accounting principles in the United States (GAAP). For a
reconciliation of these financial measures to the most directly comparable GAAP financial measures and insight into how these non-GAAP measures are considered by management, please see Annex A.
44
Table of Contents
Pay for Performance
Our executive compensation philosophy is to provide appropriate competitive compensation opportunities to our executives with actual
pay outcomes heavily influenced by achievement of Company and individual performance targets in support of our business strategy and creation of long-term stockholder value.
CEO's Realizable Total Direct Compensation Aligns
with Company Performance
The following chart shows the value of the primary elements of total direct compensation (TDC), consisting of base salary and annual short- and
long-term incentives, for our Chief Executive Officer in 2014 (i) at "target" opportunity as considered by our Compensation Committee; (ii) as disclosed in our Summary Compensation
Table; and (iii) as "realizable" at December 31, 2014. These values were calculated using the 2014 base salary, annual equity incentives, and Annual Bonus Plan award amounts for
Mr. Mahoney as set forth in the footnotes to the chart below.
Amounts in the "Target" column consist of the following:
-
-
the annual equity awards granted on February 24, 2014, with (a) stock options
valued using the Black-Scholes valuation model described in the footnotes to the Executive Compensation section titled "
Summary Compensation Table"
and
(b) service-based deferred stock units (DSUs) and performance-based DSUs valued at target (the number of units and target units awarded multiplied by the closing price of our common stock on
the date of grant);
-
-
the target 2014 Annual Bonus Plan award; and
-
-
the annual base salary approved in February 2014.
Amounts in the "Summary Compensation Table" column consist of the
following:
-
-
the annual equity awards granted on February 24, 2014, with the value of each award
determined in accordance with Financial Accounting Standards Board Accounting Standards Codification (FASB ASC) Topic 718, as described in the footnotes to the Executive Compensation section titled
"
Summary Compensation Table"
;
-
-
the actual 2014 Annual Bonus Plan award; and
-
-
the annual base salary paid in 2014.
45
Table of Contents
Amounts in the "Realizable" column consist of the
following:
-
-
the annual equity awards granted on February 24, 2014, with (a) stock options
valued at their intrinsic value (number of options awarded multiplied by the closing price of our common stock on December 31, 2014 less the exercise price of such options),
(b) service-based DSUs valued using the number of units awarded multiplied by the closing price of our common stock on December 31, 2014, (c) Total Shareholder Return (TSR)
performance-based DSUs valued at threshold due to the Company's 11.4% TSR performance in 2014 (minimum number of units multiplied by the closing price of our common stock on December 31, 2014),
and (d) the free cash flow (FCF) performance-based DSUs valued using 101.8% of the target FCF performance-based DSUs (the actual percentage of target units earned under the program) multiplied
by the closing price of our common stock on December 31, 2014;
-
-
the actual 2014 Annual Bonus Plan award; and
-
-
the annual base salary paid in 2014.
The significant difference in value of the long-term incentive compensation portion of our Chief Executive Officer's TDC reflected in the "Realizable" column of
the chart above relative to the values reflected in the "Target" and "Summary Compensation Table" columns is primarily due to:
-
-
the 2014 TSR performance-based DSUs being valued at 40% of target as a result of the 11.4% TSR performance in 2014 relative to that of
the other companies in the S&P Healthcare Index in light of our rank being 44
th
out of 50 for the 2014 performance period; and
-
-
the grant date value of the stock options determined based on accounting principles standing significantly higher than the intrinsic
value of such stock options.
We
believe this demonstrates the alignment of our executives' pay with Company performance and the long-term interests of our stockholders, providing "pay for performance."
A Significant Portion of our NEOs' 2014 Target TDC is
At-Risk, Performance-Based Compensation
Our Compensation Committee ties a significant portion of the primary elements of our executives' target TDC to at-risk, performance-based incentive
opportunities. For 2014, 83% of the target value of the primary elements of TDC for our NEOs as a group (including our CEO) consisted of at-risk, performance-based incentive compensation, which was
comprised of the following:
-
-
14% Short-Term Cash Incentive Awards, with:
-
Ø
-
Funding
of the Total Bonus Pool tied to Company performance measured against adjusted EPS and SFX net sales
performance targets.
-
Ø
-
Allocation
of the Total Bonus Pool, as funded, based on regional, business and functional performance measured
against their respective financial and/or operational performance targets.
-
Ø
-
Actual
payout adjusted based on each individual's performance.
-
-
69% Long-Term Equity Incentive Awards, with mix of opportunity comprised of:
-
Ø
-
25%
target Company performance-based deferred stock units (DSUs), a percentage of which is earned based on the
total shareholder return (TSR) of our common stock relative to that of the other companies in the S&P 500 Healthcare Index over a three-year performance period.
-
Ø
-
25%
target performance-based DSUs, a percentage of which is earned based on our adjusted free cash flow (FCF)
measured against our target performance over a one-year
46
Table of Contents
The
percentages above were calculated using the 2014 base salary, target equity values and target Annual Bonus Plan award amounts for our NEOs set forth in the footnote to the charts below. Allocation
of the target value of the primary elements of TDC for our Chief Executive Officer and for our other NEOs as a group in 2014 was as follows:
|
|
|
(1)
|
|
The charts reflect the value of the primary elements of 2014 TDC opportunity as considered by the Compensation Committee as follows: (i) the annual equity awards granted to our CEO/other NEOs on February 24,
2014, with stock options valued per the Black-Scholes valuation model described in the footnotes to the Executive Compensation section titled "
Summary Compensation Table"
and with both service-based DSUs
and Company performance-based DSUs valued at target (using the number of units and target units awarded multiplied by the closing price of our common stock on the date of grant); (ii) the target Annual Bonus Plan award; and (iii) the annual
base salary approved in February 2014.
|
We
believe our emphasis on at-risk, performance-based incentive compensation consisting of our Annual Bonus Plan awards and long-term equity awards aligns
our executives with our business strategy and the short- and long-term interests of our stockholders, providing "pay for performance" and putting a significant portion of our executives' pay "at
risk."
Executive Compensation Program Best Practices
Our Compensation Committee believes that a strong foundation for our compensation program is necessary to execute our executive
compensation philosophy effectively. The following key aspects of executive compensation best practices serve as the foundation for our compensation program:
-
ü
-
Use
a mix of short- and long-term incentive compensation, with an emphasis on
long-term compensation.
-
ü
-
Use
a mix of fixed and variable compensation, with an emphasis on variable, at-risk
performance-based compensation.
47
Table of Contents
-
ü
-
Require
a "double-trigger" (both a change in control and termination without cause or
for good reason) for cash payments and accelerated vesting of equity awards where the surviving or acquiring entity substitutes or assumes outstanding equity awards.
-
ü
-
Do
not provide income tax gross-ups (except on relocation benefits).
-
ü
-
Do
not provide any excise tax gross-ups on severance or other payments in connection
with a change in control.
-
ü
-
Maintain
stock ownership guidelines for our executives and directors.
-
ü
-
Have
a policy for the recovery, commonly referred to as a "claw-back," of all or a
portion of certain incentive compensation awards under certain circumstances.
-
ü
-
Use
internal pay equity analysis.
-
ü
-
Use
peer group company comparative analysis.
-
ü
-
Engage
an independent compensation consultant reporting directly to the Compensation
Committee.
-
ü
-
Perform
risk assessment of incentive compensation policies and programs.
-
ü
-
Do
not pay dividend equivalents paid on unvested performance-based DSUs or
service-based DSUs.
-
ü
-
Do
not permit repricing of underwater stock options without stockholder approval.
-
ü
-
Prohibit
pledging or hedging of the economic value of our common stock by our
executives and directors.
1
Say on Pay
At our 2014 Annual Meeting of Stockholders, we asked our stockholders to vote, on an advisory basis, on the 2013 compensation of our
then named executive officers as disclosed in our 2014 Proxy Statement, commonly referred to as a "say-on-pay" advisory vote. Our stockholders approved the compensation of our then-named executive
officers with approximately 89% of the votes cast voting in favor of the proposal. In connection with its review of our compensation program against our executive compensation philosophy and business
objectives, our Compensation Committee took into consideration the modifications it had already made in prior years to our compensation programs in support of our executive compensation philosophy and
best practices, the results of the say-on-pay advisory vote, as well as feedback the Company received on the matter from its stockholders in prior years. As a result, our Compensation Committee
concluded that it would retain our compensation program's emphasis on at-risk, performance-based incentive compensation.
|
|
|
1
Hedging and pledging arrangements of any of our directors that were in existence prior to January 1, 2011 are exempt from the policy.
|
|
|
48
Table of Contents
How We Determine Executive Compensation
Executive Compensation Philosophy and Objectives
Our executive compensation philosophy is to provide appropriate competitive compensation opportunities to our executives with actual
pay outcomes heavily influenced by achievement of Company, business and individual performance targets/objectives in support of our business strategy and creation of long-term stockholder value. The
core objectives of our compensation program are to:
-
-
Attract, retain, and engage top talent.
-
-
Reinforce our culture of quality.
-
-
Align management's interests with the long-term interests of our stockholders.
-
-
Incentivize achievement of key Company, business and individual targets/objectives to support our business strategy.
-
-
Appropriately manage compensation risk in light of our business strategy.
Our
Compensation Committee evaluates executive compensation best practices and makes modifications to our compensation program that it determines are appropriate to support our executive compensation
philosophy.
Competitive Market Analysis
Our Compensation Committee considers executive compensation comparative data of our peer group companies in order to facilitate an
understanding of trends and comparative practices in executive compensation generally, as well as with respect to the specific levels and mix of target compensation opportunities provided to our
executives and program design in the market within which we compete for top talent. The companies in our peer group (i) are in two Global Industry Classification Standard (GICS) Industry
Groups, which include companies generally focused on a comparable industry (customer base and product offerings) such as pharmaceuticals, biotechnology & life sciences and healthcare
equipment & services companies, and (ii) generally have a comparable size (0.5x to 2x) in relation to one or both of our revenue and market capitalization. Additional characteristics of
our peer group companies may include being listed in three or more of our comparable companies' peer groups and being in our GICS Sub-Industry (healthcare equipment).
Our
Compensation Committee reviews the composition and appropriateness of our peer group companies for executive compensation comparative purposes annually. Following a review in February 2014, our
Compensation Committee made no changes to our 2013 peer group companies for 2014 executive compensation comparative purposes. Our 2014 peer group companies are listed below. At the time of review, our
revenue for 2013 was within a reasonable range of the median revenue of our
49
Table of Contents
peer
group companies for the prior four quarters and our market capitalization as of December 31, 2013 was within a reasonable range of the median market capitalization of our peer group
companies.
|
|
|
|
|
Allergan, Inc.
|
|
C.R. Bard
|
|
St. Jude Medical, Inc.
|
Baxter International Inc.
|
|
Edwards Lifesciences
|
|
Stryker Corporation
|
Becton, Dickinson and Company
|
|
Hospira, Inc.
|
|
Thermo Fisher Scientific, Inc.
|
CareFusion Corp
|
|
Medtronic, Inc.
|
|
Zimmer Holdings, Inc.
|
Covidien Ltd.
|
|
|
|
|
For
2014, general industry survey data was also used for executive compensation comparative purposes for positions where sufficient peer group proxy data was not available. When making its
determinations, the Compensation Committee was not aware of the constituent companies used in the general industry survey.
Internal Pay Equity and Other Considerations
Our Compensation Committee considers the primary elements of each executive's TDC opportunity compared to that of our other
executives as well as the economic and retentive value of prior equity awards received by our executives in determining their current and future compensation.
Risk Considerations
Our Compensation Committee considers whether our executive compensation program is appropriately aligned with business risk by
examining the potential effects that elements of our executive compensation program may have on such business risk. This includes, among other things, the mix of fixed and variable compensation; the
mix of short- and long-term compensation; the mix of long-term equity incentives; mix of performance metrics, weighting, measurement, and payout timing; discretion and caps on short-term incentives;
award size, vesting schedules and performance and other terms of long-term equity incentives; and other incentive opportunities and their features. Our Compensation Committee also considers mitigating
design elements, including among other things, our recovery of short-term incentive awards policy and other recovery and forfeiture provisions relating to incentive compensation awards and other
benefits, executive stock ownership guidelines, and hedging/pledging prohibition. For more details on these policies and guidelines, please see "
Recovery of Incentive
Compensation Awards Policy and Provisions
,"
"
Executive Stock Ownership Guidelines
" and "
Prohibition on Pledging and Hedging the Economic Value of our Common
Stock
". For more information about our assessment of compensation policies and practices as they relate to our risk management, please see "
Risk
Assessment of our Compensation Programs
".
Performance Considerations
We utilize a performance, development and coaching (PDC) process to help guide individual development and performance discussions and
assess annual performance. With respect to each of our executives that report directly to him, our Chief Executive Officer undertakes their annual PDC reviews, assesses their performance results and
makes related compensation recommendations for them to our Compensation Committee for its consideration. Our Compensation Committee confirms our Chief Executive Officer's performance objectives and
oversees the evaluation of our Chief Executive Officer's performance in relation to those objectives. For 2014, the overall performance of our executives, including our NEOs was rated on a 3-point
scale designed to support a culture of high performance and accountability with clear expectations. This scale consisted of "outstanding," "successful" and "improvement required." These performance
achievement indicators, among the other considerations reviewed in this discussion and analysis, influence our executives' base salary, the individual
50
Table of Contents
component
of their Annual Bonus Plan award and, as an indication of future performance potential, their long-term equity incentive awards.
Chief Executive Officer and Compensation Committee
Judgment
The application of Chief Executive Officer and Compensation Committee judgment is an important factor in setting and determining
executive pay. We do not employ a purely formulaic approach to our executive compensation program. Target market guidelines and individual target TDC, financial and operational targets, individual
performance objectives and funding formulae are established in advance; however, Company and individual performance and other considerations (such as budgets, costs to the Company, our quality
objectives, changes in executive roles or
responsibilities and current economic conditions) may also be taken into account. For example, while the funding formula tied to Company-level financial performance targets are set in advance under
our Annual Bonus Plan, our Compensation Committee is able to reduce the Total Bonus Pool funding percentage (to not less than 50% of the target) based on its assessment of the Company's progress
toward achievement of our quality objectives.
Participants in the Compensation Process
Our Compensation Committee bears principal responsibility for, among other things, structuring our executive compensation program and
making individual executive compensation determinations. To help facilitate informed determinations with respect to their responsibilities, our Compensation Committee engages an independent
compensation consultant, Frederic W. Cook & Co. (Cook & Co.), which serves at the direction and under the supervision of our Compensation Committee. For further information
about our Compensation Committee and its composition, processes and responsibilities and about the services provided by Cook & Co., please see the Meetings and Board Committees section
titled "
Executive Compensation and Human Resources Committee.
" Cook & Co. and certain members of management support our Compensation
Committee with respect to the following, among other things:
|
|
|
Frederic W. Cook & Co.
(independent compensation consultant)
|
|
Expertise-based advice, research and
analytical services, including peer group composition and trends and comparative practices in executive compensation, program design and non-employee director compensation.
Commentary and/or recommendations as to the foregoing.
Participation in Compensation Committee meetings.
|
Management
|
|
|
Senior Vice President, Human Resources and Total Rewards Management
(in consultation with our Chief Executive Officer and other executives, as appropriate)
|
|
Expertise-based advice, research and
analytical services, including trends and comparative practices in executive compensation and program design.
Commentary and/or recommendations as to the foregoing.
Participation in Compensation Committee meetings.
|
Chief Executive Officer and other Executives
|
|
Individual executive PDC performance reviews
for direct reports.
Through our Chief Executive
Officer, performance assessment for executives (other than the Chief Executive Officer) and recommendations as to payments and adjustments.
Participation in Compensation Committee meetings.
|
51
Table of Contents
Elements of 2014 Executive Compensation
Primary Elements of Total Direct Compensation
We compensate our executives primarily through total direct compensation, namely in the form of base salary and short- and long-term
incentives (the primary elements of TDC). Our primary elements of TDC are heavily weighted towards variable, at-risk performance-based elements. For 2014, only 17% of the target value of the primary
elements of TDC for our NEOs as a group (including our CEO) consisted of fixed compensation in the form of base salary, while variable, at-risk performance-based compensation accounted for the
remaining 83% of their primary elements of TDC. The percentages were calculated using the 2014 base salary, target equity values and target Annual Bonus Plan award amounts for our NEOs set forth in
the footnotes to the charts below.
Allocation
of the target value of the primary elements of TDC between fixed and at-risk, performance-based compensation for our Chief Executive Officer and for our other NEOs as a group in 2014 was as
follows:
The charts reflect the value of the primary elements of 2014 TDC between fixed and variable, at-risk performance-based compensation opportunity as considered by
the Compensation Committee as follows:
-
(1)
-
The
"At-Risk Compensation" portion of the charts reflect: (i) the annual equity awards granted to our NEOs on February 24, 2014, with stock
options valued per the Black-Scholes valuation model described in the footnotes to the Executive Compensation section titled "
Summary Compensation Table"
and with both service-based DSUs and Company performance-based DSUs valued at target (using the number of units and target units awarded multiplied by the closing price of our common stock on the date
of grant); and (ii) the target Annual Bonus Plan award.
-
(2)
-
The
"Fixed Compensation" portion of the charts reflects the annual base salary approved in February 2014.
52
Table of Contents
The key features and objectives of the primary elements of our NEOs' 2014 TDC are summarized in the table below.
|
|
|
|
|
TDC Elements
|
|
Key Features
|
|
Objectives
|
|
Base Salary
|
|
Fixed annual cash amount, paid at regular intervals.
|
|
Provide stable source of income.
|
Short-Term Incentives Annual Bonus Plan Awards
|
|
At risk, performance-based annual cash incentive opportunity.
|
|
Align executive compensation with our business strategy and quality objectives.
|
|
|
Funding of Total Bonus Pool based on Company performance against important financial performance targets; allocation of Total Bonus Pool, as funded, based on regional, business and functional performance against their
specific financial and/or operational performance targets; and actual payout based on individual performance.
|
|
Focus talent/organization and reward based on important Company-wide financial measures; specific regional, business or functional unit financial and/or operational measures; and individual performance
objectives.
|
Long-Term Incentives Equity Awards
|
|
At risk, performance-based equity incentive opportunity.
|
|
Focus talent/organization on important financial measures and long-term stockholder value.
|
|
|
Mix of opportunity comprised of:
|
|
Reward based on:
|
|
|
25% target TSR performance-based DSUs
|
|
Our TSR relative to that of other S&P 500 Healthcare Index companies
|
|
|
25% target FCF performance-based DSUs
|
|
Our adjusted free cash flow measured against our target performance
|
|
|
25% stock options
|
|
Our stock price
|
|
|
25% service-based DSUs
|
|
Our stock price
|
While
our Compensation Committee considers the median market position relative to our peer group companies for comparable positions, individual target opportunities may vary based on our Compensation
Committee's consideration of other factors, including those discussed under "
How We Determine Executive Compensation.
" The target value of the primary
elements of the TDC for our NEOs as a group for 2014 was below the market median. The primary elements of NEO TDC paid for 2014 is discussed below and reported in the Executive Compensation section
titled "
Summary Compensation Table
" under the Salary, Stock Awards, Option Awards and Non-Equity Incentive Plan Compensation columns.
Base Salary
In setting base salaries for our executives, our Compensation Committee generally considers their market position relative to our
peer group companies' executives with comparable positions and scope of responsibilities, our annual merit-increase budget, our performance for the prior year, the executive's experience and scope of
responsibilities, internal pay equity relative to other executives and the executive's performance for the prior year as determined under that year's PDC process. The overall performance of our
executives, including our NEOs, under the PDC for the prior year was rated on a 3-point scale designed to support a culture of high performance and accountability with clear expectations. This scale
consisted of "outstanding," "successful" and "improvement required."
2014 NEO Base Salaries
In determining the 2014 base salaries of our NEOs (other than our Chief Executive Officer and Chief Financial Officer), our Compensation Committee
also considered the recommendations of our Chief Executive Officer in light of the general factors discussed above, including their overall performance
53
Table of Contents
ratings
for the prior year with Messrs. Ballinger, Fitzgerald and Pratt successfully meeting the high expectations of each of them for 2013 and Mr. Pucel delivering
outstanding performance for 2013. In addition, the Compensation Committee also considered Mr. Fitzgerald's promotion to Executive Vice President and President, Rhythm Management in determining
his 2014 base salary. In determining the 2014 base salary of Mr. Mahoney, our Compensation Committee considered the general factors discussed above, including his overall performance
successfully meeting the high expectations of him for 2013 as our President and Chief Executive Officer.
The
2014 base salaries (rounded to the nearest thousand) of our NEOs (other than Mr. Brennan) as well as the percentage increase from their 2013 base salaries are set forth below:
|
|
|
|
|
|
|
Name
|
|
2013 Base Salary
|
|
2014 Base Salary
|
|
% Increase
|
|
Michael F. Mahoney
|
|
$900,000
|
|
$925,000
|
|
2.8%
|
Kevin J. Ballinger
|
|
$380,000
|
|
$395,000
|
|
3.9%
|
Joseph M. Fitzgerald
|
|
$420,000
|
|
$460,000
|
|
9.5%
|
Timothy A. Pratt
|
|
$612,000
|
|
$630,000
|
|
2.9%
|
Kenneth J. Pucel(1)
|
|
$520,000
|
|
$545,000
|
|
4.8%
|
|
|
|
(1)
|
|
Mr. Pucel left the Company effective November 28, 2014.
|
Chief Financial Officer Base Salary
Daniel J. Brennan
. In October 2013, our Board appointed Mr. Brennan as our Executive Vice President
and Chief Financial Officer effective January 1, 2014 with an annual base salary of $450,000 pursuant to his offer letter. In setting Mr. Brennan's 2014 salary, our Compensation
Committee considered preliminary target TDC recommendations by Cook & Co., external Chief Financial Officer compensation comparators of our peer group companies, internal pay equity
relative to our other executives and Mr. Brennan's experience and existing compensation package.
Short-Term Incentives
Our Compensation Committee annually reviews the design of our Annual Bonus Plan to help ensure that the program continues to support
our executive compensation philosophy and core compensation program objectives. In finalizing the design for 2014, our Compensation Committee retained the provisions of our 2013 Annual Bonus Plan,
which was designed to reinforce the concept of "pay for performance," further align our short-term incentives with important financial and operational measures and the long-term interests of our
stockholders, and to incent and reward individual performance.
54
Table of Contents
Total Bonus Pool Funded Based on Company Performance
Under the 2014 Annual Bonus Plan, a single Company-wide Total Bonus Pool is funded by the Company's performance measured against important
Company-level financial performance metric targets, thereby reinforcing the importance of the Company's performance as a whole (which reflects the performance of our regions, businesses and
functions). For 2014, our Compensation Committee:
-
-
Selected adjusted EPS and SFX net sales as our Company-level financial performance metrics, which measures were used to set important
Company financial and operational performance goals for the year.
-
-
Set Company performance level targets for those metrics at $0.77 and $7.358 billion, respectively, to coincide with our Board
approved 2014 operating plan and within the Company's guidance range for 2014 announced in February 2014.
For
a description of how we calculate these non-GAAP financial measures as well as a reconciliation of these measures to the most directly comparable GAAP measures and insight into how these non-GAAP
measures are considered by management, please see the Executive Compensation section titled "
Narrative Disclosure to Summary Compensation Table and Grants of Plan-Based Awards
Table
2014 Annual Bonus Plan
" and Annex A, respectively.
The
Total Bonus Pool funding scale for the Company's 2014 performance measured against our 2014 Company-level performance metric targets for adjusted EPS and SFX net sales is set forth in the table
below. Each metric has a 50% weighting.
|
|
|
Adjusted EPS and SFX Net Sales
(As a Percent of Plan)
|
|
Total Bonus Pool
Funding Range
|
|
|
|
<90%
|
|
50%
|
90% to <95%
|
|
50% to 60%
|
95% to <97%
|
|
65% to 85%
|
97% to <103%
|
|
90% to 110%
|
103% to <105%
|
|
110% to 130%
|
105% to 110%+
|
|
130% to 150%
|
However,
in order to reinforce the importance of "top line" growth to the Company, Total Bonus Pool funding is capped at 90% in the event that the Company's SFX net sales are below 97% of target. In
addition, our Compensation Committee has the discretion to decrease the Total Bonus Pool funding percentage (to not less than 50% of the target) based on its assessment of the Company's performance
relative to our quality objectives. For 2014, our quality objectives related to our quality culture, training, audits, reporting, product performance, compliance environment and quality systems
operations. Our Compensation Committee considers quality objectives to be appropriate in emphasizing our commitment to continually improving and sustaining our quality systems, our quality compliance
and product performance, thereby enhancing stockholder value.
For
2014, based on our adjusted EPS of $0.84 per share and SFX net sales of $7.429 billion, we achieved 109.1% of the target level for adjusted EPS (in the range of 105% to 110%+ of plan) and
100.9% of the target level for SFX net sales (in the range of 97% to <103% of plan). Accordingly, the funding range for our 2014 Total Bonus Pool was between 110% and 130%. In accordance
with the terms of the plan and after taking into consideration the Company's overall 2014 performance, our Chief Executive Officer recommended, and our Compensation Committee approved, funding the
2014 Total Bonus Pool at 120%, which is the midpoint of the funding range. Our performance of quality objectives had no impact on the 2014 Total Bonus Pool funding.
55
Table of Contents
Funded Total Bonus Pool Allocated to Participating
Units
Under the 2014 Annual Bonus Plan, the Total Bonus Pool, as funded, is allocated by the Compensation Committee to each participating regional,
business, and functional unit based on our Chief Executive Officer's recommendations in light of that participating unit's performance measured against its operational and/or financial performance
metric targets (and other factors the Compensation Committee deems appropriate), thereby incentivizing and rewarding each participating unit's performance contributions. For
2014:
-
-
Mr. Ballinger, who leads Interventional Cardiology, received his Annual Bonus Plan award from the allocation of the funded
Total Bonus Pool to his funding unit based on Interventional Cardiology's performance measured against SFX net sales, adjusted operating income and constant currency growth compared to market targets
coinciding with the business's operating plan for the year. Due to its overall performance measured against these performance metrics, the performance percentage for Interventional Cardiology was
140%.
-
-
Mr. Fitzgerald, who leads Rhythm Management, received his Annual Bonus Plan award from the allocation of the funded Total Bonus
Pool to his funding unit based on Rhythm Management's performance measured against SFX net sales, adjusted operating income and constant currency growth compared to market targets coinciding with the
business's operating plan for the year. Due to its overall performance measured against these performance metrics, the performance percentage for Rhythm Management was 120%.
-
-
Our other NEOs (other than Mr. Pucel), who support our corporate functions, received their Annual Bonus Plan award from the
allocation of the funded Total Bonus Pool to their respective funding units at the Total Bonus Pool funding level taking into account their respective performance. Accordingly, the performance
percentage for the corporate funding units was 115%. Mr. Pucel, who left the Company effective November 28, 2014, was not eligible to receive an Annual Bonus Plan award.
The
Company does not disclose the specific targets for business, regional and functional participating units' performance metrics as they are highly confidential. Disclosing such confidential
information would provide competitors and third parties with insight into the Company's internal planning
processes that may allow them to predict certain of our business-, region- or function-specific financial or operational strategies, which could cause us competitive harm. Business and regional unit
targets related to SFX net sales, adjusted operating income and constant currency growth compared to market are established in support of Company-wide targets such as sales, operating income, earnings
per share and growth. These are based on a range of factors, including growth outlooks for our product portfolio, the competitive environment, our internal budgets, external market economic conditions
and market expectations. For example, growth rates implicit in targets for any one business or regional unit may be above or below the growth rates targeted for the entire Company, due to faster or
slower growth in relevant markets or smaller or larger market shares. These considerations result in business and regional unit targets that are intended to coincide with Company-wide targets in their
level of difficulty to achieve and probability for success. Performance targets are set at a level that the Company believes is aggressive enough to inspire top performance but reasonable enough to be
achievable through the efficient and diligent execution of their operating plans.
Individual Target Incentive Award Opportunity
Each incentive award opportunity under the Annual Bonus Plan is expressed as a percentage of annual base salary based on the scope of the executive's
responsibilities. For 2014, our Compensation
56
Table of Contents
Committee
maintained the target award opportunities for our NEOs within a range of 60% to 80% of their base salaries (other than Mr. Mahoney) and maintained the target award opportunity for
Mr. Mahoney at 120% of his base salary. Other than Messrs. Brennan and Fitzgerald, whose target award opportunity increased for 2014 in connection with Mr. Brennan's appointment
as our Executive Vice President and Chief Financial Officer effective January 1, 2014, and Mr. Fitzgerald's promotion to Executive Vice President and President, Rhythm Management
effective February 24, 2014, the target award opportunity percentages for our NEOs did not change from 2013.
Individual Performance Component
After year end, individual performance is considered pursuant to the PDC process described in the "
Performance
Considerations
" section. Based on the performance assessment
rating under our annual PDC process, an individual performance percentage from 0% to 200% is applied as a multiplier to an executive's funded Annual Bonus Plan award to determine the actual amount to
be paid. As applied to our Annual Bonus Plan for 2014, a rating of (i) "outstanding" generally permits an individual performance percentage of at least 115%, (ii) "successful" generally
permits an individual performance percentage between 90% and 105%, and (iii) "improvement required" generally permits an individual performance percentage between 0% and 75%.
2014 Annual Bonus Plan Awards Paid to Our NEOs
After funding the Total Bonus Pool based on the Company's performance measured against our Company-level adjusted EPS and SFX net sales performance
targets, the actual amount of an executive's Annual Bonus Plan award is ultimately determined by (i) multiplying the product of the executive's annual base salary for 2014 and his or her target
award percentage by the executive's participating unit's performance percentage, and then (ii) multiplying the result of the foregoing by his or her individual performance percentage, as
illustrated below:
|
|
|
|
|
|
|
|
|
|
|
|
|
Annual Base
Salary
×
Target Award
Percentage
|
|
×
|
|
Participating
Unit
Performance
Percentage
|
|
×
|
|
Individual
Performance
Percentage
|
|
=
|
|
Annual
Bonus
Plan
Award
|
Details
regarding the short-term incentive awards paid to our NEOs under our 2014 Annual Bonus Plan are set forth in the table below.
|
|
|
|
|
|
|
|
|
Name
|
|
2014
Target Award
|
|
Individual
Target Award
Opportunity (As
a % of Base
Salary)
|
|
2014
Actual Award
|
|
Actual
as % of
Target*
|
|
|
|
|
|
|
|
|
|
Michael F. Mahoney
|
|
$1,110,000
|
|
120%
|
|
$1,404,150
|
|
127%
|
Daniel J. Brennan
|
|
$315,000
|
|
70%
|
|
$416,588
|
|
132%
|
Kevin J. Ballinger
|
|
$237,000
|
|
60%
|
|
$414,750
|
|
175%
|
Joseph M. Fitzgerald
|
|
$322,000
|
|
70%
|
|
$425,040
|
|
132%
|
Timothy A. Pratt
|
|
$504,000
|
|
80%
|
|
$579,600
|
|
115%
|
Kenneth J. Pucel(1)
|
|
$381,500
|
|
70%
|
|
|
|
N/A
|
|
|
|
*
|
|
Rounded to the nearest whole percent.
|
(1)
|
|
Mr. Pucel left the Company effective November 28, 2014 and, as a result, was not eligible to receive a 2014 Annual Bonus Plan award.
|
57
Table of Contents
Our
NEOs had certain performance objectives intended to support our strategic imperatives, as applicable to their roles, including (i) with respect to our NEOs who support corporate functions,
those aimed at driving Company-level financial performance objectives, and (ii) with respect to our NEOs who support regions and businesses, those aimed at supporting regional- and
business-level financial and operational performance objectives. The individual performance objectives discussed below do not represent objective performance goals that must be achieved but rather
factors that may be considered by the Compensation Committee and management in determining each NEO's individual performance percentage. Further, no single factor is determinative or required to be
considered.
For
2014, Mr. Mahoney's individual performance objectives also included those aimed at driving regional, business, and functional performance objectives as well as those aimed at building
diversity, driving employee engagement and developing our people. Mr. Mahoney's individual performance percentage was 110% due primarily to his overall performance successfully meeting the high
expectations of him for 2014 as our President and Chief Executive Officer, with notable performance achieving Company level financial performance, strengthening execution and improving results within
our core businesses, implementing sales optimization initiatives and helping to strengthen Company culture and drive employee development and engagement. Accordingly, his 2014 Annual Bonus Plan award
was 127% of his target award.
For
2014, Mr. Brennan's individual performance objectives also included driving the achievement of financial goals, risk management and those aimed at evaluating potential strategic
transactions and strengthening investor relations capabilities and the culture within Finance. Mr. Brennan's individual performance percentage was 115% due primarily to his overall outstanding
performance for 2014, with notable performance driving the Company's disciplined focus on financial performance, providing leadership on strategic projects and strengthening investor relations
capabilities. Accordingly, his 2014 Annual Bonus Plan award was 132% of his target award.
For
2014, Mr. Ballinger's individual performance objectives also included implementing pricing programs, optimizing sales force capabilities and achieving product development and key milestones
and effectively executing product launches. Mr. Ballinger's individual performance percentage was 125% due primarily to his overall outstanding performance for 2014, with notable performance
exceeding both revenue and operating income targets as well as very successfully delivering on key product launches. Accordingly, his 2014 Annual Bonus Plan award was 175% of his target award.
For
2014, Mr. Fitzgerald's individual performance objectives also included achieving cost-savings and optimization goals and those related to research & development and clinical goals.
Mr. Fitzgerald's individual performance percentage was 110% due primarily to his overall performance successfully meeting the high expectations of him for 2014, with notable performance driving
revenue and operating income growth, leading the integration of the electrophysiology business of C.R. Bard Inc. and executing on the global sales strategy for the Company's subcutaneous
implantable cardioverter defibrillator, the S-ICD® System. Accordingly, his 2014 Annual Bonus Plan award was 132% of his target award.
For
2014, Mr. Pratt's individual performance objectives also included driving functional unit performance objectives over which he had responsibility, including cost savings and optimization
initiatives, developing the culture within the functional units over which he had responsibility and those aimed at legal risk management and mitigation, social media and corporate communications and
the strategic planning process; as well as objectives aimed at connecting with the customers, government officials and business and regional leaders. Mr. Pratt's individual performance
percentage was 100% due primarily to his overall performance successfully meeting the high expectations of him for 2014, with notable performance managing litigation risks, strengthening employee
engagement in
58
Table of Contents
Legal
and providing broad leadership across the Company. Accordingly, his 2014 Annual Bonus Plan award was 115% of his target award.
Mr. Pucel
left the Company effective November 28, 2014 and, as a result, was not eligible to receive a 2014 Annual Bonus Plan award.
Long-Term Incentives
Our Compensation Committee annually reviews the design of our Long-Term Incentive Program (LTI Program) to help ensure that the
program continues to support our executive compensation philosophy and core compensation program objectives. In setting the design for 2014, our Compensation Committee retained the mix of equity award
opportunities for our executives under our 2013 LTI Program that were designed to further reinforce "pay for performance" and align the interests of our executives and their compensation with
important Company financial measures and the long-term interests of our stockholders.
In
addition to aligning executive compensation with our business strategy and the long-term interests of our stockholders, the key features and objectives of each type of equity vehicle included in
the mix of equity awards comprising our NEOs' 2014 long-term equity incentive compensation are summarized in the table below.
|
|
|
|
|
|
|
|
|
Equity Vehicle and
Percentage of Aggregate
LTI Program Target
Values
|
|
Key Features
|
|
Objectives
|
|
|
|
|
|
|
|
|
|
TSR performance-based DSUs (25%)*
|
|
TSR performance-based DSUs represent an opportunity to receive shares of our common stock based on our TSR measured against that of the other companies in the S&P 500 Healthcare Index (of which a significant portion of our peer group
companies are a part) over a three-year performance period.
|
|
Reinforce "pay for performance" by directly linking number of shares earned under the award to our TSR relative to that of industry-related companies.
|
|
|
For the 2014 Total Shareholder Return Performance Share Program (TSR PSP), the number of target TSR performance-based DSUs as to which the performance criteria could be satisfied would be within a range of 0% to 200% of the target units awarded as
follows:
|
|
|
|
|
TSR Performance
Percentile Rank
|
|
TSR
Performance-Based
DSUs as a Percent of
Target
|
|
|
|
|
90th Percentile or above
|
|
200%
|
|
|
|
|
80th Percentile
|
|
150%
|
|
|
|
|
50th Percentile
|
|
100%
|
|
|
|
|
30th Percentile
|
|
40%
|
|
|
|
|
Below 30th Percentile
|
|
0%
|
|
|
|
|
If the threshold level of performance is achieved, the number of TSR performance-based DSUs would be calculated linearly in accordance with the chart above.
|
|
|
|
|
These awards typically vest upon satisfaction of both the performance criteria and the service criteria at the end of the three-year performance period.
|
|
|
59
Table of Contents
|
|
|
|
|
|
|
|
|
Equity Vehicle and
Percentage of Aggregate
LTI Program Target
Values
|
|
Key Features
|
|
Objectives
|
|
|
|
|
|
|
|
|
|
FCF performance-based DSUs (25%)*
|
|
FCF performance-based DSUs represent an opportunity to receive shares of our common stock based on our adjusted free cash flow over a one-year performance period measured against our target performance for the same
period; under the 2014 Free Cash Flow Performance Share Program (FCF PSP), our Compensation Committee set the target adjusted free cash flow at $1.250 billion to coincide with our Board approved 2014 internal cash flow plan.
For the 2014 FCF PSP, the number of target FCF performance-based DSUs as to which the performance criteria under the program was satisfied would be within a range of 0% to 150% of the target units awarded as follows:
|
|
Align executive compensation opportunity with an important Company financial measure in our internal financial plan.
Reinforce "pay for performance" by directly linking the number of shares earned under the award to our adjusted free cash flow performance measured against our target performance.
|
|
|
FCF Performance
Percentile
Compared to
Plan
|
|
FCF
Performance-Based
DSUs
as a Percent of
Target
|
|
|
|
|
125% or above
|
|
150%
|
|
|
|
|
110%
|
|
120%
|
|
|
|
|
100%
|
|
100%
|
|
|
|
|
90%
|
|
80%
|
|
|
|
|
50%
|
|
25%
|
|
|
|
|
Less than 50%
|
|
0%
|
|
|
|
|
If the threshold level of performance is achieved, the number of FCF performance-based DSUs would be calculated linearly in accordance with
the chart above.
|
|
|
|
|
These awards typically vest upon satisfaction of both the performance criteria after the end of the one-year performance period and the
service criteria after the end of a three-year period (inclusive of the performance period).
|
|
|
Stock options (25%)*
|
|
Stock options represent the right to purchase shares of our common stock at an exercise price equal to the closing price of our common stock on the date of grant.
|
|
Reinforce "pay for performance" by linking the ultimate value of the award to the performance of our stock price.
|
|
|
These awards typically vest in four equal annual installments.
|
|
|
Service-based DSUs (25%)*
|
|
Service-based DSUs represent the opportunity to receive shares of our common stock based on the performance of future service.
|
|
Reinforce "pay for performance" by linking the ultimate value of the award to the performance of our stock price.
|
60
Table of Contents
|
|
|
|
|
|
|
|
|
Equity Vehicle and
Percentage of Aggregate
LTI Program Target
Values
|
|
Key Features
|
|
Objectives
|
|
|
|
|
|
|
|
|
|
|
|
These awards typically vest in five equal annual installments.
|
|
Retain top talent and promote executive long-term share owner perspective in a share-efficient manner.
|
|
|
|
*
|
|
We do not pay dividends on stock options, unvested Company performance-based DSUs or service-based DSUs.
|
For
further discussion of the performance share programs for our Company performance-based DSUs and the equity awards granted pursuant to our Long-Term Incentive Plans (LTIPs) and a description of how
we calculate adjusted free cash flow, please see the Executive Compensation sections titled "
Narrative Disclosure to Summary Compensation Table and Grants of Plan-Based Awards
Table
2014 Total Shareholder Return Performance Share Program,
" "
Narrative
Disclosure to Summary Compensation Table and Grants of Plan-Based Awards Table
2014 Free Cash Flow Performance Share
Program
" and "
Narrative Disclosure to Summary Compensation Table and Grants of Plan-Based Awards Table
2011 Long-Term Incentive
Plan
," respectively.
2014 Long-Term Incentive Awards for Our NEOs
In setting long-term incentive award opportunities for our executives, our Compensation Committee generally considers their market position relative
to our peer group companies' executives with comparable positions and scope of responsibilities, and their experience and scope of responsibilities.
In
determining the 2014 long-term equity incentive award amounts for our NEOs, our Compensation Committee also considered the recommendations of the Chief Executive Officer in light of the general
factors discussed above, including as an indication of future performance potential, the executive's performance for the prior year determined under our that year's PDC process. The overall
performance of our executives, including our NEOs (other than our Chief Executive Officer) under the PDC for the prior year was also rated on the 3-point scale consisting of "outstanding,"
"successful" and "improvement required." In February 2014, our Compensation Committee approved the grant of long-term equity incentive awards to our NEOs in the following amounts based on the target
value of annual equity awards for our NEOs considered by the Compensation Committee (see discussion of such target annual equity award values below):
|
|
|
|
|
|
|
|
|
Name
|
|
Target FCF
Performance-Based
DSUs(1)(2)
|
|
Target TSR
Performance-Based
DSUs(1)
|
|
Stock
Options(1)
|
|
Service-Based
DSUs(1)
|
|
|
|
|
|
|
|
|
|
Michael F. Mahoney
|
|
145,259
|
|
145,259
|
|
346,083
|
|
145,259
|
Daniel J. Brennan
|
|
28,669
|
|
28,669
|
|
68,306
|
|
28,669
|
Kevin J. Ballinger
|
|
14,334
|
|
14,334
|
|
34,153
|
|
14,334
|
Joseph M. Fitzgerald
|
|
23,891
|
|
23,891
|
|
56,921
|
|
23,891
|
Timothy A. Pratt
|
|
22,935
|
|
22,935
|
|
54,644
|
|
22,935
|
Kenneth J. Pucel
|
|
32,492
|
|
32,492
|
|
77,413
|
|
32,492
|
|
|
|
(1)
|
|
2014 Company performance-based DSUs, stock options and service-based DSUs were granted as of February 24, 2014; stock options have an exercise price of $13.08 per share (the closing price of our common stock on the
date of grant).
|
61
Table of Contents
|
|
|
(2)
|
|
As a result of our adjusted free cash flow performance percentile for the one-year performance period ending December 31, 2014 achieving 100.9% relative to target performance, 101.8% of the 2014 target FCF
performance-based DSUs listed in this column met the performance criteria. The number of shares of our common stock to be delivered or otherwise made available to our NEOs after satisfaction of individual service criteria is discussed below under the
section titled "
Company Performance-Based DSUs Results for Performance Periods Ending December 31, 2014.
"
|
The
target value of long-term equity incentive awards for our NEOs considered by our Compensation Committee in February 2014 were as follows: (i) $7.60 million for Mr. Mahoney;
(ii) $1.50 million for Mr. Brennan; (iii) $0.75 million for Mr. Ballinger, (iv) $1.25 million for Mr. Fitzgerald;
(v) $1.20 million for Mr. Pratt; and (vi) $1.70 million for Mr. Pucel. The target equity award values were then allocated in accordance with our LTI Program
to 25% TSR performance-based DSUs, 25% FCF performance-based DSUs, 25% service-based DSUs and 25% stock options. Both service-based DSUs and Company performance-based DSUs were valued using the number
of units and target units awarded multiplied by the closing price of our common stock on the date of grant and stock options were valued using the Black-Scholes valuation model described in the
footnotes to the Executive Compensation section titled "
Summary Compensation Table
."
Company Performance-Based DSUs
Results for Performance Periods Ending December 31, 2014
In February 2015, our Compensation Committee determined the number of target performance-based DSUs as to which the performance criteria have been
satisfied under our 2012 TSR PSP and our 2014 FCF PSP.
Under
the 2012 TSR PSP, our TSR performance percentile rank was 81.6 relative to that of the other companies in the S&P 500 Healthcare Industry Index over the three-year performance period
ending December 31, 2014. Accordingly, our Compensation Committee determined that pursuant to the terms of the program, 158.0% of the target awards had satisfied the performance criteria
thereunder. As a result, the following number of shares of our common stock were delivered to our NEOs (other than Mr. Pucel) in settlement of the 2012 target units awarded to them:
(i) 452,865 shares for Mr. Mahoney; (ii) 20,442 shares for Mr. Brennan, (iii) 25,159 shares for Mr. Ballinger, (iv) 47,174 shares for
Mr. Fitzgerald and (v) 75,478 shares for Mr. Pratt. Mr. Pucel was not eligible to receive shares of our common stock under the 2012 TSR PSP due to the termination of his
employment prior to the end of the performance period.
Under
the 2014 FCF PSP, our adjusted free cash flow performance percentile over the one-year performance period ending December 31, 2014 was 100.9% relative to target performance. Accordingly,
our Compensation Committee determined that pursuant to the terms of the program, 101.8% of the target awards had satisfied the performance criteria thereunder. As a result and so long as the
individual service criteria is also satisfied, the following number of shares of our common stock will be delivered to our NEOs (other than Mr. Pucel) no later than January 15, 2017 in
settlement of the 2014 target units awarded to them: (i) 147,873 shares for Mr. Mahoney; (ii) 29,185 shares for Mr. Brennan; (iii) 14,592 shares for
Mr. Ballinger; (iv) 24,321 shares for Mr. Fitzgerald; and (v) 23,347 shares for Mr. Pratt. Mr. Pucel was not eligible to receive shares of our common stock
under the 2014 FCF PSP due to the termination of his employment prior to the end of the performance period.
62
Table of Contents
Primary Elements of Indirect Executive Compensation
We also compensate our executives, including our NEOs, using indirect compensation, namely in the form of benefits and limited
perquisites. Generally, our benefits and perquisites are targeted to be competitive relative to our peer group companies. The primary elements of and objectives for our NEOs' 2014 indirect
compensation are summarized below.
General Employee Benefits
We provide employee benefits to eligible employees, including our NEOs, to promote personal health and well-being and to provide certain financial
security and protection upon retirement or in the event of death, disability or illness. As U.S.-based employees, our NEOs are eligible to receive employee benefits under our U.S. employee benefits
program, which consists of the following key elements that are generally the same as those provided to our other U.S. salaried employees: (i) health and welfare benefits based primarily on a
preferred provider model with executives sharing approximately 20% of the cost; (ii) Company-paid term life insurance policies that provide a benefit equal to base salary, with a minimum
benefit of $50,000 and a maximum benefit of up to $1 million, payable upon death; and (iii) a qualified 401(k) retirement plan with a Company match of 6% of eligible salary up to
$260,000 in 2014 resulting in a maximum possible match of $15,600. In October 2013, our Board of Directors, upon recommendation of our Compensation Committee, approved an annual executive level
physical examination program effective for 2014 that is designed to encourage the proactive management of executive health. In making its recommendation, the Compensation Committee considered the
overall cost of the program (estimated to be less than $10,000 per participant), that more than 60% of our peer group companies offered some form of benefit related to executive level annual physical
examinations, and the importance of good health to an executive's ability to focus on the short and long-term needs of the Company. Company-paid term life insurance premium amounts (and related
imputed income), Company matches of 401(k) plan contributions for our NEOs, Company-paid executive level annual physical examination costs, and certain other reimbursements in 2014 are reported in the
footnotes to the Executive Compensation section titled "
Summary Compensation Table
."
Deferred Compensation Programs
We maintain a Deferred Bonus Plan for certain of our management, including our NEOs, in order to provide them with the opportunity to defer up to 75%
of their annual award under our Annual Bonus Plan until the earlier of termination of employment or an elected distribution date. In 2014, Messrs. Mahoney, Ballinger and Fitzgerald deferred
35%, 75% and 50%, respectively, of their 2014 Annual Bonus Plan award, which were paid in 2015, under the Deferred Bonus Plan. For additional discussion of the Deferred Bonus Plan, please see the
narrative to the Executive Compensation section titled "
Nonqualified Deferred Compensation
."
Global Relocation Programs
We provide tiered relocation benefits under our global relocation program to eligible employees, including our NEOs, whom we request to move in
connection with their current position or a promotion and for eligible new hires we require to move in connection with accepting a position with us. Our objectives in providing global relocation
benefits are to attract and redeploy top talent. We provide "tax gross-ups" on applicable relocation benefits provided under our global relocation program as we believe that this benefit is integral
to the Company's ability to attract and retain employees whose skill or knowledge enhance the Company's competitive position. The U.S. executive tier of the program covers reasonable expenses
associated with the move and certain relocation services to
63
Table of Contents
minimize
the inconvenience and cost of moving, including as applicable, lump sum payments for temporary living, home search and miscellaneous expenses; new home search assistance; departure area home
sales assistance; reimbursement of duplicative housing costs; moving household goods; reimbursement of final trip expenses to the new area; spousal/partner career assistance; and cost of living
allowance for increases of at least eight percent in the cost of living from the previous residence location, paid as taxable income over four years in decreasing percentages. Under our global
relocation program, participants are generally required to sign a reimbursement agreement that requires them to pay back expenses incurred by the Company for their relocation in the event that they
voluntarily terminate their employment or are terminated for "cause" at a rate of 100% for termination within one year of the date on which payments were first made and 50% for termination within two
years of the date on which payments were first made.
Personal Use of Aircraft
Pursuant to Mr. Mahoney's offer letter, he is permitted reasonable personal use of our corporate aircraft up to $100,000 per annum in
aggregate incremental cost to the Company. Our other executives are permitted limited personal use of our corporate aircraft with prior approval. These executives are personally taxable on their
personal use of our corporate aircraft and we do not provide our executives with income tax gross-up payments. The aggregate incremental cost to the Company (and disallowed tax deductions of the
Company) for our NEOs' personal use of our corporate aircraft in 2014 is included in the footnotes to the Executive Compensation section titled "
Summary Compensation
Table
."
Our Post-Employment and Change in Control Arrangements
Primary Elements of Post-Employment and Change in
Control Arrangements
We provide post-employment and change in control payments and benefits to our executives under certain circumstances. We believe that
offering our executives these payments and benefits facilitates the operation of our business, allows them to better focus their time, attention and capabilities on our business, and assists the
Company in recruiting and retaining key executives. The primary elements of and objectives for our NEOs' 2014 post-employment and change in control agreements are summarized below.
Executive Retirement Plan
Our executives are eligible to participate in our Executive Retirement Plan. The objective of our Executive Retirement Plan is to provide a clear and
consistent approach to managing retirement-eligible executive departures with a standard, mutually understood separation and post-employment relationship. The Executive Retirement Plan provides
retiring executives with a lump sum benefit of 2.5 months of salary for each completed year of service, up to a maximum of 36 months' pay. The amount is payable in the first payroll
period after the last day of the six-month period following retirement. Receipt of payment is conditioned upon the retiring executive entering into an agreement with the Company that includes a
release of claims and customary non-disclosure, non-competition, non-solicitation and non-disparagement clauses in favor of the Company. To be eligible for benefits under the Executive Retirement
Plan, an executive's age plus his or her years of service with the Company must total at least 65 years (provided that the executive is at least 55 years old and has been with the
Company for at least five years). For further discussion of our Executive Retirement Plan, please see the narrative to the Executive Compensation section titled "
Pension
Benefits.
"
64
Table of Contents
Severance Plans
We maintain severance plans for eligible employees, including certain of our NEOs, under which participants are entitled to receive certain severance
payments, subsidized COBRA health benefits and dental benefits for specified periods of time based on position level and classification and completed years of service to the Company and to receive
outplacement services in the event of certain involuntary terminations. The payment of severance benefits under the plans is subject to the Company's receipt of a release of claims. Executives,
including certain of our NEOs, who are eligible to receive payments under our Executive Retirement Plan or a Change in Control Agreement are not eligible to receive payments and benefits under our
severance plans. For further discussion of our severance plans, please see the Executive Compensation section titled "
Potential Payments Upon Termination or Change in
Control
Severance Plans.
"
Change in Control Agreements
We provide Change in Control Agreements to our executives, including our NEOs, and other key employees. The possibility of a change in control and
the uncertainty that it may raise among our executives as to their continued employment after or in connection with a change in control may result in their departure or distraction. Our objective in
providing Change in Control Agreements is to retain and encourage the continued attention and dedication of our executives during a potentially critical time, even if they fear that their position
will be eliminated after or in connection with the change in control. Our Change in Control Agreements require both a change in control and termination without cause or resignation for good reason
within two years after the change in control event, commonly referred to as a "double-trigger," for cash payments to be made under the agreement and vesting to be accelerated under the agreement for
equity awards where the surviving or acquiring entity substitutes or assumes outstanding equity awards. Our Change in Control Agreements include a release of claims as well as customary non-disclosure
and non-solicitation clauses in favor of the Company. Executives, including our NEOs, who are eligible to receive payments under our Change in Control Agreements are not eligible to receive payments
and benefits under our Executive Retirement Plan or our severance plans. For further discussion of our Change in Control Agreements, please see the Executive Compensation section titled
"
Potential Payments Upon Termination or Change in Control Change in Control Agreements.
" Potential payments to our NEOs under our
Change in Control Agreements are included in the tables in the Executive Compensation section titled "
Potential Payments Upon Termination or Change in
Control
."
For
a discussion of our other plans and arrangements under which a change in control and/or termination of employment triggers payments or benefits, please see the Executive Compensation section
titled "
Potential Payments Upon Termination or Change in Control
." Potential payments to our NEOs in 2014 under such plans or arrangements are included
in the tables in the Executive Compensation section titled "
Potential Payments Upon Termination or Change in Control
."
Recovery of Incentive Compensation Awards Policy and Provisions
In February 2007, our Compensation Committee adopted a policy regarding the recovery or adjustment of short-term incentive awards
paid to an executive after the policy was adopted in the event relevant Company performance measures are restated in a manner that would have reduced the size of a previously granted award. In such an
event, and to the extent permitted by applicable law, the Company would seek to recover the amount of the short-term incentive award paid to such executive that was in excess of the amount that would
have been awarded based on the restated financial results, subject to and in accordance with the terms of the policy. Our Compensation
65
Table of Contents
Committee
monitors regulatory developments with respect to applicable executive compensation recovery policies required by the Dodd-Frank Wall Street Reform and Consumer Protection Act and it expects
to consider such changes to the Company's current recovery policy as are necessary to comply with final rules (and related guidance, if any) to be issued by the SEC in accordance with such act.
In
May 2013, our Compensation Committee adopted a policy regarding the recovery of certain short-and long-term incentive compensation awards paid or granted to an executive after the policy was
adopted in the event of executive misconduct or gross dereliction of duty that resulted in a material violation of Company policy and caused significant harm to the Company. In such an event, and to
the extent permitted by applicable law, the Company may seek reimbursement of all or a portion of cash incentive compensation awards paid within a certain time period and/or recovery of all or a
portion of equity incentive awards granted to such executive over which the Company retains control, subject to and in accordance with the terms of the policy.
For
a discussion of other recovery and forfeiture provisions relating to incentive compensation awards and other benefits provided to our executives, please see the section titled
"
Global Relocation Program
" above, and the Executive Compensation sections titled "
Pension Benefits
" and
"
Narrative Disclosure to Summary Compensation Table and Grants of Plan-Based Awards Table
."
Executive Stock Ownership Guidelines
Our executives are required to have a significant personal investment in the Company through their ownership of shares of our common
stock. The Board has adopted minimum stock ownership guidelines for executives, including our NEOs, in the following amounts:
-
-
Chief Executive Officer: 240,000 shares
-
-
Executive Vice Presidents: 75,000 shares
-
-
Senior Vice Presidents: 20,000 shares
Each
executive is expected to attain his or her ownership target within five years after such individual becomes an executive. All of our executives either currently meet our executive stock ownership
guidelines or we expect that they will meet them within five years after becoming an executive. The Nominating and Governance Committee monitors compliance with these guidelines on an annual basis.
Prohibition on Pledging and Hedging the Economic Value of our Common Stock
Our executives, including our NEOs, and our directors are prohibited from speculating in the Company's securities, engaging in
transactions designed to "hedge" the value of our common stock, and pledging their common stock as collateral for a loan. Hedging and pledging arrangements of any directors that were in existence
prior to January 1, 2011 are exempt from the policy. Executives and directors appointed after December 31, 2010 must unwind pre-existing hedging or pledging arrangements within nine
months of their election or appointment. Pre-existing hedging or pledging arrangements of such executives and directors will be disclosed at the time of their election or appointment in the Company's
related Form 8-K.
66
Table of Contents
No Tax Gross-Ups (other than for Relocation Benefits)
In 2009, the Company eliminated tax gross-ups for its executives except for relocation benefits, which the Compensation Committee
retained because the benefit generally applies to all employees eligible to receive relocation benefits, including our executives, and the Compensation Committee believes it is integral to the
Company's ability to attract and redeploy employees whose skill or knowledge enhance the Company's competitive position.
During
2014, Mr. Ballinger was erroneously paid a tax gross-up related to the cost of travel for a guest to accompany him to a business-related meeting. In 2015, Mr. Ballinger reimbursed
the Company for the erroneous tax gross-up payment. Please see footnote 7(e) to the Executive Compensation section titled "
Summary Compensation Table
"
for further information regarding the tax gross-up paid to Mr. Ballinger.
Our Equity Award Grant Policy and Practices
Under our Equity Award Grant Policy, grants of equity awards to our executives are approved and effective as
follows:
-
-
Annual equity awards (if any) for our employees, including our executives, are generally approved by our Compensation Committee at a
regularly scheduled meeting. Such awards are effective on the date of approval.
-
-
New hire, promotion, retention and other special or ad hoc awards for our executive officers are generally approved by our
Compensation Committee. New hire or promotion awards for executive officers are effective on the first trading day of the month following both the date of hire or promotion and the date approval.
Retention and other special or ad hoc awards for our executive officers are effective on the first trading day of the month following approval.
-
-
Stock options are granted with an exercise price equal to the closing price of our common stock on the date of grant.
Tax and Accounting Considerations
Section 162(m) of the Internal Revenue Code generally disallows a tax deduction to public companies for compensation over
$1 million paid to a company's chief executive officer and the three other most highly compensated executive officers, other than the chief financial officer, employed by the company at the end
of the year. Qualifying performance-based compensation is not subject to the deduction limit if certain requirements are met. Although we have plans that are intended to permit the award of deductible
compensation under Section 162(m) of the Internal Revenue Code, our Compensation Committee does not necessarily limit executive compensation to the amount deductible thereunder.
The
Company accounts for stock-based compensation in accordance with FASB ASC Topic 718, which requires the Company to recognize compensation expense for share-based payments (including stock
options and other forms of equity compensation). FASB ASC Topic 718 is taken into account by the Compensation Committee in determining to use a portfolio approach to equity grants, awarding
both stock options and DSUs.
67
Table of Contents
RISK ASSESSMENT OF OUR COMPENSATION PROGRAMS
With the assistance of the senior members of our Global Compensation and Benefits organization, certain senior executive officers and
the Compensation Committee's independent compensation consultant, Cook & Co., in December 2014 the Compensation Committee reviewed a risk assessment of our compensation programs and
policies to determine if the provisions and operations of our programs create undesired or unintentional risk of a material nature.
Our
risk assessment included two work streams one focused on reviewing areas of enterprise risk and the other focused on identifying compensation design risk. Our enterprise risk
analysis examined the types and magnitudes of risks our business areas present to the Company. Our compensation design risk analysis examined the potential risks in the design of our performance-based
incentive compensation arrangements. As part of this assessment, we analyzed the mix of fixed and variable compensation; the mix of short- and long-term compensation; the mix of long-term equity
incentives; performance metric mix, weighting, measurement, and payout timing, discretion and caps on short-term incentives; award size, vesting schedules and performance and other terms of long-term
equity incentives; and other incentive opportunities and their features. We also analyzed our recovery of incentive awards policy, executive stock ownership guidelines and hedging and pledging
prohibitions. Finally, we evaluated on a combined basis the results of the enterprise and compensation risk assessments, on a business-area-by-business-area basis.
As
a result of our analysis, the Compensation Committee believes that our compensation programs do not create risks that are reasonably likely to have a material adverse effect on the Company.
COMPENSATION COMMITTEE REPORT
The Executive Compensation and Human Resources Committee of the Board of Directors (the Compensation Committee) of Boston Scientific
has reviewed and discussed the Compensation Discussion & Analysis contained in this Proxy Statement with management and, based on such review and discussions, the Compensation Committee
approved the inclusion of the Compensation Discussion & Analysis in this Proxy Statement and in the Company's Annual Report on Form 10-K for the fiscal year ended December 31,
2014 for filing with the SEC.
This Compensation Committee Report does not constitute soliciting material and should not be deemed filed or incorporated by reference into any other Boston Scientific filing
with the SEC, except to the extent that Boston Scientific specifically incorporates this Report by reference into another Boston Scientific filing.
THE
COMPENSATION COMMITTEE
Ernest
Mario,
Chairman
Bruce L. Byrnes
Kristina M. Johnson
Edward J. Ludwig
68
Table of Contents
EXECUTIVE COMPENSATION
Summary Compensation Table
The table below summarizes the total compensation for each of our named executive officers for the fiscal years ended
December 31, 2014, 2013 and 2012. For a narrative description of material factors helpful to understand the information disclosed in the table below for 2014, please see the Compensation
Discussion & Analysis and the narrative to this table.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Name and Principal Position
|
|
Year
|
|
Salary
($)(1)
|
|
Bonus
($)(2)
|
|
Stock
Awards
($)(3)
|
|
Option
Awards
($)(4)
|
|
Non-Equity
Incentive Plan
Compensation
($)(5)
|
|
Change in
Pension Value
and
Nonqualified
Deferred
Compensation
Earnings
($)(6)
|
|
All Other
Compensation
($)(7)
|
|
Total
($)
|
|
Michael F. Mahoney
|
|
2014
|
|
$921,302
|
|
$0
|
|
$6,044,228
|
|
$1,899,718
|
|
$1,404,150
|
|
$198,620
|
|
$59,866
|
|
$10,527,884
|
President and Chief
|
|
2013
|
|
$900,000
|
|
$0
|
|
$6,647,490
|
|
$1,874,997
|
|
$1,242,000
|
|
$132,399
|
|
$54,544
|
|
$10,851,430
|
Executive Officer
|
|
2012
|
|
$900,000
|
|
$750,000
|
|
$5,867,193
|
|
$1,732,439
|
|
$1,026,000
|
|
$145,729
|
|
$362,421
|
|
$10,783,782
|
Daniel J. Brennan*
|
|
2014
|
|
$450,000
|
|
$0
|
|
$1,192,917
|
|
$374,945
|
|
$416,588
|
|
$1,107,712
|
|
$16,478
|
|
$3,558,640
|
Executive Vice
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
President and Chief
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Financial Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Kevin J. Ballinger*
|
|
2014
|
|
$392,781
|
|
$0
|
|
$596,438
|
|
$187,473
|
|
$414,750
|
|
$141,967
|
|
$203,900
|
|
$1,937,309
|
Senior Vice President
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
and President,
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interventional Cardiology
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Joseph M. Fitzgerald*
|
|
2014
|
|
$454,082
|
|
$0
|
|
$994,105
|
|
$312,451
|
|
$425,040
|
|
$189,420
|
|
$16,881
|
|
$2,391,979
|
Executive Vice President
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
and President,
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rhythm Management
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Timothy A. Pratt
|
|
2014
|
|
$627,337
|
|
$0
|
|
$954,325
|
|
$299,952
|
|
$579,600
|
|
$152,513
|
|
$19,183
|
|
$2,632,910
|
Executive Vice President,
|
|
2013
|
|
$612,000
|
|
$0
|
|
$1,107,893
|
|
$312,499
|
|
$563,040
|
|
$134,221
|
|
$18,922
|
|
$2,748,575
|
Chief Administrative Officer,
|
|
2012
|
|
$612,000
|
|
$0
|
|
$1,052,874
|
|
$288,739
|
|
$465,120
|
|
$147,386
|
|
$18,724
|
|
$2,584,843
|
General Counsel and Secretary
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Kenneth J. Pucel**
|
|
2014
|
|
$492,027
|
|
$0
|
|
$1,351,992
|
|
$424,935
|
|
$0
|
|
$0
|
|
$67,781
|
|
$2,336,735
|
Former Executive Vice
|
|
2013
|
|
$517,740
|
|
$0
|
|
$1,240,858
|
|
$349,999
|
|
$481,390
|
|
$0
|
|
$14,416
|
|
$2,604,403
|
President, Global Operations, Quality and Technology
|
|
2012
|
|
$505,000
|
|
$0
|
|
$1,052,874
|
|
$288,739
|
|
$369,408
|
|
$132,157
|
|
$14,004
|
|
$2,362,182
|
|
|
|
*
|
|
Messrs. Brennan, Ballinger and Fitzgerald were not NEOs during 2012 or 2013. In accordance with SEC rules, we are reporting data only for the fiscal year in which Messrs. Brennan, Ballinger and Fitzgerald were
NEOs.
|
**
|
|
Mr. Pucel left the Company effective November 28, 2014 in order to pursue another opportunity.
|
(1)
|
|
Base salaries for our executive officers are generally effective for one year starting in late February of each year. The amounts in this column for 2014 reflect an amount calculated by prorating 2013 salaries from
January 1, 2014 through February 2014 and 2014 salaries for the remainder of the year. These figures differ from those in the Compensation Discussion & Analysis, which lists amounts approved by the Compensation Committee in February
2014.
|
(2)
|
|
Amounts in this column reflect cash bonuses paid to our NEOs other than pursuant to our 2014 Annual Bonus Plan. Cash bonuses paid to our NEOs pursuant to our 2014 Annual Bonus Plan are reflected in the "Non-Equity
Incentive Plan Compensation" column.
|
(3)
|
|
The amounts included in the "Stock Awards" column represent the aggregate grant date fair value of all service-based and Company performance-based DSUs granted in 2014, 2013 and 2012 under our Long-Term Incentive Plan
(LTIP). These values have been determined in accordance with FASB ASC Topic 718.
|
69
Table of Contents
|
|
|
|
|
The attainment of the Company performance-based DSUs awarded to our NEOs in 2014 is based on either (i) the Total Shareholder Return (TSR) of our common stock relative to the TSR of the common stock of the other
companies in the S&P 500 Healthcare Index over a three-year performance and service period, or (ii) our adjusted free cash flow over a one-year performance period measured against our internal financial plan for the same period, subject
to the satisfaction of the individual service criteria over a three-year period (inclusive of the performance period). For additional information with respect to these Company performance-based DSUs, including the vesting thereof, please see the
sections titled "
2014 Total Shareholder Return Performance Share Program"
and
"2014 Free Cash Flow Performance Share Program"
in the narrative to this
table.
|
|
|
We determined the grant date fair value of the 2014 TSR performance-based DSUs using a Monte Carlo simulation methodology, utilizing the following key assumptions:
|
|
|
|
Stock price on date of grant
|
|
$13.08
|
Risk-free rate
|
|
0.66%
|
Measurement period (in years)
|
|
3
|
|
|
|
|
|
The TSR performance metric for the 2014 TSR performance-based DSUs is a market condition as defined under FASB ASC Topic 718. Since these awards do not have performance conditions as defined under FASB ASC Topic 718,
such awards have no maximum grant date fair values that differ from the fair values presented in this Summary Compensation Table.
|
|
|
The grant date fair value of the 2014 FCF performance-based DSUs was determined based on management's evaluation of the Company's 2014 internal financial plan for adjusted free cash flow, assuming target achievement
of the adjusted free cash flow performance criteria and utilizing the closing market price of shares of our common stock on the date of grant. The fair values of the 2014 target FCF performance-based DSUs at the grant date assuming achievement of the
highest level of performance(as required to be disclosed by the SEC), which assumes actual adjusted free cash flow for 2014 at or above 125% of the Company's 2014 internal financial plan, are as follows: $2,849,982 for Mr. Mahoney's award,
$562,486 for Mr. Brennan's award, $281,233 for Mr. Ballinger's award, $468,741 for Mr. Fitzgerald's award, $449,985 for Mr. Pratt's award and $637,493 for Mr. Pucel's award.
|
|
|
We value service-based DSUs based on the closing market price of shares of our common stock on the date of grant. The 2012 awards for Messrs. Pratt and Pucel each include 11,943 service-based DSUs granted to
those of our executives, including such NEOs, who participated in our historic executive allowance program at its termination effective December 31, 2011, and who signed an acknowledgment of its termination. Because the program was frozen for
new participants at the time Mr. Mahoney joined the Company, he was not eligible for this grant.
|
|
|
For more information regarding the stock awards we granted in 2014, please see the Grants of Plan-Based Awards table. For a more detailed description of the assumptions used in determining grant date fair values of
DSUs granted in 2014, please see
Note M Stock Ownership Plans
to our 2014 consolidated financial statements included in Item 8 of our Annual Report on Form 10-K for the year
ended December 31, 2014.
|
(4)
|
|
The amounts included in the "Option Awards" column represent the aggregate grant date fair value of all stock options granted during 2014, 2013 and 2012 under our LTIP. These values have been determined in accordance
with FASB ASC Topic 718. For a description of the assumptions used for purposes of determining grant date fair value of stock options granted in 2014, please see
Note M Stock Ownership Plans
to our 2014 consolidated financial statements included in Item 8 of our Annual Report filed on Form 10-K for the year ended December 31, 2014. For more information regarding the stock option awards we granted in 2014, please
see the Grants of Plan-Based Awards table.
|
(5)
|
|
Amounts in the "Non-Equity Incentive Plan Compensation" column represent payments made under our Annual Bonus Plan to our NEOs prior to March 15 in the year following the fiscal year to which the payment relates.
Our NEOs' Annual Bonus Plan awards were made as cash payments.
|
|
|
For further information regarding the 2014 Annual Bonus Plan awards, please see the Compensation Discussion & Analysis section titled "
Short-Term Incentives
" and
the narrative to this table.
|
70
Table of Contents
|
|
|
(6)
|
|
The amounts shown in the "Change in Pension Value and Nonqualified Deferred Compensation Earnings" column reflect the change in the actuarial present value of the accumulated benefit under our Executive Retirement
Plan for each pension plan measurement date used for financial statement reporting purposes with respect to the Company's audited financial statements fiscal as compared to the prior pension plan measurement date.
|
|
|
Mr. Brennan became eligible to participate in the Executive Retirement plan as of January 1, 2014. As such, the amount disclosed for him in this column reflects the full present value of the accumulated
benefit under the plan.
|
|
|
During 2013, total pension value for Mr. Pucel decreased by $6,442. In accordance with SEC rules, any negative amounts have been reported as $0 in this table. Additionally, upon Mr. Pucel's departure from
the Company effective November 28, 2014, Mr. Pucel became no longer eligible to participate in our Executive Retirement Plan. Because Mr. Pucel had not met the retirement criteria prescribed by this plan, he did not receive any
benefits pursuant to this plan.
|
|
|
Please see the narrative and footnotes to the Pension Benefits table for more information regarding the accrued benefits for each NEO under this plan. No amount is included with respect to nonqualified deferred
compensation earnings because there were no above-market or preferential earnings on nonqualified deferred compensation.
|
(7)
|
|
The amounts shown for 2014 in the "All Other Compensation" column are comprised of the following components:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Name
|
|
Match
(401(k) Plan)
(a)
|
|
Personal
Use of
Aircraft
(b)
|
|
Term
Life
Insurance
(c)
|
|
Relocation-
Related
Payments
(d)
|
|
Certain
Other
Payments
(e)
|
|
Total All
Other
Compensation
|
|
Michael F. Mahoney
|
|
$15,600
|
|
$42,366
|
|
$1,900
|
|
$0
|
|
$0
|
|
$59,866
|
Daniel J. Brennan
|
|
$15,600
|
|
$0
|
|
$878
|
|
$0
|
|
$0
|
|
$16,478
|
Kevin J. Ballinger
|
|
$14,623
|
|
$0
|
|
$554
|
|
$175,364
|
|
$13,358
|
|
$203,900
|
Joseph M. Fitzgerald
|
|
$15,600
|
|
$0
|
|
$1,281
|
|
$0
|
|
$0
|
|
$16,881
|
Timothy A. Pratt
|
|
$14,377
|
|
$0
|
|
$4,806
|
|
$0
|
|
$0
|
|
$19,183
|
Kenneth J. Pucel
|
|
$13,475
|
|
$0
|
|
$1,030
|
|
$0
|
|
$53,276
|
|
$67,781
|
|
|
|
(a)
|
|
The amounts shown in this column represent matching contributions made by the Company for each NEO under our 401(k) Retirement Savings Plan. All individual and matching contributions to the 401(k) Retirement Savings Plan
are fully vested upon contribution.
|
(b)
|
|
Pursuant to Mr. Mahoney's offer letter, he is permitted reasonable personal use of our corporate aircraft up to $100,000 per annum in aggregate incremental cost to the Company, but is not entitled to
reimbursement from the Company for any taxes resulting from imputed income attributable to his personal use of the corporate aircraft. The amount reflected in the "Personal Use of Corporate Aircraft" column represents the aggregate incremental costs
to us for Mr. Mahoney's personal use of our corporate aircraft, as well as any incremental costs associated with persons accompanying Mr. Mahoney on business travel. We calculate the incremental cost to us by dividing the total annual
variable operating costs for the corporate aircraft by the number of in-flight hours during the year. The resulting dollar per hour amount is then multiplied by the number of hours flown for personal use by the executive during the year, including
the "dead head" costs of flying the aircraft to and from locations for personal use. Our corporate aircraft are used predominately for business travel. Therefore, we do not include the fixed operating costs, such as pilot salary, general taxes and
insurance, in the incremental cost calculation. Incremental cost does not include amounts attributable to the NEO for increased income taxes we incurred in 2014 as a result of disallowed deductions related to personal use under Internal Revenue
Service rules. For 2014, the reflected amount excludes $202,807 of disallowed corporate income tax deductions attributable to Mr. Mahoney's personal use of the aircraft during the year. Mr. Mahoney was taxed on the imputed income
attributable to his personal use of the corporate aircraft and did not receive tax assistance from the Company with respect to this amount.
|
(c)
|
|
Amounts in the "Term Life Insurance" column consist of premiums and the imputed income for Company-paid term life insurance attributable to our NEOs. For Messrs. Mahoney, Brennan, Ballinger, Fitzgerald, Pratt and
Pucel, the premium paid was $332, $162, $142, $164, $226, and $179, respectively.
|
(d)
|
|
Mr. Ballinger temporarily relocated to Japan for several weeks during 2014 to support a critical product launch. The amounts shown represent (i) relocation-related expenses in the amount of $115,887and
(ii) associated tax gross ups for taxable relocation amounts in the amount of $59,477. For more information about our global relocation program, please see "
Global Relocation Programs
" in the
Compensation Discussion & Analysis section.
|
(e)
|
|
The amount for Mr. Ballinger includes the cost of travel for Mr. Ballinger's guest of $8,206 to accompany him to a business-related meeting, the associated tax gross-up of $4,152, and a $1,000 gift card
issued to him as a participant in a Company sales meeting. In 2015, Mr. Ballinger reimbursed the Company for the tax gross-up payment, which was erroneously made.
|
|
|
The amount for Mr. Pucel represents the amount paid to him for accrued, unused vacation at the time of his departure.
|
71
Table of Contents
Grants of Plan Based Awards
The table below presents information regarding awards under the Company's 2014 Annual Bonus Plan and 2011 Long-Term Incentive Plan,
including those pursuant to the Company's 2014 Performance Share Programs, during the fiscal year ended December 31, 2014. For a description of material factors helpful for an understanding of
the information in the table below, please see the Compensation Discussion & Analysis and the narrative to this table.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
All
Other
Stock
Awards:
Number
of
Shares
of Stock
or Units
(#)(3)
|
|
|
|
|
|
Grant
Date
Fair
Value
of
Stock
and
Option
Awards
($)(4)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
All Other
Option
Awards:
Number of
Securities
Underlying
Options
(#)(3)
|
|
Exercise
or Base
Price
of
Option
Awards
($/Sh)
|
|
|
|
|
Compensation
Committee
Approval Date
(if different
than
Grant Date)
|
|
Estimated Future Payouts
under Non-Equity Incentive Plan
Awards(1)
|
|
Estimated Future Payouts
under Equity Incentive Plan
Awards(2)
|
Name
|
|
Grant Date
|
|
Threshold
($)
|
|
Target
($)
|
|
Maximum
($)
|
|
Threshold
(#)
|
|
Target
(#)
|
|
Maximum
(#)
|
|
Michael F. Mahoney
|
|
|
|
$0
|
|
$1,110,000
|
|
$3,250,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2/24/2014(5)
|
|
|
|
|
|
|
|
|
|
58,103
|
|
145,259
|
|
290,518
|
|
|
|
|
|
|
|
$2,244,252
|
|
|
2/24/2014(6)
|
|
|
|
|
|
|
|
|
|
36,314
|
|
145,259
|
|
217,888
|
|
|
|
|
|
|
|
$1,899,988
|
|
|
2/24/2014(7)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
145,259
|
|
|
|
|
|
$1,899,988
|
|
|
2/24/2014(7)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
346,083
|
|
$13.08
|
|
$1,899,719
|
Daniel J. Brennan
|
|
|
|
$0
|
|
$315,000
|
|
$945,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2/24/2014(5)
|
|
|
|
|
|
|
|
|
|
11,467
|
|
28,669
|
|
57,338
|
|
|
|
|
|
|
|
$442,936
|
|
|
2/24/2014(6)
|
|
|
|
|
|
|
|
|
|
7,167
|
|
28,669
|
|
43,003
|
|
|
|
|
|
|
|
$374,991
|
|
|
2/24/2014(7)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
28,669
|
|
|
|
|
|
$374,991
|
|
|
2/24/2014(7)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
68,306
|
|
$13.08
|
|
$374,945
|
Kevin J. Ballinger
|
|
|
|
$0
|
|
$237,000
|
|
$711,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2/24/2014(5)
|
|
|
|
|
|
|
|
|
|
5,733
|
|
14,334
|
|
28,668
|
|
|
|
|
|
|
|
$221,460
|
|
|
2/24/2014(6)
|
|
|
|
|
|
|
|
|
|
3,583
|
|
14,334
|
|
21,501
|
|
|
|
|
|
|
|
$187,489
|
|
|
2/24/2014(7)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
14,334
|
|
|
|
|
|
$187,489
|
|
|
2/24/2014(7)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
34,153
|
|
$13.08
|
|
$187,473
|
Joseph M. Fitzgerald
|
|
|
|
$0
|
|
$322,000
|
|
$966,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2/24/2014(5)
|
|
|
|
|
|
|
|
|
|
9,556
|
|
23,891
|
|
47,782
|
|
|
|
|
|
|
|
$369,116
|
|
|
2/24/2014(6)
|
|
|
|
|
|
|
|
|
|
5,972
|
|
23,891
|
|
35,836
|
|
|
|
|
|
|
|
$312,494
|
|
|
2/24/2014(7)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
23,891
|
|
|
|
|
|
$312,494
|
|
|
2/24/2014(7)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
56,921
|
|
$13.08
|
|
$312,451
|
Timothy A. Pratt
|
|
|
|
$0
|
|
$504,000
|
|
$1,512,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2/24/2014(5)
|
|
|
|
|
|
|
|
|
|
9,174
|
|
22,935
|
|
45,870
|
|
|
|
|
|
|
|
$354,346
|
|
|
2/24/2014(6)
|
|
|
|
|
|
|
|
|
|
5,733
|
|
22,935
|
|
34,402
|
|
|
|
|
|
|
|
$299,990
|
|
|
2/24/2014(7)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
22,935
|
|
|
|
|
|
$299,990
|
|
|
2/24/2014(7)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
54,644
|
|
$13.08
|
|
$299,952
|
Kenneth J. Pucel
|
|
|
|
$0
|
|
$381,500
|
|
$1,144,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2/24/2014(5)
|
|
|
|
|
|
|
|
|
|
12,996
|
|
32,492
|
|
64,984
|
|
|
|
|
|
|
|
$502,001
|
|
|
2/24/2014(6)
|
|
|
|
|
|
|
|
|
|
8,123
|
|
32,492
|
|
48,738
|
|
|
|
|
|
|
|
$424,995
|
|
|
2/24/2014(7)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
32,492
|
|
|
|
|
|
$424,995
|
|
|
2/24/2014(7)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
77,413
|
|
$13.08
|
|
$424,935
|
|
|
|
(1)
|
|
The amounts in these columns reflect target and maximum payouts under the 2014 Annual Bonus Plan. There is no threshold-level payout under the 2014 Annual Bonus Plan. The maximum possible payout under the 2014 Annual
Bonus Plan is 300% of the target payout, representing the product of (i) a maximum of 150% of the target payout based on Company performance metrics and (ii) a maximum of 200% of the target payout based on individual performance objectives.
Under the 2014 Annual Bonus Plan, bonuses to executives covered by Internal Revenue Code Section 162(m) are capped at $3.25 million. The actual amount earned by each NEO under the 2014 Annual Bonus Plan is reported under the Non-Equity
Incentive Plan Compensation column in the Summary Compensation Table. For additional information about our 2014 Annual Bonus Plan and a discussion of how these amounts are determined, please see the Compensation Discussion & Analysis section
titled "
Short-Term Incentives
" and the section titled "
2014 Annual Bonus Plan
" in the narrative to this table.
|
(2)
|
|
The amounts in these columns reflect threshold, target and maximum share issuance under our 2014 TSR PSP and 2014 FCF PSP. The target performance-based DSUs awarded under these programs were granted to our NEOs in
February 2014 as part of our annual review process and were awarded under our 2011 LTIP. For additional details regarding the awards to our NEOs pursuant to our 2014 TSR PSP and our 2014 FCF PSP, please see footnotes 5 and 6 to this Grants of
Plan-Based Awards table, respectively.
|
(3)
|
|
The amounts in these columns reflect the number of service-based DSUs and stock options granted to our NEOs under our 2011 LTIP during 2014.
|
72
Table of Contents